<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004246.pub4" GROUP_ID="INFECTN" ID="569302072513080777" MERGED_FROM="" MODIFIED="2016-12-05 15:39:30 +0000" MODIFIED_BY="Anne-Marie Stephani" NOTES="&lt;p&gt;Exported from Review Manager 4.2.6&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2016-11-22 09:19:07 +0000" NOTES_MODIFIED_BY="Anne-Marie Stephani" REVIEW_NO="" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2016-12-05 15:39:30 +0000" MODIFIED_BY="Anne-Marie Stephani">
<TITLE MODIFIED="2016-10-28 18:06:05 +0100" MODIFIED_BY="[Empty name]">Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals</TITLE>
<CONTACT MODIFIED="2016-12-05 15:39:30 +0000" MODIFIED_BY="Anne-Marie Stephani"><PERSON ID="7E01F44282E26AA200E51E67BD33208D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lawrence</FIRST_NAME><LAST_NAME>Mbuagbaw</LAST_NAME><EMAIL_1>mbuagblc@mcmaster.ca</EMAIL_1><ADDRESS><DEPARTMENT>Centre for the Development of Best Practices in Health (CDBPH)</DEPARTMENT><ORGANISATION>Yaoundé Central Hospital</ORGANISATION><ADDRESS_1>Henri Dunant Avenue</ADDRESS_1><ADDRESS_2>PO Box 87</ADDRESS_2><CITY>Yaoundé</CITY><COUNTRY CODE="CM">Cameroon</COUNTRY><PHONE_1>(237) 75552864</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-12-05 15:39:30 +0000" MODIFIED_BY="Anne-Marie Stephani"><PERSON ID="7E01F44282E26AA200E51E67BD33208D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lawrence</FIRST_NAME><LAST_NAME>Mbuagbaw</LAST_NAME><EMAIL_1>mbuagblc@mcmaster.ca</EMAIL_1><ADDRESS><DEPARTMENT>Centre for the Development of Best Practices in Health (CDBPH)</DEPARTMENT><ORGANISATION>Yaoundé Central Hospital</ORGANISATION><ADDRESS_1>Henri Dunant Avenue</ADDRESS_1><ADDRESS_2>PO Box 87</ADDRESS_2><CITY>Yaoundé</CITY><COUNTRY CODE="CM">Cameroon</COUNTRY><PHONE_1>(237) 75552864</PHONE_1></ADDRESS></PERSON><PERSON ID="z1403310615428354436438361445762" ROLE="AUTHOR"><FIRST_NAME>Sara</FIRST_NAME><LAST_NAME>Mursleen</LAST_NAME><POSITION>Graduate Student</POSITION><EMAIL_1>sara.mursleen@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Clinical Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>McMaster University</ORGANISATION><ADDRESS_1>1280 Main Street West</ADDRESS_1><CITY>Hamilton</CITY><ZIP>L8S 4L8</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON><PERSON ID="14095" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>James</FIRST_NAME><MIDDLE_INITIALS>H</MIDDLE_INITIALS><LAST_NAME>Irlam</LAST_NAME><POSITION>Senior Lecturer &amp; Acting Director</POSITION><EMAIL_1>James.Irlam@uct.ac.za</EMAIL_1><ADDRESS><DEPARTMENT>Primary Health Care Directorate</DEPARTMENT><ORGANISATION>University of Cape Town</ORGANISATION><ADDRESS_1>E47 OMB</ADDRESS_1><ADDRESS_2>Groote Schuur Hospital</ADDRESS_2><CITY>Cape Town</CITY><ZIP>7925</ZIP><REGION>Western Cape</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 21 406 6377</PHONE_1><FAX_1>+27 21 448 5653</FAX_1></ADDRESS></PERSON><PERSON ID="93412557042899932784091103222430" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Alicen</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Spaulding</LAST_NAME><POSITION>Epidemiologist</POSITION><EMAIL_1>alicenspaulding@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Laboratory of Clinical Infectious Diseases</DEPARTMENT><ORGANISATION>National Institute of Allergy and Infectious Diseases</ORGANISATION><ADDRESS_1>2953 TERRACE DR</ADDRESS_1><CITY>Bethesda</CITY><ZIP>20892</ZIP><REGION>MD</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON><PERSON ID="7065" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>George</FIRST_NAME><MIDDLE_INITIALS>W</MIDDLE_INITIALS><LAST_NAME>Rutherford</LAST_NAME><POSITION>Co-ordinating Editor, Cochrane HIV/AIDS Group</POSITION><EMAIL_1>george.rutherford@ucsf.edu</EMAIL_1><MOBILE_PHONE>+1 510 501-4368</MOBILE_PHONE><ADDRESS><DEPARTMENT>Global Health Sciences</DEPARTMENT><ORGANISATION>University of California, San Francisco</ORGANISATION><ADDRESS_1>50 Beale Street</ADDRESS_1><ADDRESS_2>Suite 1200</ADDRESS_2><CITY>San Francisco</CITY><ZIP>94105</ZIP><REGION>California</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 415 597 9108</PHONE_1><FAX_1>+1 415 597 8299</FAX_1></ADDRESS></PERSON><PERSON ID="4979" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Nandi</FIRST_NAME><LAST_NAME>Siegfried</LAST_NAME><POSITION>Independent Clinical Epidemiologist</POSITION><EMAIL_1>nandi.siegfried@gmail.com</EMAIL_1><ADDRESS><ORGANISATION/><CITY>Cape Town</CITY><COUNTRY CODE="ZA">South Africa</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-09-26 12:15:01 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="12" MONTH="8" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="12" MONTH="8" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="8" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="12" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="12" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-11-18 09:32:00 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-11-18 09:32:00 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="11" YEAR="2016"/>
<DESCRIPTION>
<P>The review was updated with five new studies.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-11-18 09:26:58 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="11" YEAR="2016"/>
<DESCRIPTION>
<P>The review was updated with five new studies.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-11-09 10:29:40 +0000" MODIFIED_BY="Anne-Marie Stephani">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-11-09 10:29:40 +0000" MODIFIED_BY="Anne-Marie Stephani">
<DATE DAY="6" MONTH="1" YEAR="2011"/>
<DESCRIPTION>
<P>We amended the sources of support.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-11-03 17:34:38 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2016-11-03 17:34:00 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-09-10 13:45:00 +0100" MODIFIED_BY="[Empty name]">
<NAME>South African Cochrane Centre, Medical Research Council</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2008-09-10 13:45:59 +0100" MODIFIED_BY="[Empty name]">
<NAME>Cochrane HIV/AIDS Mentoring Programme</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2016-11-03 17:34:00 +0000" MODIFIED_BY="[Empty name]">
<NAME>Liverpool School of Tropical Medicine</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2016-11-03 17:34:38 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2016-11-03 17:34:16 +0000" MODIFIED_BY="[Empty name]">
<NAME>Centers for Disease Control and Prevention (CDC)</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>Cooperative Agreement #U2GPS001468 "Atlanta HQ UCSF Technical Assistance to Support the President's Emergency Plan for AIDS Relief" from the CDC, with funds from the National Center for HIV, Viral Hepatitis, STDs and TB Prevention (NCHSTP). Its contents are solely the responsibility of the review authors and do not necessarily represent the official views of the CDC.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2016-11-03 17:34:26 +0000" MODIFIED_BY="[Empty name]">
<NAME>World Health Organization (WHO)</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION>
<P>WHO #200106621, Systematic reviews and development of GRADE profiles, based on the new WHO GRC guidelines, for the "WHO Guidelines on antiretroviral therapy for HIV infection in adults and adolescents - 2009 revision."</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2016-11-03 17:34:38 +0000" MODIFIED_BY="[Empty name]">
<NAME>Department for International Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Grant: 5242</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-11-22 09:19:07 +0000" MODIFIED_BY="Anne-Marie Stephani">
<SUMMARY MODIFIED="2016-11-18 09:47:13 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2015-06-26 20:59:24 +0100" MODIFIED_BY="[Empty name]">Effectiveness of EFV compared to NVP in the suppression of HIV infection when used as part of initial three-drug combination</TITLE>
<SUMMARY_BODY MODIFIED="2016-11-18 09:47:13 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Research question</B>
</P>
<P>For people living with HIV who have never received antiretroviral therapy (ART), which drug is more effective in suppressing HIV infection in combination with two nucleoside reverse transcriptase inhibitors (NRTI): efavirenz (EFV) or nevirapine (NVP)?</P>
<P>
<B>Background</B>
</P>
<P>The introduction of highly active ART as treatment for HIV infection has greatly reduced mortality and morbidity for adults and adolescents living with HIV around the world. The recommended initial treatments for HIV infection include two drugs from a class of drugs known as NRTI and one from a related class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTI). The two NNRTIs most commonly used are NVP and EFV. However, NVP can cause liver damage and severe rash, both of which can be fatal. EFV may also cause a rash, impair mental function, and cause foetal malformations.</P>
<P>
<B>Main results</B>
</P>
<P>Cochrane researchers examined the available literature up to 12 August 2016 and identified 12 randomized controlled trials, with a total of 3278 people, that met the inclusion criteria of this review. None of the included trials included children. Four trials included people who were also receiving treatment for tuberculosis. There was little or no difference in suppression of HIV infection (<I>high quality evidence</I>), probably little or no difference in mortality, progression to AIDS, stopping treatment early and changes in blood cells affected by HIV (<I>moderate quality evidence</I>). There may be little or no difference in treatment failure (<I>low quality evidence</I>). We are uncertain whether there is a difference in side-effects (<I>very low quality evidence</I>). No studies were found that looked at sexual transmission of HIV. Development of drug resistance is probably slightly less in the EFV group (<I>moderate quality evidence</I>). When the side effects were examined individually, EFV probably caused more impaired mental function (6% in the EFV group and 2% in the NVP group; <I>moderate quality evidence</I>), while NVP probably caused more people to have a rash (3% in the EFV group and 6% in the NVP group; <I>moderate quality evidence</I>), caused more people to have reduced white blood cells (2% in the EFV group and 5% in the NVP group; <I>high quality evidence</I>), and signs of liver damage (6% in the EFV group and 11% in the NVP group; h<I>igh quality evidence</I>). There was probably little or no difference in increases in liver enzymes and levels of cholesterol (<I>moderate quality evidence</I>). There may be little or no difference in digestive side-effects, fever, enzymes from the liver and pancreas, and fat in the blood (<I>low quality evidence</I>). People on NVP were probably more likely to die when given a once-daily regimen (2% in the EFV group and 4% in the NVP group; <I>moderate quality evidence</I>). In people who were taking treatment for tuberculosis compared to those who were not, there was probably little or no difference in suppression of HIV, deaths, progression to AIDS or stopping treatment early (<I>moderate to high quality evidence</I>).</P>
<P>
<B>Conclusion</B>
</P>
<P>EFV and NVP are similarly effective in viral suppression, preventing HIV progression and reducing mortality. EFV is more likely to affect mental function, while NVP is more likely to cause signs of liver damage, reduced white blood cells and rash.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-11-18 09:39:56 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-11-09 10:30:41 +0000" MODIFIED_BY="Anne-Marie Stephani">
<P>The advent of highly active antiretroviral therapy (ART) has reduced the morbidity and mortality due to HIV infection. The World Health Organization (WHO) ART guidelines focus on three classes of antiretroviral drugs, namely nucleoside or nucleotide reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI) and protease inhibitors. Two of the most common medications given as first-line treatment are the NNRTIs, efavirenz (EFV) and nevirapine (NVP). It is unclear which NNRTI is more efficacious for initial therapy. This systematic review was first published in 2010.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-11-04 18:14:05 +0000" MODIFIED_BY="[Empty name]">
<P>To determine which non-nucleoside reverse transcriptase inhibitor, either EFV or NVP, is more effective in suppressing viral load when given in combination with two nucleoside reverse transcriptase inhibitors as part of initial antiretroviral therapy for HIV infection in adults and children.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-10-20 09:19:58 +0100" MODIFIED_BY="[Empty name]">
<P>We attempted to identify all relevant studies, regardless of language or publication status, in electronic databases and conference proceedings up to 12 August 2016. We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov to 12 August 2016. We searched LILACS (Latin American and Caribbean Health Sciences Literature) and the Web of Science from 1996 to 12 August 2016. We checked the National Library of Medicine (NLM) Gateway from 1996 to 2009, as it was no longer available after 2009.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-11-04 18:20:37 +0000" MODIFIED_BY="[Empty name]">
<P>We included all randomized controlled trials (RCTs) that compared EFV to NVP in people with HIV without prior exposure to ART, irrespective of the dosage or NRTI's given in combination.</P>
<P>The primary outcome of interest was virological success. Other primary outcomes included mortality, clinical progression to AIDS, severe adverse events, and discontinuation of therapy for any reason. Secondary outcomes were change in CD4 count, treatment failure, development of ART drug resistance, and prevention of sexual transmission of HIV.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-10-20 09:23:57 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors assessed each reference for inclusion using exclusion criteria that we had established a priori. Two review authors independently extracted data from each included trial using a standardized data extraction form. We analysed data on an intention-to-treat basis. We performed subgroup analyses for concurrent treatment for tuberculosis and dosage of NVP. We followed standard Cochrane methodological procedures.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-11-18 09:39:41 +0000" MODIFIED_BY="[Empty name]">
<P>Twelve RCTs, which included 3278 participants, met our inclusion criteria. None of these trials included children. The length of follow-up time, study settings, and NRTI combination drugs varied greatly. In five included trials, participants were receiving concurrent treatment for tuberculosis.</P>
<P>There was little or no difference between EFV and NVP in virological success (RR 1.04, 95% CI 0.99 to 1.09; 10 trials, 2438 participants; <I>high quality evidence</I>), probably little or no difference in mortality (RR 0.84, 95% CI 0.59 to 1.19; 8 trials, 2317 participants; <I>moderate quality evidence</I>) and progression to AIDS (RR 1.23, 95% CI 0.72 to 2.11; 5 trials, 2005 participants; <I>moderate quality evidence</I>). We are uncertain whether there is a difference in all severe adverse events (RR 0.91, 95% CI 0.71 to 1.18; 8 trials, 2329 participants; <I>very low quality evidence</I>). There is probably little or no difference in discontinuation rate (RR 0.93, 95% CI 0.69 to 1.25; 9 trials, 2384 participants; <I>moderate quality evidence</I>) and change in CD4 count (MD &#8722;3.03; 95% CI &#8722;17.41 to 11.35; 9 trials, 1829 participants; <I>moderate quality evidence</I>). There may be little or no difference in treatment failure (RR 0.97, 95% CI 0.76 to 1.24; 5 trials, 737 participants; <I>low quality evidence</I>). Development of drug resistance is probably slightly less in the EFV arms (RR 0.76, 95% CI 0.60 to 0.95; 4 trials, 988 participants; <I>moderate quality evidence</I>). No studies were found that looked at sexual transmission of HIV.</P>
<P>When we examined the adverse events individually, EFV probably is associated with more people with impaired mental function (7 per 1000) compared to NVP (2 per 1000; RR 4.46, 95% CI 1.65 to 12.03; 6 trials, 2049 participants; <I>moderate quality evidence</I>) but fewer people with elevated transaminases (RR 0.52, 95% CI 0.35 to 0.78; 3 trials, 1299 participants; <I>high quality evidence</I>), fewer people with neutropenia (RR 0.48, 95% CI 0.28 to 0.82; 3 trials, 1799 participants; <I>high quality evidence</I>), and probably fewer people withrash (229 per 100 with NVP versus 133 per 1000 with EFV; RR 0.58, 95% CI 0.34 to 1.00; 7 trials, 2277 participants; <I>moderate quality evidence</I>). We found that there may be little or no difference in gastrointestinal adverse events (RR 0.76, 95% CI 0.48 to 1.21; 6 trials, 2049 participants; <I>low quality evidence</I>), pyrexia (RR 0.65, 95% CI 0.15 to 2.73; 3 trials, 1799 participants; <I>low quality evidence</I>), raised alkaline phosphatase (RR 0.65, 95% CI 0.17 to 2.50; 1 trial, 1007 participants; <I>low quality evidence</I>), raised amylase (RR 1.40, 95% CI 0.72 to 2.73; 2 trials, 1071 participants; <I>low quality evidence</I>) and raised triglycerides (RR 1.10, 95% CI 0.39 to 3.13; 2 trials, 1071 participants; <I>low quality evidence</I>). There was probably little or no difference in serum glutamic oxaloacetic transaminase (SGOT; MD 3.3, 95% CI -2.06 to 8.66; 1 trial, 135 participants; <I>moderate quality evidence</I>), serum glutamic- pyruvic transaminase (SGPT; MD 5.7, 95% CI -4.23 to 15.63; 1 trial, 135 participants; <I>moderate quality evidence</I>) and raised cholesterol (RR 6.03, 95% CI 0.75 to 48.78; 1 trial, 64 participants; <I>moderate quality evidence</I>).</P>
<P>Our subgroup analyses revealed that NVP slightly increases mortality when given once daily (RR 0.34, 95% CI 0.13 to 0.90; 3 trials, 678 participants; <I>high quality evidence</I>). There were little or no differences in the primary outcomes for patients who were concurrently receiving treatment for tuberculosis.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-11-18 09:39:56 +0000" MODIFIED_BY="[Empty name]">
<P>Both drugs have similar benefits in initial treatment of HIV infection when combined with two NRTIs. The adverse events encountered affect different systems, with EFV more likely to cause central nervous system adverse events and NVP more likely to raise transaminases, cause neutropenia and rash.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-11-22 09:19:07 +0000" MODIFIED_BY="Anne-Marie Stephani">
<BACKGROUND MODIFIED="2016-11-04 19:19:30 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2016-11-04 18:29:42 +0000" MODIFIED_BY="[Empty name]">
<P>A total of 36.7 million people were living with HIV in 2015. This is an increase from previous years, mostly due to the use of antiretroviral therapy (ART) (<LINK REF="REF-UNAIDS-2016" TYPE="REFERENCE">UNAIDS 2016</LINK>). In many countries, ART has reduced hospitalization, morbidity, and mortality among people living with HIV (<LINK REF="REF-Gilks-2006" TYPE="REFERENCE">Gilks 2006</LINK>; <LINK REF="REF-Hogg-1997" TYPE="REFERENCE">Hogg 1997</LINK>; <LINK REF="REF-Mocroft-1998" TYPE="REFERENCE">Mocroft 1998</LINK>).</P>
<P>Significant public and private resources have been devoted to rapidly scale up efforts in low- and middle-income countries (LMICs) to provide access to first-line ART. In 2014, only 40% of eligible people in LMICs were receiving ART. These efforts to scale-up access to ART should be accompanied by initiatives to determine the most effective first-line therapy (<LINK REF="REF-UNAIDS-2016" TYPE="REFERENCE">UNAIDS 2016</LINK>), which can be used in diverse populations.</P>
<P>ART guidelines were first published by the World Health Organization (WHO) in 2002 (<LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>), and were updated in 2006, 2010, 2013, 2014, and 2015 (<LINK REF="REF-WHO-2015b" TYPE="REFERENCE">WHO 2015b</LINK>). For countries with limited resources, the WHO recommends a public health approach to ART to improve access, simplify clinical decision making, standardize regimens, and standardize the monitoring and management of toxicity and drug interactions (<LINK REF="REF-Gilks-2006" TYPE="REFERENCE">Gilks 2006</LINK>). For any initial regimen, the potency, durability of efficacy, ease of administration and storage, tolerability, and toxicity need to be balanced with cost and availability (<LINK REF="REF-Gilks-2006" TYPE="REFERENCE">Gilks 2006</LINK>). These guidelines provide a framework for choice of medication in most countries. However, when the recommended drugs have different costs and toxicity profiles, head-to head comparisons are necessary to determine which medication should be the choice of preference for clinicians. The more recent guidelines integrate more evidence and are in favour of an earlier start to ART (CD4 cell count of 500 cells/mm<SUP>3</SUP> or less as opposed to the previous threshold of 350 cells/mm<SUP>3</SUP>) in active tuberculosis, hepatitis B co-infection with severe liver disease, pregnant and breastfeeding women, children under five years of age, and sero-discordant couples (<LINK REF="REF-WHO-2014" TYPE="REFERENCE">WHO 2014</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-11-04 19:19:30 +0000" MODIFIED_BY="[Empty name]">
<P>The WHO Model List of Essential Medicines describes three classes of antiretroviral drugs for treatment and prevention of HIV infection: Nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI) and protease inhibitors (<LINK REF="REF-WHO-2015a" TYPE="REFERENCE">WHO 2015a</LINK>). In 2006 the WHO recommended that initial ART should be with one of three regimens: two NRTIs plus efavirenz (EFV), two NRTIs plus nevirapine (NVP), or two NRTIs plus abacavir (ABC) (<LINK REF="REF-Gilks-2006" TYPE="REFERENCE">Gilks 2006</LINK>; <LINK REF="REF-WHO-2006" TYPE="REFERENCE">WHO 2006</LINK>). ABC is not a NNRTI and didn't qualify for evaluation in this review. The NRTI combination drugs could either be zidovudine (AZT) plus lamivudine (3TC), or stavudine (d4T) plus 3TC. Stavudine is no longer recommended as a first-line regimen, given its known metabolic toxicities and should be used only when no other drug can be offered (<LINK REF="REF-WHO-2015b" TYPE="REFERENCE">WHO 2015b</LINK>). The current recommendations suggest that the preferred first-line regimen be composed of tenofovir (TDF) and 3TC or emcitrabine (FTC) with EFV. TDF could be replaced with AZT and EFV with NVP in the event that drugs in the preferred regimen are unavailable or contraindicated (<LINK REF="REF-WHO-2015b" TYPE="REFERENCE">WHO 2015b</LINK>). Protease inhibitors can also be used in special circumstances (<LINK REF="REF-WHO-2015b" TYPE="REFERENCE">WHO 2015b</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2016-11-04 19:16:43 +0000" MODIFIED_BY="[Empty name]">
<P>Protease inhibitors cost more, have higher pill burdens, and have dietary constraints associated with their use. Protease inhibitors are also linked to serious long-term metabolic disorders, most notably an increased risk of lipodystrophy and hyperlipidaemia (<LINK REF="REF-Moyle-2000" TYPE="REFERENCE">Moyle 2000</LINK>; <LINK REF="REF-BHIVA-2001" TYPE="REFERENCE">BHIVA 2001</LINK>). Moreover, a meta-analysis of 12 trials revealed that NNRTI-based regimens were better than protease inhibitor-based regimens for virologic suppression (<LINK REF="REF-Chou-2006" TYPE="REFERENCE">Chou 2006</LINK>).</P>
<P>NNRTIs have a more favourable adverse effect profile than protease inhibitors, are cheaper, and are easier to administer. They are also more cost-effective (<LINK REF="REF-Beck-2008" TYPE="REFERENCE">Beck 2008</LINK>). Their main disadvantage is that a single mutation may confer resistance to the entire class of NNRTIs, since cross-resistance among agents of this class is nearly universal (<LINK REF="REF-Deeks-2001" TYPE="REFERENCE">Deeks 2001</LINK>; <LINK REF="REF-Dybul-2002" TYPE="REFERENCE">Dybul 2002</LINK>).</P>
<P>NVP may be responsible for severe or fatal hepatotoxicity, and a rash which may present in severe form as Stevens-Johnson syndrome. Nevertheless, NVP is the NNRTI of choice for pregnant women because EFV may be teratogenic(<LINK REF="REF-DHHS-2001a" TYPE="REFERENCE">DHHS 2001a</LINK>). EFV may cause a rash and central nervous system symptoms such as dizziness, somnolence, insomnia, drowsiness, nightmares, hallucinations, and poor concentration (<LINK REF="REF-DHHS-2001b" TYPE="REFERENCE">DHHS 2001b</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-10-28 18:09:16 +0100" MODIFIED_BY="[Empty name]">
<P>Providing evidence on the more appropriate choice of NNRTI with respect to efficacy, durability, and tolerability, is important to patients, caregivers, and policymakers worldwide. In the previous version of our review we found that EFV and NVP had similar efficacies, but different toxicity profiles (<LINK REF="REF-Mbuagbaw-2010" TYPE="REFERENCE">Mbuagbaw 2010</LINK>).</P>
<P>The current review update represents a collaborative effort between the Cochrane Infectious Diseases Group, the University of California, San Francisco (UCSF), the School of Public Health of the University of Minnesota, the U.S. Centers for Disease Control and Prevention (CDC), the University of Cape Town, and the WHO to address questions through systematic reviews regarding the optimum first-line ART regimen in patients living with HIV in low- and middle-income countries. The previous review was used in the development of the 2009 WHO ART treatment guidelines (<LINK REF="REF-WHO-2009" TYPE="REFERENCE">WHO 2009</LINK>).</P>
<P>In the past five years, the body of evidence on NNRTI's has grown, especially among people co-infected with tuberculosis. This Cochrane Review update responds to the need for evidence-based recommendations for managing HIV and tuberculosis co-morbidity.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-10-28 18:12:24 +0100" MODIFIED_BY="[Empty name]">
<P>To determine which non-nucleoside reverse transcriptase inhibitor, either EFV or NVP, is more effective in suppressing viral load when given in combination with two nucleoside reverse transcriptase inhibitors as part of initial antiretroviral therapy for HIV infection in adults and children.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-11-22 09:14:05 +0000" MODIFIED_BY="Anne-Marie Stephani">
<SELECTION_CRITERIA MODIFIED="2016-11-04 18:37:29 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2016-10-28 18:12:47 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials (RCTs) <BR/>
</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-10-28 18:13:02 +0100" MODIFIED_BY="[Empty name]">
<P>We included adults and children infected with HIV and without prior exposure to antiretroviral therapy (ART), and women who had received short courses of NNRTIs for the prevention of mother-to-child transmission. We excluded pregnant or lactating women and children under five years of age.</P>
<P>Relevant subpopulations of interest were participants with the following:<BR/>
</P>
<UL>
<LI>concurrent hepatitis B virus infection;</LI>
<LI>concurrent hepatitis C virus infection;</LI>
<LI>concurrent tuberculosis.</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-11-04 18:37:29 +0000" MODIFIED_BY="[Empty name]">
<P>We considered triple-drug antiretroviral combination regimens for initial therapy containing two NRTIs plus either EFV or NVP at any dose (EFV + 2NRTIs versus NVP + 2NRTIs). The NRTIs in each combination did not need to be specified, but if they were specified, they must have been the same in both the EFV and NVP arms, such that the only difference in the regimens was the NNRTI. We included trials with additional trial arms, but we only evaluated the EFV-containing and NVP-containing trial arms in this review.</P>
<P>We compared EFV-containing and NVP-containing triple-drug regimens with regard to therapeutic efficacy, using plasma HIV ribonucleic acid (RNA) concentration as a surrogate marker for clinical progression. Plasma HIV RNA has been demonstrated to be a reliable predictor of HIV disease progression (<LINK REF="REF-Lau-2007" TYPE="REFERENCE">Lau 2007</LINK>; <LINK REF="REF-Mellors-2007" TYPE="REFERENCE">Mellors 2007</LINK>).</P>
<P>An earlier Cochrane review of stavudine (d4T), lamivudine (3TC) and NVP, <LINK REF="REF-Siegfried-2006" TYPE="REFERENCE">Siegfried 2006</LINK>, analysed studies that compared this regimen to any other available regimen used in the treatment of HIV/AIDS in treatment-naïve or previously-treated adults and adolescents. We included one trial in this review, <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>, which was also included in <LINK REF="REF-Siegfried-2006" TYPE="REFERENCE">Siegfried 2006</LINK> as it compared this regimen to another that contained d4T, 3TC, and EFV in participants who had never received ART.</P>
<P>We planned to extract data from trials that included participants irrespective of their exposure to ART, but provided separate reporting and analysis of the ART-naïve group. By so doing, we could analyse the data for participants of interest from papers that included both ART-naïve and ART-exposed populations.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-11-03 16:42:31 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-11-03 16:42:31 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>The percentage of participants achieving undetectable plasma HIV RNA concentration (viral load) over time (virological success). For this outcome we used the lower limit of HIV RNA detection, and the time frame reported by the trial authors.</LI>
<LI>Mortality.</LI>
<LI>Progression to AIDS (clinical). We assessed clinical progression by the proportion of participants that progressed either to the Centers for Disease Control and Prevention (CDC)-defined AIDS (stage III to stage IV disease) or who developed a second opportunistic infection or malignancy.</LI>
<LI>All severe adverse events. We classified these according to grade 1 to 4 of the Adverse Event Toxicity Scale (<LINK REF="REF-NIAID_x002f_NIH-2004" TYPE="REFERENCE">NIAID/NIH 2004</LINK>), and reported them as the proportion of participants that experienced grade 3 and 4 clinical or laboratory adverse events. Using this scale, grade 1 and 2 denote mild to moderate symptoms, grade 3 denotes serious symptoms, and grade 4 denotes life-threatening events requiring significant clinical intervention.</LI>
<LI>Discontinuation rate. We defined this variable as the proportion of study participants who either stopped their treatment regimens totally or switched for any reason associated with the regimen.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-10-28 18:16:25 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Change in mean CD4 cell count (immunological response).</LI>
<LI>Treatment failure. We defined this variable as the proportion of participants with incomplete viral load suppression or who experienced a virological rebound in the time frame reported by the trial authors.</LI>
<LI>Prevention of sexual transmission of HIV. We defined this as the risk of sexual partners not acquiring HIV from the study participant.</LI>
<LI>Development of ART drug resistance. We defined this as the acquisition of major genotypic resistance mutations as reported by the trial authors.</LI>
<LI>Individual adverse events</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-11-22 09:14:05 +0000" MODIFIED_BY="Anne-Marie Stephani">
<P>We performed the literature searches with the assistance of the HIV/AIDS Review Group Information Specialist. We formulated a comprehensive and exhaustive search strategy in an attempt to identify all relevant studies, regardless of language or publication status (published, unpublished, in press, or in progress).</P>
<ELECTRONIC_SEARCHES MODIFIED="2016-11-22 09:14:05 +0000" MODIFIED_BY="Anne-Marie Stephani">
<P>Our initial search included the following electronic databases.</P>
<UL>
<LI>MEDLINE from 1996 to 12 August 2016 (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</LI>
<LI>Embase from 1996 to 12 August 2016 (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) from 1996 to 12 August 2016 (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</LI>
<LI>National Library of Medicine (NLM) Gateway from 1996 to 2009 (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</LI>
<LI>The World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov for ongoing trials (inception to 12 August 2016).</LI>
<LI>LILACS (Latin American and Caribbean Health Sciences Literature) from 1996 to 12 August 2016.</LI>
<LI>Web of Science from 1996 to 12 August 2016.</LI>
</UL>
<P>The search strategy included text terms such as efavirenz, EFV, EFZ , Sustiva, Stocrin, nevirapine, NVP, Viramune, Nevimune, non-nucleoside reverse transcriptase inhibitor, NNRTI, protease inhibitor-sparing, non-protease inhibitor- containing.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-11-04 19:19:39 +0000" MODIFIED_BY="[Empty name]">
<P>We handsearched the reference lists of all pertinent reviews and studies found. We contacted research organizations and experts in the field for unpublished and ongoing studies. We conducted literature searches from 1996 to 2016 the years during which NNRTIs have been approved and been available on the market.</P>
<SUBSECTION>
<HEADING LEVEL="4">Limits</HEADING>
<P>We performed the literature searches without limits to language or setting. The searches were limited to human studies published from 1996 (start of the triple-drug combination ART era) to the present.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<UL>
<LI>RCTs</LI>
<LI>Trials evaluating first-line ART regimens that compared EFV to NVP as part of a three-drug treatment regimen.</LI>
<LI>Trials that provided sufficient regimen-specific information (dosage, presentation, NRTI combination drugs) about first-line drugs to compare regimens and outcomes of interest.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<UL>
<LI>Non-RCTs.</LI>
<LI>Studies evaluating first-line single or double antiretroviral regimens.</LI>
<LI>Studies evaluating first-line ART with more than three antiretroviral drugs.</LI>
</UL>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-11-04 18:45:52 +0000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<STUDY_SELECTION MODIFIED="2016-11-03 18:47:01 +0000" MODIFIED_BY="[Empty name]">
<P>At least two review authors screened all identified citations from the literature search results by title/abstract to identify articles for inclusion in the review (LM, SM, JI, AS, NS). We retrieved the full-text articles of citations that potentially met the inclusion criteria of the review. We assessed the articles for inclusion based on study design, types of participants, interventions, and outcome measures. We resolved any disagreements by discussion or by consulting a third review author. If we were unable to resolve disagreements because we required further information, we allocated the study to the list of studies awaiting classification. We listed all excluded studies and the reasons for exclusion in a '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table. In addition, we constructed a PRISMA flow diagram to illustrate the study selection process (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-11-03 18:47:28 +0000" MODIFIED_BY="[Empty name]">
<P>We designed and tested a data extraction form. Two review authors independently extracted data from each included trial using the data extraction form (AS, LM, SM). Both review authors verified the extracted data, which included methods, participant characteristics, interventions, and outcomes. Both review authors then compared the extracted data and resolved any discrepancies by discussion. In the event that the review authors disagreed on the abstraction of study details, we contacted a third review author to resolve the disagreement. We attempted to contact the principal investigators of the included trials in the case of any missing data or if we required clarification about the included trials.<BR/>
</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-11-04 18:45:52 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed the risk of bias by the following criteria.</P>
<UL>
<LI>Sequence generation: how the allocation sequence was generated and whether it was adequate.</LI>
<LI>Allocation concealment: how the allocation sequence was concealed and whether it was adequate.</LI>
<LI>Blinding of participants, personnel, and outcome assessors.</LI>
<LI>The description of the completeness of outcome data for each main outcome.</LI>
<LI>Selective outcome reporting.</LI>
<LI>Other potential sources of bias (for example, funding).</LI>
<LI>Baseline data reported.</LI>
</UL>
<P>We rated studies as being at either high, low, or unclear risk of bias. At least two review authors independently completed the 'Risk of bias' tables (see <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-10-28 18:34:21 +0100" MODIFIED_BY="[Empty name]">
<P>We used Review Manager (RevMan) 5 for statistical analyses (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We presented the results with 95% confidence intervals (CIs). We calculated the risk ratio (RR) and the odds ratio (OR) for binary data, the weighted mean difference (WMD) for continuous data measured on the same scale, and the standardized mean difference (SMD) for continuous data measured on different scales.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-10-28 18:34:40 +0100" MODIFIED_BY="[Empty name]">
<P>The unit of analysis was the individual participant.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-10-28 18:34:49 +0100" MODIFIED_BY="[Empty name]">
<P>We analysed the data according to the intention-to-treat (ITT) principle, with participants analysed in the groups to which they were randomized. We did not make any assumptions regarding the outcomes of participants who were lost to follow-up and we conducted complete case analyses. We also attempted to contact the trial authors for missing data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-10-28 18:34:53 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed statistical heterogeneity by inspecting the forest plots for overlap in the confidence intervals (CIs) and by applying the Chi<SUP>2</SUP> test of homogeneity (P &lt; 0.10 was the threshold for statistical significance) and the I<SUP>2</SUP> statistic, with values of less than 50% denoting moderate heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-10-28 18:34:58 +0100" MODIFIED_BY="[Empty name]">
<P>We used funnel plots to explore publication bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-10-28 18:35:03 +0100" MODIFIED_BY="[Empty name]">
<P>We analysed the data using RevMan 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We used a random-effect model to account for heterogeneity.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-10-28 18:36:38 +0100" MODIFIED_BY="[Empty name]">
<P>First we assessed the included trials for clinical heterogeneity. If we found that trials were similar enough to combine, we performed a meta-analysis and assessed statistical heterogeneity. If there was significant unexplained statistical heterogeneity, we conducted a meta-analysis using a random-effects model.</P>
<P>If there was clinical heterogeneity and the data were available, we planned to explore this using the following subgroup analyses: age (children/adolescents/adults), sex (male/ female), baseline CD4 count, dosage, concurrent illness (hepatitis, tuberculosis) and study design. The efficacy of NVP may be associated with dosage (<LINK REF="REF-Veldkamp-2001" TYPE="REFERENCE">Veldkamp 2001</LINK>).</P>
<P>For the purposes of this Cochrane Review, undetectable plasma HIV RNA (viral load) served as the primary endpoint. For the meta-analyses, we defined an undetectable viral load as less than 500 copies/mL cut-off, in order to include as many trials as possible.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-10-28 18:36:56 +0100" MODIFIED_BY="[Empty name]">
<P>We pooled the results from the included trials to determine the RR of achieving undetectable viral load. We planned to perform a sensitivity analysis to evaluate bias introduced by variability in study design, threshold of undetectable viral load, and specification of the two NRTIs. Finally, we conducted a test for homogeneity to ensure that the differences among the results of each trial could be expected by chance. We also performed a sensitivity analysis for studies with a high risk of bias.</P>
<P>When interventions and study populations were sufficiently similar across different studies, we pooled the outcomes and examined the differences between the two models using both fixed-effect and random-effects models. Since there were no significant differences between the two models, we presented the final results using a random-effects model.</P>
<SUBSECTION>
<HEADING LEVEL="3">Quality of the evidence</HEADING>
<P>We assessed the quality of the body of evidence using the GRADE approach (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>), which defines the quality of evidence for each outcome as the extent to which one can be confident that an estimate of effect or association is close to the quantity of specific interest (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). The quality rating across studies has four levels: high, moderate, low, or very low. RCTs are categorized as high quality but can be downgraded; similarly, other types of controlled trials and observational studies are categorized as low quality but can be upgraded. Factors that decrease the quality of evidence include limitations in design, indirectness of evidence, unexplained heterogeneity or inconsistency of results, imprecision of results, or high probability of publication bias. Factors that can increase the quality level of a body of evidence include having a large magnitude of effect, whether plausible confounding would reduce a demonstrated effect, and if there is a dose-response gradient. We used GRADEpro Guideline Development Tool (GDT) to construct 'Summary of findings' tables (<LINK REF="REF-GRADEpro-2014" TYPE="REFERENCE">GRADEpro 2014</LINK>).</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-11-22 09:17:08 +0000" MODIFIED_BY="Anne-Marie Stephani">
<STUDY_DESCRIPTION MODIFIED="2016-11-22 09:17:08 +0000" MODIFIED_BY="Anne-Marie Stephani">
<SEARCH_RESULTS MODIFIED="2016-11-22 09:17:08 +0000" MODIFIED_BY="Anne-Marie Stephani">
<P>We conducted the literature searches up to 12 August 2016, which yielded an additional 1232 titles. Three review authors (LM, AS, and GR) independently screened the titles, abstracts, and descriptor terms of all downloaded material from the electronic searches to identify potentially relevant studies. We discarded reports that were irrelevant to this Cochrane Review, and we obtained the full-text articles of all potentially relevant or uncertain reports. Three review authors (LM, AS and GR) independently assessed the full-text articles. A fourth review author, NS, acted as arbiter where there was disagreement. The review authors LM, AS, GR, and JI independently extracted data from trials that met the inclusion criteria. Finally, where resolution was not possible because we required further information, we assigned the study to the list of those awaiting classification. We attempted to contact the trial authors for further clarification of data. We had previously identified seven randomized trials as meeting inclusion criteria. From the updated searches, we screened 1176 articles for eligibility after removal of duplicates. Agreement on screening for full text appraisal in this update was moderate (&#408; 0.52; 95% CI 0.26 to 0.76; P &lt; 0.001). We selected 16 full-text articles for detailed appraisal, of which we identified six new studies. Agreement on inclusion/exclusion in this update was very good (&#408; 0.86; 85% CI 0.59 to 1.00; P &lt; 0.001) One of these was the full text publication of a study previously included as an abstract (<LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>), so only five trials were newly published studies, giving a total of 12 studies. We have presented a PRISMA diagram, which illustrates the study selection process, in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-11-04 18:54:53 +0000" MODIFIED_BY="[Empty name]">
<P>Twelve trials met the inclusion criteria of this Cochrane Review. We included seven RCTs in <LINK REF="REF-Mbuagbaw-2010" TYPE="REFERENCE">Mbuagbaw 2010</LINK>, the previous version of this review (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>; <LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>; <LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>). In this review update five articles that reported on five trials met the inclusion criteria (<LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK>; <LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK>; <LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>; <LINK REF="STD-Wester-2010" TYPE="STUDY">Wester 2010</LINK>). The findings reported here are from published papers.</P>
<P>See the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table.</P>
<SUBSECTION>
<HEADING LEVEL="4">Locations</HEADING>
<P>One trial was a multinational trial that included 17 countries (<LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>). Five trials were conducted in Africa: one in Botswana (<LINK REF="STD-Wester-2010" TYPE="STUDY">Wester 2010</LINK>), one in Mozambique (<LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>), one in Burkina Faso (<LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK>), one in Senegal (<LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK>), and one in both Senegal and Cameroon (<LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK>). There were two trials from India (<LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>) and one trial each: from Mexico (<LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>), Spain (<LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>), Thailand (<LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>), and the USA (<LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>All included trials used EFV 600 mg and compared it to either NVP 400 mg once daily (<LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>), or NVP 200 mg twice daily (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK>; <LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>; <LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK>; <LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>; <LINK REF="STD-Wester-2010" TYPE="STUDY">Wester 2010</LINK>). The 2NN trial, <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>, had trial arms that used NVP 400 mg once daily and NVP 200 mg twice daily.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>Ten trials reported virological success (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK>; <LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>; <LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>; <LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>). Eight trials reported mortality (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>; <LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>). Five trials reported progression to AIDS (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>). Eight trials reported adverse events (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>; <LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>; <LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>). Nine trials reported a discontinuation rate (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>; <LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>; <LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>). Nine trials reported change in CD4 count (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK>; <LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>; <LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>; <LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>). Five trials reported treatment failure (<LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK>; <LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>; <LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>), and four reported development of drug resistance (<LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK>; <LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>; <LINK REF="STD-Wester-2010" TYPE="STUDY">Wester 2010</LINK>). None of the included trials reported on sexual transmission of HIV.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Co-morbidities</HEADING>
<P>In five included trials, the participants were concurrently receiving treatment for tuberculosis (<LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK>; <LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>). Only one trial reported baseline co-infection with hepatitis B and C virus (<LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Length of follow-up</HEADING>
<P>The shortest length of follow-up was 24 weeks (<LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>), and the longest was 156 weeks (<LINK REF="STD-Wester-2010" TYPE="STUDY">Wester 2010</LINK>). Five trials ran for 48 weeks (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>), two trials for 96 weeks (<LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK>; <LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>), one for 36 weeks (<LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>), and one for 72 weeks (<LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK>).</P>
<P>We have provided further details on the included studies in an additional table (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-11-04 18:59:19 +0000" MODIFIED_BY="[Empty name]">
<P>We have provided our reasons for excluding 26 potentially relevant studies in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table. In this update, 11/26 studies were excluded: 5 did not have the comparison of interest (<LINK REF="STD-Antela-2004" TYPE="STUDY">Antela 2004</LINK>; <LINK REF="STD-He-2011" TYPE="STUDY">He 2011</LINK>; <LINK REF="STD-Musiime-2012" TYPE="STUDY">Musiime 2012</LINK>; <LINK REF="STD-PENPACT-2011" TYPE="STUDY">PENPACT 2011</LINK>; <LINK REF="STD-Prendergast-2011" TYPE="STUDY">Prendergast 2011</LINK>), 4 were sub-studies of already included studies (<LINK REF="STD-Bonnet-2013b" TYPE="STUDY">Bonnet 2013b</LINK>; <LINK REF="STD-Mankhatitham-2011" TYPE="STUDY">Mankhatitham 2011</LINK>; <LINK REF="STD-Mankhatitham-2012" TYPE="STUDY">Mankhatitham 2012</LINK>; <LINK REF="STD-Padmapriyadarsini-2013" TYPE="STUDY">Padmapriyadarsini 2013</LINK>), 1 was not an RCT(<LINK REF="STD-Puthanakit-2009b" TYPE="STUDY">Puthanakit 2009b</LINK>) and another was a duplicate (<LINK REF="STD-Swaminathan-2009" TYPE="STUDY">Swaminathan 2009</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-11-04 19:38:44 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed the risk of bias in each included study using the Cochrane 'Risk of bias' assessment tool (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>). We assessed the risk of bias in individual trials across six domains: sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential biases. See the 'Risk of bias' summary (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) and 'Risk of bias' graph (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<ALLOCATION MODIFIED="2016-11-04 17:39:33 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Generation of allocation sequence</HEADING>
<P>Only five trials reported how the allocation sequence was generated. (<LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>; <LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>). The other included trials did not report how they generated the allocation sequence (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK>; <LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>; <LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK>; <LINK REF="STD-Wester-2010" TYPE="STUDY">Wester 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>Only five trials reported that allocation was concealed (<LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>; <LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>). In seven trials, allocation concealment was unclear (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK>; <LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>; <LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>; <LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK>; <LINK REF="STD-Wester-2010" TYPE="STUDY">Wester 2010</LINK>).</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2016-11-03 16:58:12 +0000" MODIFIED_BY="[Empty name]">
<P>Ten trials were reported as open-label studies and we judged them to be at high risk of bias (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK>; <LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK>; <LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>; <LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>; <LINK REF="STD-Wester-2010" TYPE="STUDY">Wester 2010</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>). Only one was blinded (<LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>). <LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK> did not report blinding and therefore we considered it to be at unclear risk of bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-10-28 18:52:09 +0100" MODIFIED_BY="[Empty name]">
<P>We judged three trials as having unclear risk of attrition bias (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK>; <LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK>). The other nine included trials were at low risk of bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-11-04 19:35:28 +0000" MODIFIED_BY="[Empty name]">
<P>One trial did not report all outcomes (<LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>). Two studies did not provide sufficient information to enable us to make a judgement (<LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK>; <LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Reporting of baseline data</HEADING>
<P>Two trials, Sow (<LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK>) and Mateelli (<LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK>,) did not report baseline data, and we considered them as being at unclear risk of bias.</P>
</SUBSECTION>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-11-04 19:38:44 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Funding</HEADING>
<P>Eight trials received funding from governmental sources (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>; <LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>; <LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>; <LINK REF="STD-Wester-2010" TYPE="STUDY">Wester 2010</LINK>) and were judged as low risk of bias. The 2NN study, <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>, was funded by Boehringer-Ingelheim. <LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK> also received funding from Gilead Sciences, Merck, Sharp &amp; Dome, and Abbott Laboratories. We judged them as high risk of bias. <LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK> and <LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK> did not report any source of funding. We judged them as unclear risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Publication bias</HEADING>
<P>We designed our search strategy to detect both published and unpublished studies. We appraised publication bias for our primary outcome of virologic suppression using a funnel plot and found no evidence of publication bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). See <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>.</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-11-11 11:49:37 +0000" MODIFIED_BY="[Empty name]">
<P>All included trials compared EFV 600 mg once daily to NVP 200 mg twice daily or 400 mg once daily.</P>
<P>We performed a primary meta-analysis to compare EFV 600 mg versus all dosages of NVP. We then conducted subgroup analyses to investigate the effect of NVP dosage (200 mg twice daily versus 400 mg once daily) and concurrent treatment for tuberculosis.</P>
<SUBSECTION>
<HEADING LEVEL="4">Efavirenz 600 mg versus nevirapine at any dosage</HEADING>
<P>These results are summarized in 'Summary of findings' table 1 (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Virological success</HEADING>
<P>Virological success was comparable in both treatment groups (risk ratio (RR) 1.04, 95% confidence interval (CI) 0.99 to 1.09; 10 trials, 2438 participants; P = 0.11; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mortality</HEADING>
<P>There were no differences in mortality between the EFV- and NVP-containing regimens (RR 0.84, 95% CI 0.59 to 1.19; 8 trials, 2317 participants; P = 0.32; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Progression to AIDS</HEADING>
<P>In both EFV- and NVP-containing regimens progression to AIDS was comparable (RR 1.23, 95% CI 0.72 to 2.11; 5 trials, 2005 participants; P = 0.46). Statistical heterogeneity was moderate (I<SUP>2 </SUP>statistic = 33%, P = 0.22; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">All severe adverse events</HEADING>
<P>Severe adverse events were comparable in both treatment groups (RR 0.91, 95% CI 0.71 to 1.18; 8 trials, 2329 participants; P = 0.48). Statistical heterogeneity was moderate (I<SUP>2 </SUP>statistic = 43%, P = 0.11; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Discontinuation rate</HEADING>
<P>There was no difference in discontinuation rate between treatment groups (RR 0.93, 95% CI 0.69 to 1.25; 9 trials, 2384 participants; P = 0.62). Statistical heterogeneity was moderate (I<SUP>2</SUP>statistic = 35%, P = 0.14; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in CD4 count/immunological response</HEADING>
<P>Change in CD4 count was comparable in both EFV- and NVP-containing regimens (MD &#8722;3.03; 95% CI &#8722;17.41 to 11.35; 9 trials, 1829 participants; P = 0.68). Statistical heterogeneity was moderate (I<SUP>2</SUP> statistic = 29%, P = 0.19; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Treatment failure</HEADING>
<P>Treatment failure was comparable in both treatment groups (RR 0.97, 95% CI 0.76 to 1.24; 5 trials, 737 participants; P = 0.82; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Sexual transmission of HIV</HEADING>
<P>None of the included studies reported on this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Development of drug resistance</HEADING>
<P>Four studies (988 participants) reported this outcome. Development of drug resistance was lower in the EFV arm (RR 0.76, 95% CI 0.60 to 0.95; 4 trials, 988 participants; P = 0.02; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Individual adverse events</HEADING>
<P>Individual comparisons for each of the adverse events: gastrointestinal (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>), pyrexia (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>), raised alkaline phosphatases (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>), elevated amylase (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>), elevated triglycerides (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>), elevated SGOT (<LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>), elevated SGPT (<LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>) and elevated cholesterol (<LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK>) did not reveal any differences. Central nervous system adverse events were higher in the EFV arm (RR 4.46, 95% CI 1.65 to 12.03; 6 trials, 2049 participants; P = 0.003). Statistical heterogeneity was moderate (I<SUP>2 </SUP>statistic = 44%, P = 0.13; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). Participants in the EFV arm were less likely to have raised transaminases than those in the NVP arm (RR 0.52, 95% CI 0.35 to 0.78; 3 trials, 1799 participants; P = 0.001; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). Participants in the EFV arm were less likely to have neutropenia (RR 0.48, 95% CI 0.28 to 0.82; 3 trials, 1799 participants; P = 0.007; <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>). Participants in the EFV arms were also less likely to have a rash (RR 0.58, 95% CI 0.34 to 1.00; 7 trials, 2277 participants; P = 0.05; <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>). We have summarized the findings for the individual adverse events in 'Summary of findings' table 2 (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Hepatitis co-morbidity</HEADING>
<P>There were insufficient data to explore this subgroup.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Concurrent treatment for tuberculosis</HEADING>
<P>There were no significant subgroup effects for tuberculosis treatment: virological success (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>), mortality (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>), progression to AIDS (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>), discontinuation rate (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Dosage</HEADING>
<P>We found that mortality was lower in the EFV arm than in the NVP 400 mg subgroup (RR 0.34, 95% CI 0.13 to 0.90; P = 0.03; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). One study did not report the dosage of NVP used (<LINK REF="STD-Wester-2010" TYPE="STUDY">Wester 2010</LINK>), and we excluded it from this analysis. Virological success (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>), progression to AIDS (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>) and discontinuation rate (<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>) were similar for both dosages.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-11-22 09:19:07 +0000" MODIFIED_BY="Anne-Marie Stephani">
<SUMMARY_OF_RESULTS MODIFIED="2016-11-22 09:19:07 +0000" MODIFIED_BY="Anne-Marie Stephani">
<P>Twelve randomized controlled trials (RCTs) that included 3278 participants met the inclusion criteria of this Cochrane Review.</P>
<P>There was little or no difference between EFV and NVP in virological success (<I>high quality evidence</I>), probably little or no difference in mortality (<I>moderate quality evidence</I>) and progression to AIDS (<I>moderate quality evidence</I>). We are uncertain whether there is a difference in all severe adverse events (<I>very low quality evidence</I>). There is probably little or no difference in discontinuation rate (<I>moderate quality evidence</I>) and change in CD4 count (<I>moderate quality evidence</I>). There may be little or no difference in treatment failure (<I>low quality evidence</I>). Development of drug resistance is probably slightly less in the EFV arms (<I>moderate quality evidence</I>). No studies were found that looked at sexual transmission of HIV.</P>
<P>When we examined the adverse events individually, EFV probably increased impaired mental function (<I>moderate quality evidence</I>) but reduced elevated transaminases (<I>high quality evidence</I>), reduced cases of neutropenia (<I>high quality evidence</I>), and probably reduced cases of rash (<I>moderate quality evidence</I>). We found that there may be little or no difference in gastrointestinal adverse events (<I>low quality evidence</I>), pyrexia (<I>low quality evidence</I>), raised alkaline phosphatase (<I>low quality evidence</I>), raised amylase (<I>low quality evidence</I>) and raised triglycerides (<I>low quality evidence</I>). There was probably little or no difference in serum glutamic oxaloacetic transaminase (<I>moderate quality evidence</I>), serum glutamic- pyruvic transaminase (<I>moderate quality evidence</I>) and raised cholesterol (<I>moderate quality evidence</I>). NVP slightly increases mortality when given once daily (<I>high quality evidence</I>). There were little or no differences in the primary outcomes for patients who were concurrently receiving treatment for tuberculosis.</P>
<P>This literature is dominated by the landmark 2NN study, <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>, which found no difference between EFV and NVP in a non-inferiority randomized open-label, industry-funded, four-arm trial. Overall <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK> accounted for 1007 (31%) of the 3278 participants randomized.</P>
<P>We did not conduct subgroup analyses by NRTI combination drugs even though of the nine trials that had a NVP 200 mg twice daily arm (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK>; <LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>; <LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK>; <LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>); five used a 3TC/AZT (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK>; <LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>), one trial used the 3TC/d4Tand switched to the 3TC/AZT backbone in the last year (<LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>), and three trials (<LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>; <LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>; <LINK REF="STD-Wester-2010" TYPE="STUDY">Wester 2010</LINK>) used at least two NRTI combinations including 3TC/AZT, 3TC/ABC, 3TC/d4T, or ddI/d4T. Moreover, all of the trials using NVP 400 mg once daily had different NRTI combination drugs. None of the included trials reported the outcome of sexual transmission of HIV. The length of follow-up time, cut-off point for undetectable viral load, dosage of NVP, and study settings varied greatly. We did not find any statistically significant heterogeneity for any of the key outcomes, and the I<SUP>2</SUP> statistic value ranged from 0% to 40%.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-11-03 18:03:43 +0000" MODIFIED_BY="[Empty name]">
<P>We identified literature that met the inclusion criteria of this Cochrane Review that clearly highlights the clinical equivalence of EFV and NVP based on RCTs.</P>
<P>This update includes studies from a wide variety of settings including a large multicentre trial with participants from the USA, Europe, Australia, Thailand, and South Africa (<LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>), but also trials with participants from Mexico (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>), Senegal (<LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK>; <LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK>), Cameroon (<LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK>), Thailand (<LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>), Spain (<LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>), India (<LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>), USA (<LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>), Mozambique (<LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>) and Botswana (<LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK>). These diverse populations support the applicability and generalizability of our findings.</P>
<P>Given optimal adherence, EFV, NVP 200 mg, and NVP 400 mg once daily may result in comparable virological suppression. However, there is a increased risk of mortality in the patients receiving the once-daily NVP regimen. There is insufficient evidence to recommend the use of once daily NVP in regular clinical practice (<LINK REF="REF-Cooper-2007" TYPE="REFERENCE">Cooper 2007</LINK>), and our findings do not support its use.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-11-04 19:42:12 +0000" MODIFIED_BY="[Empty name]">
<P>This body of evidence includes twelve RCTs (3278 participants). The main methodological limitation in the included studies was the lack of blinding. Only one study was blinded (<LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>). In most instances, this did not affect our rating of the quality of evidence for outcomes unlikely to be affected by a lack of blinding such as virological success, mortality and progression to AIDS. In two studies reported as abstracts, risk of bias was unclear in almost all the domains (<LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK>; <LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK>). The cut-off point used to define virological success also differed across studies, but this was related to the quality of the equipment available and did not seem to introduce any heterogeneity in measures of virological success. We did not downgraded for this. We downgraded when adverse events were graded using different scales, the definition of treatment failure varied across studies, industry funded studies contributed most of the data for certain outcomes and confidence intervals were too wide. Overall the quality of the evidence ranged from high to very low.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-11-03 18:44:30 +0000" MODIFIED_BY="[Empty name]">
<P>We minimized biases in the review process by not limiting the literature search by language, by performing a comprehensive search of databases and conference proceedings, and by contacting experts in the field for unpublished and ongoing studies. However, we were unable to fully appraise the trials published only as abstracts and is it unclear what methodological or data items were not captured in this review. We used a funnel plot and found no evidence of publication bias.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-11-11 11:49:50 +0000" MODIFIED_BY="[Empty name]">
<P>A systematic review that compared EFV to NVP in patients co-infected with TB found superior virologic suppression in the EFV arm at the 400 copies/mL cut-off point (but not at the 50 copies/mL cut-off point). Mortality was comparable, but more participants in the NVP arm discontinued treatment (<LINK REF="REF-Jiang-2014" TYPE="REFERENCE">Jiang 2014</LINK>). We found comparable effective of EFV and NVP (using all cut-off points), comparable mortality and no differences in our subgroup analysis of participants on treatment for TB. Another systematic review found EFV to be less likely to lead to virological failure and more likely to induce virological success (<LINK REF="REF-Pillay-2013" TYPE="REFERENCE">Pillay 2013</LINK>). A systematic review of adverse events found EFV to be less likely to be associated with hepatic and cutaneous adverse events, but more likely to be associated with central nervous system adverse events (<LINK REF="REF-Shubber-2013" TYPE="REFERENCE">Shubber 2013</LINK>). The main difference between these systematic reviews and ours is their use of non-randomized studies which may lead to differences in estimates. More so, the apparent poorer performance of NVP might also be induced by the once daily 400 mg regimen, which we found to be inferior to EFV with regard to mortality.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-11-01 20:23:19 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-11-01 20:23:19 +0000" MODIFIED_BY="[Empty name]">
<P>EFV and NVP provide comparable levels of viral load suppression, but have different side-effects. Clinicians need to determine which is the more appropriate for their patients by weighing other factors like availability, pill burden, cost, and concomitant medication. They must also consider individual tolerability and watch carefully for side-effects, some of which can be fatal.</P>
<P>While subtle differences in risk of toxicity, discontinuation, and resistance may exist, we found that EFV and NVP have similar clinical efficacies. NVP given at the once daily dose of 400 mg led to higher mortality rates than EFV.</P>
<P>The use of NVP or EFV in paediatric populations has not been examined in randomized controlled trials (RCTs), and all inferences need to be drawn from trials conducted in adults.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-11-01 19:59:44 +0000" MODIFIED_BY="[Empty name]">
<P>Although more trials would provide a more robust body of evidence, it is unlikely that additional trials will be conducted, at least in adults and adolescents. Prospective cohort studies are the most likely source of improved data on side effects, discontinuation, and development of resistance. One particular population of interest is women who have received single-dose NVP for prevention of mother-to-child transmission of HIV, although the World Health Organization (WHO) no longer recommends it.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-11-01 20:05:05 +0000" MODIFIED_BY="[Empty name]">
<P>Dr Lawrence Mbuagbaw was awarded a Reviews for Africa Programme Fellowship, funded by a grant from the Nuffield Commonwealth Programme, through The Nuffield Foundation.</P>
<P>We acknowledge the assistance of the South African Cochrane Centre and the Cochrane HIV/AIDS Review Group Mentoring Programme. James Irlam provided mentorship to Lawrence Mbuagbaw for the first version of this review (<LINK REF="REF-Mbuagbaw-2010" TYPE="REFERENCE">Mbuagbaw 2010</LINK>).</P>
<P>We gratefully acknowledge the contributions of Nancy Santesso and Holger Schünemann for their consultation and technical expertise with GRADEpro and GRADE tables presented in the prior versions of this review. We also thank Hacsi Horvath and Joy Oliver for their assistance with the literature searches. We thank Gail Kennedy, Dr Eliza Humphreys, Dr Larry Chang, and Dr Jamal Harris for their collaboration and support.</P>
<P>We also acknowledge the trial authors who shared their data.</P>
<P>The editorial base of the Cochrane Infectious Diseases Group is funded by UK aid from the UK Government for the benefit of developing countries (Grant: 5242). The views expressed in this review do not necessarily reflect UK government policy.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-11-04 16:27:20 +0000" MODIFIED_BY="[Empty name]">
<P>Disclaimer: we prepared this article while Alicen Spaulding was employed at the University of Minnesota. The opinions expressed in this article are those of the review authors' and do not reflect the view of the National Institutes of Health, the Department of Health and Human Services, or the United States Government. Alice Spaulding received salary support from the WHO for this project. Lawrence Mbuagbaw, James Irlam, Sara Mursleen and George Rutherford have no known conflicts of interest. Nandi Siegfried provides technical consultation on the efficacy of drugs for a managed care organization (MEDSCHEME), for which she receives an honorarium.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-11-01 20:11:26 +0000" MODIFIED_BY="[Empty name]">
<P>All review authors contributed to the design and conduct of this review, as well as with manuscript drafting and submission. LM, SM, JI, AS and NS screened articles for inclusion. AS, LM and SM extracted data and assessed risk of bias. LM, AS, GR and NS worked on the summary of findings tables. </P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-11-03 16:58:12 +0000" MODIFIED_BY="[Empty name]">
<P>AIDSearch was no longer available at the time of the literature searches.</P>
<P>We searched the National Library of Medicine Gateway in 2009, but this was unavailable in 2016.</P>
<P>In the protocol we stated that we would include randomized controlled trials and observational cohorts (<LINK REF="REF-Mbuagbaw-2009" TYPE="REFERENCE">Mbuagbaw 2009</LINK>). We did not include any observational cohorts in this review because we found sufficient evidence for randomized trials.</P>
<P>In the protocol, we defined undetectable viral load as less than 500 copies/mL in order to enable inclusion of as many trials as possible and 50 copies/mL limit of detection for subgroup analyses. Six included trials used the 50 copies/mL cut-off (<LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>; <LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>) and two trials used a cut-off of 400 copies/mL (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>). The other included trials did not specify what cut-off point they used (<LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK>; <LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>; <LINK REF="STD-Wester-2010" TYPE="STUDY">Wester 2010</LINK>).</P>
<P>We did not extract any time-to-event data.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2016-11-01 20:15:41 +0000" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-12-05 15:39:30 +0000" MODIFIED_BY="Anne-Marie Stephani">
<STUDIES MODIFIED="2016-11-09 18:06:27 +0000" MODIFIED_BY="Anne-Marie Stephani">
<INCLUDED_STUDIES MODIFIED="2016-11-04 20:11:21 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ayala-Gayt_x00e1_n-2004" MODIFIED="2016-11-04 19:11:36 +0000" MODIFIED_BY="[Empty name]" NAME="Ayala Gaytán 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-11-04 19:11:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ayala Gaytán JJ, Zapata de La Garza ER, Chávez García M, Valdovinos Chávez SB</AU>
<TI>[Nevirapine or efavirenz in combination with two nucleoside analogues in HIV-infected antiretroviral-naïve patients]</TI>
<SO>Medicina Interna de México</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>1</NO>
<PG>24-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811951"/><IDENTIFIER TYPE="OTHER" VALUE="CN-00641209"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811950"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonnet-2013a" MODIFIED="2016-11-03 16:12:02 +0000" MODIFIED_BY="[Empty name]" NAME="Bonnet 2013a" YEAR="2013">
<REFERENCE MODIFIED="2016-11-03 16:12:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonnet M, Bhatt N, Baudin E, Silva C, Michon C, Taburet AM, et al</AU>
<TI>Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial</TI>
<SO>Lancet Infectious diseases</SO>
<YR>2013</YR>
<VL>13</VL>
<NO>4</NO>
<PG>303-12</PG>
<IDENTIFIERS MODIFIED="2014-04-11 19:33:01 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811953"/><IDENTIFIER TYPE="PUBMED" VALUE="23433590"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811952"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Landman-2014" MODIFIED="2016-11-03 16:08:59 +0000" MODIFIED_BY="[Empty name]" NAME="Landman 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-11-03 16:08:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Landman R, Koulla-Shiro S, Sow PS, Ngolle M, Diallo MB, Guèye NF, et al</AU>
<TI>Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial</TI>
<SO>Antiviral Therapy</SO>
<YR>2014</YR>
<VL>19</VL>
<NO>1</NO>
<PG>51-9</PG>
<IDENTIFIERS MODIFIED="2014-09-15 17:59:17 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811955"/><IDENTIFIER TYPE="PUBMED" VALUE="23970206"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811954"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manosuthi-2009a" MODIFIED="2016-11-03 16:09:07 +0000" MODIFIED_BY="[Empty name]" NAME="Manosuthi 2009a" YEAR="2009">
<REFERENCE MODIFIED="2016-11-03 16:09:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, et al</AU>
<TI>A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2009</YR>
<VL>48</VL>
<NO>12</NO>
<PG>1752-9</PG>
<IDENTIFIERS MODIFIED="2009-07-01 10:12:17 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811957"/><IDENTIFIER TYPE="PUBMED" VALUE="19438397"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811956"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Mateelli-2013" MODIFIED="2016-11-04 20:11:21 +0000" MODIFIED_BY="[Empty name]" NAME="Mateelli 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-11-04 20:11:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mateelli A, Kouanda S, Saleri N, Ouedraogo G</AU>
<TI>Efficacy and safety of nevirapine- vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study</TI>
<SO>20th Conference on Retroviruses and Opportunistic Infections. 3-16 March, 2013</SO>
<YR>2013</YR>
<PG>Abstract 47462</PG>
<CY>Atlanta, USA</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811959"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-10-14 14:54:08 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811958"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-N_x00fa__x00f1_ez-2002" MODIFIED="2016-11-04 19:11:53 +0000" MODIFIED_BY="[Empty name]" NAME="Núñez 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-11-04 19:11:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Núñez M, Soriano V, Martin-Carbonero L, Barrios A, Barreiro P, Blanco F, et al</AU>
<TI>SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naïve individuals</TI>
<SO>HIV Clinical Trials</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>3</NO>
<PG>186-94</PG>
<IDENTIFIERS MODIFIED="2009-06-19 07:43:30 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811961"/><IDENTIFIER TYPE="PUBMED" VALUE="12032877"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811960"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sinha-2013" MODIFIED="2016-11-04 19:12:06 +0000" MODIFIED_BY="[Empty name]" NAME="Sinha 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-11-04 19:12:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sinha S, Raghunandan P, Chandrashekhar R, Sharma SK, Kumar S, Dhooria S, et al</AU>
<TI>Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naïve patients with HIV and tuberculosis infections in India: a pilot study</TI>
<SO>BMC Infectious Diseases</SO>
<YR>2013</YR>
<VL>13</VL>
<PG>482</PG>
<IDENTIFIERS MODIFIED="2014-09-15 17:56:48 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811963"/><IDENTIFIER TYPE="PUBMED" VALUE="24134449"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811962"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sow-2006" MODIFIED="2016-11-04 20:11:02 +0000" MODIFIED_BY="[Empty name]" NAME="Sow 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-11-04 20:11:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sow PG, Badiane M, Diallo PD, Lo I, Ndiaye B, Gaye AM</AU>
<TI>Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]</TI>
<SO>XVI International AIDS Conference; 13-18 August, 2006</SO>
<YR>2006</YR>
<CY>Toronto, Canada</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811965"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811964"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swaminathan-2011" MODIFIED="2016-11-03 17:07:29 +0000" MODIFIED_BY="[Empty name]" NAME="Swaminathan 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-11-03 17:07:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Ramesh Kumar S, Iliayas S, et al</AU>
<TI>Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial</TI>
<SO>Clinical infectious disease</SO>
<YR>2011</YR>
<VL>53</VL>
<NO>7</NO>
<PG>716-724</PG>
<IDENTIFIERS MODIFIED="2016-11-03 16:57:24 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811967"/><IDENTIFIER MODIFIED="2016-11-03 16:57:24 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=""/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811966"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-den-Berg_x002d_Wolf-2008" MODIFIED="2016-09-26 12:07:46 +0100" MODIFIED_BY="[Empty name]" NAME="van den Berg-Wolf 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-09-26 12:07:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, Chen L, et al</AU>
<TI>Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons</TI>
<SO>HIV Clinical Trials</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>5</NO>
<PG>324-36</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811969"/><IDENTIFIER TYPE="PUBMED" VALUE="18977721"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811968"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Leth-2004" MODIFIED="2016-09-26 12:08:33 +0100" MODIFIED_BY="[Empty name]" NAME="van Leth 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-09-26 12:08:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al</AU>
<TI>Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<NO>9417</NO>
<PG>1253-63</PG>
<IDENTIFIERS MODIFIED="2009-06-19 07:43:30 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811971"/><IDENTIFIER TYPE="PUBMED" VALUE="15094269"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811970"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wester-2010" MODIFIED="2016-09-26 12:09:08 +0100" MODIFIED_BY="[Empty name]" NAME="Wester 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-09-26 12:09:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wester CW, Thomas AM, Bussmann H, Moyo S, Makhema JM, Gaolathe T, et al</AU>
<TI>Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana</TI>
<SO>AIDS (London, England)</SO>
<YR>2010</YR>
<VL>24 Suppl 1</VL>
<PG>S27-36</PG>
<IDENTIFIERS MODIFIED="2014-09-15 17:57:59 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811973"/><IDENTIFIER TYPE="PUBMED" VALUE="20023437"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811972"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-11-09 18:06:27 +0000" MODIFIED_BY="Anne-Marie Stephani">
<STUDY DATA_SOURCE="PUB" ID="STD-Antela-2004" MODIFIED="2016-11-04 20:11:48 +0000" MODIFIED_BY="[Empty name]" NAME="Antela 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-11-04 20:11:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Antela A, Iribarren JA, Mahillo B, Santos I, Ribera E, Gutierrez C, et al</AU>
<TI>Final analysis of a prospective, randomized, open-label, multicentre trial in naïve, HIV-1-infected patients, comparing ZDV/3TC vs d4T/ddI, plus efavirenz, nevirapine or indinavir/ritonavir (AMADEUS 01 study)</TI>
<SO>International Conference on AIDS; 11-16 July, 2004; Bangkok, Thailand</SO>
<YR>2004</YR>
<VL>15</VL>
<PG>Abstract no. B11920</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811975"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811974"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bannister-2008" MODIFIED="2016-09-30 17:11:07 +0100" MODIFIED_BY="[Empty name]" NAME="Bannister 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-09-30 17:11:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, et al</AU>
<TI>Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA</TI>
<SO>AIDS (London, England)</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>3</NO>
<PG>367-76</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811977"/><IDENTIFIER TYPE="PUBMED" VALUE="18195563"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811976"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonnet-2013b" MODIFIED="2016-11-03 16:15:51 +0000" MODIFIED_BY="[Empty name]" NAME="Bonnet 2013b" YEAR="2013">
<REFERENCE MODIFIED="2016-11-03 16:15:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonnet M, Baudin E, Jani IV, Nunes E, Verhoustraten F, Calmy A, et al</AU>
<TI>Incidence of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome and impact on patient outcome</TI>
<SO>PLOS ONE</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>12</NO>
<PG>e84585</PG>
<IDENTIFIERS MODIFIED="2014-09-15 18:09:53 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811979"/><IDENTIFIER TYPE="PUBMED" VALUE="24367678"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811978"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Br_x00fc_ck-2008" MODIFIED="2016-11-03 16:16:02 +0000" MODIFIED_BY="[Empty name]" NAME="Brück 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-11-03 16:16:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brück S, Witte S, Brust J, Schuster D, Mosthaf F, Procaccianti M, et al</AU>
<TI>Hepatotoxicity in patients prescribed efavirenz or nevirapine</TI>
<SO>European Journal of Medical Research</SO>
<YR>2008</YR>
<VL>13</VL>
<NO>7</NO>
<PG>343-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811981"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811980"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Beaudrap-2008" MODIFIED="2016-11-03 16:16:07 +0000" MODIFIED_BY="[Empty name]" NAME="de Beaudrap 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-11-03 16:16:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Beaudrap P, Etard JF, Guèye FN, Guèye M, Landman R, Girard PM, et al</AU>
<TI>Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients</TI>
<SO>AIDS Research and Human Retroviruses</SO>
<YR>2008</YR>
<VL>24</VL>
<NO>6</NO>
<PG>753-60</PG>
<IDENTIFIERS MODIFIED="2009-06-24 21:56:34 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811983"/><IDENTIFIER MODIFIED="2009-06-24 21:56:34 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1089/aid.2007.0295"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811982"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Han-2005" MODIFIED="2016-11-03 16:16:24 +0000" MODIFIED_BY="[Empty name]" NAME="Han 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-11-03 16:16:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Han XX, Zhang M, Cui WG, Liu BG, Wang Y, Zhang ZN, et al</AU>
<TI>Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China</TI>
<SO>Zhonghua Yi Xue Za Zhi</SO>
<YR>2005</YR>
<VL>85</VL>
<NO>11</NO>
<PG>760-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811985"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811984"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hartmann-2005a" MODIFIED="2016-09-30 17:25:53 +0100" MODIFIED_BY="[Empty name]" NAME="Hartmann 2005a" YEAR="2005">
<REFERENCE MODIFIED="2016-09-30 17:25:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hartmann M, Witte S, Brust J, Schuster D, Mosthaf F, Procaccianti M, et al</AU>
<TI>Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort)</TI>
<SO>International Journal of STD &amp; AIDS</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>6</NO>
<PG>404-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811987"/><IDENTIFIER TYPE="PUBMED" VALUE="15969773"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811986"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hartmann-2005b" MODIFIED="2016-11-03 16:16:35 +0000" MODIFIED_BY="[Empty name]" NAME="Hartmann 2005b" YEAR="2005">
<REFERENCE MODIFIED="2016-11-03 16:16:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hartmann M, Brust J, Schuster D, Mosthaf F, Procaccianti M, Rump JA, et al</AU>
<TI>Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz</TI>
<TO>Arzneimittelexantheme bei Therapie der HIV-Infektion mit Efavirenz und Nevirapin</TO>
<SO>Der Hautarzt</SO>
<YR>2005</YR>
<VL>56</VL>
<NO>9</NO>
<PG>847-53</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811989"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811988"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-He-2011" MODIFIED="2016-11-03 16:18:55 +0000" MODIFIED_BY="[Empty name]" NAME="He 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-11-03 16:18:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>He Y, Luo Y, Ding YL, Zheng YH, Li J, Huang J, et al</AU>
<TI>[Effect of highly active anti-retroviral therapy on prevention of mother to child transmission of HIV and on infant growth and development]</TI>
<SO>Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]</SO>
<YR>2011</YR>
<VL>45</VL>
<NO>10</NO>
<PG>912-5</PG>
<IDENTIFIERS MODIFIED="2014-09-15 18:11:59 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811993"/><IDENTIFIER TYPE="PUBMED" VALUE="22321592"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811992"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lapphra-2008" MODIFIED="2016-11-03 16:19:06 +0000" MODIFIED_BY="[Empty name]" NAME="Lapphra 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-11-03 16:19:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lapphra K, Vanprapar N, Chearskul S, Phongsamart W, Chearskul P, Prasitsuebsai W, et al</AU>
<TI>Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children</TI>
<SO>International Journal of Infectious Diseases</SO>
<YR>2008</YR>
<VL>12</VL>
<NO>6</NO>
<PG>e33-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811995"/><IDENTIFIER TYPE="PUBMED" VALUE="18573672"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811994"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manfredi-2004" MODIFIED="2016-11-03 16:19:14 +0000" MODIFIED_BY="[Empty name]" NAME="Manfredi 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-11-03 16:19:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manfredi R, Calza L, Chiodo F</AU>
<TI>Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study</TI>
<SO>Journal of Acquired Immune Deficiency Syndromes</SO>
<YR>2004</YR>
<VL>35</VL>
<NO>5</NO>
<PG>492-502</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811997"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811996"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manfredi-2005" MODIFIED="2016-11-03 16:19:21 +0000" MODIFIED_BY="[Empty name]" NAME="Manfredi 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-11-03 16:19:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manfredi R, Calza L, Chiodo F</AU>
<TI>Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine</TI>
<SO>HIV Clinical Trials</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>6</NO>
<PG>302-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2811999"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2811998"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manfredi-2006" MODIFIED="2016-11-03 16:19:30 +0000" MODIFIED_BY="[Empty name]" NAME="Manfredi 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-11-03 16:19:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manfredi R, Calza L</AU>
<TI>Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/microl</TI>
<SO>AIDS</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>17</NO>
<PG>2233-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2812001"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2812000"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mankhatitham-2011" MODIFIED="2016-11-03 16:19:37 +0000" MODIFIED_BY="[Empty name]" NAME="Mankhatitham 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-11-03 16:19:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mankhatitham W, Lueangniyomkul A, Manosuthi W</AU>
<TI>Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen</TI>
<SO>Southeast Asian Journal of Tropical Medicine and Public Health</SO>
<YR>2011</YR>
<VL>42</VL>
<NO>3</NO>
<PG>651-8</PG>
<IDENTIFIERS MODIFIED="2014-10-03 08:23:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2812003"/><IDENTIFIER TYPE="PUBMED" VALUE="21706943"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2812002"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mankhatitham-2012" MODIFIED="2016-11-03 16:19:58 +0000" MODIFIED_BY="[Empty name]" NAME="Mankhatitham 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-11-03 16:19:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mankhatitham W, Luaengniyomkul A, Manosuthi W</AU>
<TI>Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy</TI>
<SO>Chotmaihet thangphaet [Journal of the Medical Association of Thailand]</SO>
<YR>2012</YR>
<VL>95</VL>
<NO>2</NO>
<PG>163-9</PG>
<IDENTIFIERS MODIFIED="2014-10-03 08:23:38 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2812005"/><IDENTIFIER TYPE="PUBMED" VALUE="22435244"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2812004"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manosuthi-2004" MODIFIED="2016-11-04 19:13:36 +0000" MODIFIED_BY="[Empty name]" NAME="Manosuthi 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-11-04 19:13:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manosuthi W, Sungkanuparph S, Vibhagool A, Rattanasiri S, Thakkinstian A</AU>
<TI>Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection</TI>
<SO>HIV Medicine</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>2</NO>
<PG>105-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2812007"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2812006"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manosuthi-2009b" MODIFIED="2016-11-03 16:20:16 +0000" MODIFIED_BY="[Empty name]" NAME="Manosuthi 2009b" YEAR="2009">
<REFERENCE MODIFIED="2016-11-03 16:20:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manosuthi W, Mankatitham W, Lueangniyomkul A, Thongyen S, Prommool V, Likanonsakul S, et al</AU>
<TI>Serial monitoring of drug concentrations while on and off rifampicin between standard doses of nevirapine based and efavirenz-based antiretroviral regimens</TI>
<SO>HIV Medicine</SO>
<YR>2009</YR>
<VL>10</VL>
<NO>Suppl 2</NO>
<PG>45-221</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2812009"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2812008"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Musiime-2012" MODIFIED="2016-11-03 16:20:28 +0000" MODIFIED_BY="[Empty name]" NAME="Musiime 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-11-03 16:20:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Musiime V, Cook A, Kayiwa J, Zangata D, Nansubuga C, Arach B, et al</AU>
<TI>Differences in body circumferences, skin-fold thicknesses and lipid profiles among HIV-infected African children on and not on stavudine</TI>
<SO>Journal of the International AIDS Society</SO>
<YR>2012</YR>
<VL>15</VL>
<NO>Suppl 4</NO>
<PG>18290</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2812011"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2812010"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nachega-2008" MODIFIED="2016-11-09 18:06:27 +0000" MODIFIED_BY="Anne-Marie Stephani" NAME="Nachega 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-11-09 18:06:27 +0000" MODIFIED_BY="Anne-Marie Stephani" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nachega JB, Hislop M, Dowdy DW, Gallant JE, Chaissona RE, Regensberg L, et al</AU>
<TI>Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults</TI>
<SO>AIDS</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>16</NO>
<PG>2117-25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2812013"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2812012"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Negredo-2004" MODIFIED="2016-11-03 16:20:46 +0000" MODIFIED_BY="[Empty name]" NAME="Negredo 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-11-03 16:20:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Negredo E, Paredes R, Peraire J, Pedrol E, Côté H, Gel S, et al</AU>
<TI>Alteration of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study</TI>
<SO>Antiviral Therapy</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>6</NO>
<PG>889-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2812015"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2812014"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Padmapriyadarsini-2013" MODIFIED="2016-11-03 16:20:51 +0000" MODIFIED_BY="[Empty name]" NAME="Padmapriyadarsini 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-11-03 16:20:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Padmapriyadarsini C, Bhavani PK, Tang A, Kumar H, Ponnuraja C, Narendran G, et al</AU>
<TI>Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy</TI>
<SO>International Journal of Infectious Diseases</SO>
<YR>2013</YR>
<VL>17</VL>
<NO>12</NO>
<PG>e1154-9</PG>
<IDENTIFIERS MODIFIED="2014-10-03 08:24:01 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2812017"/><IDENTIFIER TYPE="PUBMED" VALUE="24120216"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2812016"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PENPACT-2011" MODIFIED="2016-11-03 16:21:00 +0000" MODIFIED_BY="[Empty name]" NAME="PENPACT 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-11-03 16:21:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>PENPACT-1 (PENTA 9/PACTG 390) Study Team, Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, et al</AU>
<TI>First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3trial</TI>
<SO>Lancet Infect Diseases</SO>
<YR>2011</YR>
<VL>11</VL>
<NO>4</NO>
<PG>273-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2812019"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2812018"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prendergast-2011" MODIFIED="2016-11-03 16:21:05 +0000" MODIFIED_BY="[Empty name]" NAME="Prendergast 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-11-03 16:21:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prendergast A, Bwakura-Dangarembizi MF, Cook AD, Bakeera-Kitaka S, Natukunda E, Nahirya Ntege P, et al</AU>
<TI>Hospitalization for severe malnutrition among HIV-infected children starting antiretroviral therapy</TI>
<SO>AIDS</SO>
<YR>2011</YR>
<VL>25</VL>
<NO>7</NO>
<PG>951-6</PG>
<IDENTIFIERS MODIFIED="2014-09-15 18:12:24 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2812021"/><IDENTIFIER TYPE="PUBMED" VALUE="21487251"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2812020"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Puthanakit-2009a" MODIFIED="2016-11-03 16:21:11 +0000" MODIFIED_BY="[Empty name]" NAME="Puthanakit 2009a" YEAR="2009">
<REFERENCE MODIFIED="2016-11-03 16:21:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puthanakit T, Aurpibul L, Sirisanthana T, Sirisanthana V</AU>
<TI>Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>3</NO>
<PG>246-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2812023"/><IDENTIFIER TYPE="PUBMED" VALUE="19165130"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2812022"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Puthanakit-2009b" MODIFIED="2016-11-03 16:21:19 +0000" MODIFIED_BY="[Empty name]" NAME="Puthanakit 2009b" YEAR="2009">
<REFERENCE MODIFIED="2016-11-03 16:21:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puthanakit T, Kerr SJ, Ananworanich J, Bunupuradah T, Boonrak P, Sirisanthana V</AU>
<TI>Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>6</NO>
<PG>488-92</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2812025"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2812024"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swaminathan-2009" MODIFIED="2016-11-04 20:24:04 +0000" MODIFIED_BY="[Empty name]" NAME="Swaminathan 2009" YEAR="2011">
<REFERENCE MODIFIED="2016-11-04 20:24:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Ramesh Kumar S, Iliayas S, et al</AU>
<TI>Once-daily nevirapine vs efavirenz in the treatment of HIV-infected patients with TB: a randomized clinical trial</TI>
<SO>16th conference on retroviruses and opportunistic infections. Montreal, Canada, February 8-11, 2009.</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2014-10-03 08:24:25 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2812027"/><IDENTIFIER TYPE="PUBMED" VALUE="21890776"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2812026"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-01-07 18:05:42 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2010-09-20 14:33:15 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-11-09 18:06:52 +0000" MODIFIED_BY="Anne-Marie Stephani">
<ADDITIONAL_REFERENCES MODIFIED="2016-11-09 18:06:52 +0000" MODIFIED_BY="Anne-Marie Stephani">
<REFERENCE ID="REF-Beck-2008" MODIFIED="2016-11-03 16:27:08 +0000" MODIFIED_BY="[Empty name]" NAME="Beck 2008" TYPE="JOURNAL_ARTICLE">
<AU>Beck EJ, Mandalia S, Youle M, Brettle R, Fisher M, Gompels M, et al</AU>
<TI>Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002)</TI>
<SO>International Journal of STD &amp; AIDS</SO>
<YR>2008</YR>
<VL>19</VL>
<NO>5</NO>
<PG>297-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BHIVA-2001" MODIFIED="2016-11-03 16:27:13 +0000" MODIFIED_BY="[Empty name]" NAME="BHIVA 2001" TYPE="JOURNAL_ARTICLE">
<AU>BHIVA Writing Committee; BHIVA Executive Committee</AU>
<TI>Guidelines for the treatment of HIV-infected adults with antiretroviral therapy</TI>
<SO>HIV Medicine</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>4</NO>
<PG>276-313</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chou-2006" MODIFIED="2016-11-03 16:28:19 +0000" MODIFIED_BY="[Empty name]" NAME="Chou 2006" TYPE="JOURNAL_ARTICLE">
<AU>Chou R, Rongwei F, Huffman LH, Korthuis PT</AU>
<TI>Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>368</VL>
<NO>9546</NO>
<PG>1503-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cooper-2007" MODIFIED="2016-11-03 16:28:25 +0000" MODIFIED_BY="[Empty name]" NAME="Cooper 2007" TYPE="JOURNAL_ARTICLE">
<AU>Cooper CL, van Heeswijk RPG</AU>
<TI>Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review</TI>
<SO>HIV Medicine</SO>
<YR>2007</YR>
<VL>8</VL>
<NO>1</NO>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2001" MODIFIED="2016-11-03 16:28:31 +0000" MODIFIED_BY="[Empty name]" NAME="Deeks 2001" TYPE="JOURNAL_ARTICLE">
<AU>Deeks SG</AU>
<TI>International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance</TI>
<SO>Journal of Acquired Immune Deficiency Syndromes</SO>
<YR>2001</YR>
<VL>26 Suppl 1</VL>
<PG>S25-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DHHS-2001a" MODIFIED="2016-11-03 16:46:29 +0000" MODIFIED_BY="[Empty name]" NAME="DHHS 2001a" TYPE="OTHER">
<AU>Department of Health and Human Sciences</AU>
<TI>AIDSinfo Drug Database</TI>
<SO>https://aidsinfo.nih.gov/drugs/116/nevirapine/0/professional</SO>
<YR>(accessed 10 November 2016)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DHHS-2001b" MODIFIED="2016-11-03 16:44:36 +0000" MODIFIED_BY="[Empty name]" NAME="DHHS 2001b" TYPE="OTHER">
<AU>Department of Health and Human Sciences</AU>
<TI>AIDSinfo Drug Database</TI>
<SO>https://aidsinfo.nih.gov/drugs/269/efavirenz/0/professional</SO>
<YR>(accessed 10 November 2016)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dybul-2002" MODIFIED="2016-11-03 17:28:09 +0000" MODIFIED_BY="[Empty name]" NAME="Dybul 2002" TYPE="JOURNAL_ARTICLE">
<AU>Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for the Treatment of HIV</AU>
<TI>Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV</TI>
<SO>Morbidity and Mortality Weekly Report</SO>
<YR>2002</YR>
<VL>51</VL>
<NO>RR-7</NO>
<PG>1-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2016-09-30 16:06:55 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ (Clinical research ed.)</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS MODIFIED="2015-04-03 21:31:51 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="9310563"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gilks-2006" MODIFIED="2016-11-03 17:28:16 +0000" MODIFIED_BY="[Empty name]" NAME="Gilks 2006" TYPE="JOURNAL_ARTICLE">
<AU>Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, et al</AU>
<TI>The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>368</VL>
<NO>9534</NO>
<PG>505-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2014" MODIFIED="2016-11-03 17:29:14 +0000" MODIFIED_BY="[Empty name]" NAME="GRADEpro 2014" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro GDT</TI>
<YR>2014</YR>
<EN>(assessed 03 November 2016)</EN>
<PB>GRADE Working Group, McMaster University</PB>
<CY>Hamilton (ON)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2016-11-03 17:29:22 +0000" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter, Alonso-Coello P, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2016-11-03 17:29:29 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="BOOK">
<AU>Higgins JPT, Green S, editor(s)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<ED>Higgins JPT, Green S</ED>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester (UK)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hogg-1997" MODIFIED="2016-11-09 18:06:43 +0000" MODIFIED_BY="Anne-Marie Stephani" NAME="Hogg 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hogg RS, O'Shaughnessy MV, Gataric N, Yip B, Craib K, Schechter MT, et al</AU>
<TI>Decline in deaths from AIDS due to new antiretrovirals</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<NO>9061</NO>
<PG>1294</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jiang-2014" MODIFIED="2016-11-03 17:29:38 +0000" MODIFIED_BY="[Empty name]" NAME="Jiang 2014" TYPE="JOURNAL_ARTICLE">
<AU>Jiang HY, Zhang MN, Chen HJ, Yang Y, Deng M, Ruan B</AU>
<TI>Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis</TI>
<SO>International Journal of Infectious Diseases</SO>
<YR>2014</YR>
<VL>25</VL>
<PG>130-5</PG>
<IDENTIFIERS MODIFIED="2015-04-09 21:01:29 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="24911886"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lau-2007" MODIFIED="2016-11-04 20:12:46 +0000" MODIFIED_BY="[Empty name]" NAME="Lau 2007" TYPE="CONFERENCE_PROC">
<AU>Lau B, Gange S, Kirk G, Mehta S, Merriman B, Moore R</AU>
<TI>Predictive value of plasma HIV RNA levels for rate of CD4 decline and clinical disease progression</TI>
<SO>14th Conference on Retroviruses and Opportunistic Infections (CROI); 25-28 February, 2007; Los Angeles, California</SO>
<YR>2007</YR>
<NO>Abstract 140 (oral)</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mellors-2007" MODIFIED="2016-11-09 18:06:52 +0000" MODIFIED_BY="Anne-Marie Stephani" NAME="Mellors 2007" TYPE="CONFERENCE_PROC">
<AU>Mellors J, Margolick J, Phair J, Rinaldo C, Detels R, Jaconson L, et al</AU>
<TI>Comparison of plasma HIV-1 RNA, CD4 cell count, and CD38 expression on CD8 T cells as predictors of progression to AIDS and CD4 cell decline among untreated participants in the multicenter AIDS cohort study</TI>
<SO>14th Conference on Retroviruses and Opportunistic Infections; 25-28 February, 2007; Los Angeles, California</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mocroft-1998" MODIFIED="2016-11-03 17:30:58 +0000" MODIFIED_BY="[Empty name]" NAME="Mocroft 1998" TYPE="JOURNAL_ARTICLE">
<AU>Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al</AU>
<TI>Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9142</NO>
<PG>1725-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moyle-2000" MODIFIED="2016-09-30 16:23:44 +0100" MODIFIED_BY="[Empty name]" NAME="Moyle 2000" TYPE="JOURNAL_ARTICLE">
<AU>Moyle GJ</AU>
<TI>Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infection</TI>
<SO>Current Opinion in Infectious Diseases</SO>
<YR>2000</YR>
<VL>13</VL>
<NO>1</NO>
<PG>19-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIAID_x002f_NIH-2004" MODIFIED="2016-11-03 16:42:42 +0000" MODIFIED_BY="[Empty name]" NAME="NIAID/NIH 2004" TYPE="BOOK">
<AU>Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health</AU>
<SO>Table for Grading the Severity of Adult and Pediatric Adverse Events</SO>
<YR>2004</YR>
<PB>National Institutes of Health</PB>
<CY>Bethesda, Maryland</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pillay-2013" MODIFIED="2016-11-03 16:47:45 +0000" MODIFIED_BY="[Empty name]" NAME="Pillay 2013" TYPE="JOURNAL_ARTICLE">
<AU>Pillay P, Ford N, Shubber Z, Ferrand RA</AU>
<TI>Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis</TI>
<SO>PLOS ONE</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>7</NO>
<PG>e68995</PG>
<IDENTIFIERS MODIFIED="2015-04-09 21:07:10 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="23894391"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2016-11-03 16:47:53 +0000" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager 5 (RevMan 5)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shubber-2013" MODIFIED="2016-11-03 16:48:01 +0000" MODIFIED_BY="[Empty name]" NAME="Shubber 2013" TYPE="JOURNAL_ARTICLE">
<AU>Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Théry F, Shaffer N, et al</AU>
<TI>Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis</TI>
<SO>AIDS (London, England)</SO>
<YR>2013</YR>
<VL>27</VL>
<NO>9</NO>
<PG>1403-12</PG>
<IDENTIFIERS MODIFIED="2015-04-09 21:09:09 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="23343913"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Siegfried-2006" MODIFIED="2016-09-30 16:25:22 +0100" MODIFIED_BY="[Empty name]" NAME="Siegfried 2006" TYPE="COCHRANE_REVIEW">
<AU>Siegfried NL, Van Deventer PJU, Mahomed FA, Rutherford GW</AU>
<TI>Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-09-11 11:44:53 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-09-11 11:44:53 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004535.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-UNAIDS-2016" MODIFIED="2016-11-03 16:52:59 +0000" MODIFIED_BY="[Empty name]" NAME="UNAIDS 2016" TYPE="OTHER">
<AU>UNAIDS</AU>
<TI>AIDS by the numbers 2015</TI>
<SO>http://www.unaids.org/sites/default/files/media_asset/AIDS-by-the-numbers-2016_en.pdf</SO>
<YR>(accessed 03 November 2016)</YR>
<IDENTIFIERS MODIFIED="2016-09-30 16:26:58 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Veldkamp-2001" MODIFIED="2016-11-03 17:08:03 +0000" MODIFIED_BY="[Empty name]" NAME="Veldkamp 2001" TYPE="JOURNAL_ARTICLE">
<AU>Veldkamp AI, Weverling GJ, Lange JM, Montaner JS, Reiss P, Cooper DA, et al</AU>
<TI>High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals</TI>
<SO>AIDS</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>9</NO>
<PG>1089-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2002" MODIFIED="2016-11-03 17:10:12 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 2002" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Scaling up antiretroviral therapy in low in resource-limited settings. Guidelines for a public health approach. June 2002</TI>
<SO>http://www.who.int/hiv/pub/prev_care/en/ScalingUp_E.pdf</SO>
<YR>(accessed 03 November 2016)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2006" MODIFIED="2016-11-03 17:11:00 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 2006" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision</TI>
<SO>http://whqlibdoc.who.int/publications/2006/9789241594677_eng.pdf</SO>
<YR>(accessed 25 September 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2009" MODIFIED="2016-11-03 17:21:17 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 2009" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. November 2009</TI>
<SO>http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf</SO>
<YR>(accessed 03 November 2016)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2014" MODIFIED="2016-11-03 17:19:51 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 2014" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. July 2014</TI>
<SO>http://www.who.int/hiv/pub/guidelines/keypopulations/en/</SO>
<YR>(accessed 09 September 2016)</YR>
<IDENTIFIERS MODIFIED="2016-09-30 16:42:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2015a" MODIFIED="2016-11-04 18:31:28 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 2015a" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>WHO Model List of Essential Medicines. 19th List</TI>
<SO>http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1</SO>
<YR>(accessed 10 September 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2015b" MODIFIED="2016-11-03 17:18:40 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 2015b" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Second edition</TI>
<SO>http://www.who.int/hiv/pub/arv/arv-2016/en/</SO>
<YR>(accessed 03 November 2016)</YR>
<IDENTIFIERS MODIFIED="2016-09-30 16:37:07 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-11-04 19:14:45 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Mbuagbaw-2009" MODIFIED="2016-11-04 16:13:43 +0000" MODIFIED_BY="[Empty name]" NAME="Mbuagbaw 2009" TYPE="COCHRANE_REVIEW">
<AU>Mbuagbaw LC, Irlam JH</AU>
<TI>Efavirenz versus nevirapine as a non-nucleoside reverse transcriptase inhibitor in initial combination antiretroviral therapy for HIV infection</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2016-09-30 16:40:18 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-09-30 16:40:18 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004246.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mbuagbaw-2010" MODIFIED="2016-11-04 19:14:45 +0000" MODIFIED_BY="[Empty name]" NAME="Mbuagbaw 2010" TYPE="COCHRANE_REVIEW">
<AU>Mbuagbaw LC, Irlam JH, Spaulding A, Rutherford GW, Siegfried N</AU>
<TI>Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>12</NO>
<PG>CD004246</PG>
<IDENTIFIERS MODIFIED="2016-09-30 16:38:14 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-09-30 16:38:14 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004246.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Neuwelt-MD-2002" MODIFIED="2016-11-03 17:31:34 +0000" MODIFIED_BY="[Empty name]" NAME="Neuwelt MD 2002" TYPE="COCHRANE_PROTOCOL">
<AU>Neuwelt MD</AU>
<TI>Efavirenz versus nevirapine as a non-nucleoside reverse transcriptase inhibitor in initial combination antiretroviral therapy for HIV infection</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2016-09-30 16:41:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-09-30 16:41:44 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004246"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-11-09 18:07:08 +0000" MODIFIED_BY="Anne-Marie Stephani">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-11-09 18:07:08 +0000" MODIFIED_BY="Anne-Marie Stephani" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-11-03 18:40:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004">
<CHAR_METHODS MODIFIED="2016-11-02 19:32:11 +0000" MODIFIED_BY="[Empty name]">
<P>A prospective, open, randomized trial in the department of infectiology of the Hospital de Especialidades in Moterry, Nuevo Leon, Mexico.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-02 19:32:39 +0000" MODIFIED_BY="[Empty name]">
<P>58 participants.</P>
<P>Inclusion criteria: at least 18 years old, of either gender, HIV-positive, antiretroviral-naïve.</P>
<P>Exclusion criteria: patients with contraindications to either nevirapine (NVP) or efavirenz (EFV), pregnant women, diminished renal or liver functions.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-02 19:34:04 +0000" MODIFIED_BY="[Empty name]">
<P>Zidovudine (AZT) 300 mg and Lamivudine (3TC) 150 mg with either NVP 200 mg twice daily (N = 28) or EFV 600 mg at night (N = 30).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-02 20:08:42 +0000" MODIFIED_BY="[Empty name]">
<P>Viral load (&lt; 400 copies/mL), CD4 count, adverse events, AIDS-defining conditions, death. Follow-up was for 48 weeks.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-11-03 18:40:18 +0000" MODIFIED_BY="[Empty name]">
<P>All participants provided informed consent to participate in the study. Published in Spanish.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-02 19:44:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bonnet-2013a">
<CHAR_METHODS MODIFIED="2016-11-02 19:39:46 +0000" MODIFIED_BY="[Empty name]">
<P>An open-label non-inferiority randomized trial in 3 trial sites in Maputo, Mozambique (Jose Macamo Hospital, Mavalane Hospital and Alto Mae Health Centre).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-02 19:44:25 +0000" MODIFIED_BY="[Empty name]">
<P>570 participants.</P>
<P>Inclusion criteria: adults (&gt; 18 years) , treatment naïve, treatment for tuberculosis for less then 4 weeks, Karnofsky score of 60% or more, CD4 count &lt; 250 cells, negative pregnancy test, alanine aminotransferase<B> (</B>ALAT) and bilirubin less then 5 times upper limit of normal (ULN), absence of grade 4 clinical or biological adverse events.</P>
<P>Exclusion criteria: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-02 19:44:31 +0000" MODIFIED_BY="[Empty name]">
<P>3TC + d4T + EFZ 600 mg (N = 285) versus 3TC + d4T + NVP 200 mg twice daily (N = 285)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-02 19:44:37 +0000" MODIFIED_BY="[Empty name]">
<P>Virological success (&lt; 50 copies/mL), change in CD4, mortality, progression to AIDS, discontinuation rate, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-11-02 19:44:37 +0000" MODIFIED_BY="[Empty name]">
<P>All participants provided informed consent to participate in the study. This study was funded by the French Research Agency for HIV AIDS and hepatitis (ANRS).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-02 19:48:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Landman-2014">
<CHAR_METHODS MODIFIED="2016-11-02 19:48:27 +0000" MODIFIED_BY="[Empty name]">
<P>A multicenter, open-label randomized trial conducted in 2 centres in Dakar, Senegal and Yaoundé, Cameroon.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-02 19:48:27 +0000" MODIFIED_BY="[Empty name]">
<P>120 participants.</P>
<P>Inclusion criteria: adults (&#8805; 18 years in Senegal or &#8805; 21 years in Cameroon), anti-retroviral treatment naïve, and CD4<SUP>+ </SUP>T-cell count &gt; 50 cells/mm<SUP>3</SUP>
</P>
<P>Exclusion criteria: ongoing opportunistic infection, serious disease, ongoing treatment with rifampin, severe renal or hepatic disorder, Cockcroft-Gault calculated creatinine clearance &#8804; 50 mL/min, hepatitis B surface antigen-positive, haemoglobin &lt; 8 g/dL, neutrophil count &lt; 500 cells/mm<SUP>3</SUP>, pregnant, breastfeeding, treated with any contraindicated drugs.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-02 19:48:33 +0000" MODIFIED_BY="[Empty name]">
<P>TDF/FTC 300/200 mg once daily and NVP 200 mg once daily for first 2 weeks and twice daily thereafter (N = 31) or TDF/FTC/EFV 300/200/600 mg once daily (N = 30)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-02 19:48:33 +0000" MODIFIED_BY="[Empty name]">
<P>Virological efficacy (&lt; 50 copies/mL), discontinuation rate, adherence rate, treatment failure, mortality, and adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-11-02 19:48:33 +0000" MODIFIED_BY="[Empty name]">
<P>Written informed consent was obtained from each participant. Trial number NCT00573001. Funding for the study was provided by the ANRS. Gilead Sciences, Merck Sgaro &amp; Dhome, and Abbott Laboratories provided funding for some of the antiretroviral regimens.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-02 19:49:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manosuthi-2009a">
<CHAR_METHODS MODIFIED="2016-11-02 19:49:03 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective open-label randomized, comparative trial in Nonthaburi, Thailand from December 2006 to October 2007</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-02 19:49:03 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: HIV-1 infection in individuals aged 18 to 60 years; active TB diagnosed by clinical features plus acid-fast stain or culture positive for <I>M. tuberculosis</I>, or both; receipt of treatment with a rifampicin- containing anti-TB regimen 4 to 16 weeks before enrolment,naïve to ART; and CD4+ cell count, &lt; 350 cells/mm<SUP>3</SUP>.</P>
<P>Exclusion criteria: aspartate aminotransferase and alanine aminotransferase levels &gt; 5 times the upper limit of normal range;serum creatinine level &gt; 12 mg/dL; receipt of a medication that has drug-drug interactions with nevirapine or efavirenz; receipt of immunosuppressive drugs; and pregnancy or lactation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-02 19:49:03 +0000" MODIFIED_BY="[Empty name]">
<P>Efavirenz 600 mg or nevirapine 200 mg twice daily with 3TC 150 mg/D4T 30 or 40 mg BID. Follow-up was for 48 weeks.</P>
<P>142 participants with 71 in each trial arm.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-02 19:49:03 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome: proportion of participants achieving a plasma HIV-RNA level &lt; 50 copies/mL after 48 weeks of ART.</P>
<P>Secondary outcomes: proportion of participants with concentrations of NNRTI at 12 hours after dosing, lower than the recommended minimal level, CD4 cell count at week 48 of ART, incidence of NNRTI-associated adverse reactions.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-11-02 19:49:11 +0000" MODIFIED_BY="[Empty name]">
<P>Written consent was obtained from the participants.</P>
<P>This is also referred to as the N2R study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 18:07:08 +0000" MODIFIED_BY="Anne-Marie Stephani" STUDY_ID="STD-Mateelli-2013">
<CHAR_METHODS MODIFIED="2016-11-02 19:51:05 +0000" MODIFIED_BY="[Empty name]">
<P>A randomized, open-label, parallel group study in Burkina Faso</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-02 19:51:05 +0000" MODIFIED_BY="[Empty name]">
<P>People with TB/HIV co-infection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-02 19:51:05 +0000" MODIFIED_BY="[Empty name]">
<P>Stavudine (d4T) and lamivudine (3TC) with either EFV 600 mg once daily or NVP 200 mg twice daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-09 22:35:24 +0100" MODIFIED_BY="[Empty name]">
<P>The outcomes reported were: mean CD4 increase, viral success, TB treatment success.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-11-09 18:07:08 +0000" MODIFIED_BY="Anne-Marie Stephani">
<P>This study was reported in abstract form</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-02 19:54:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-N_x00fa__x00f1_ez-2002">
<CHAR_METHODS MODIFIED="2016-11-02 19:51:41 +0000" MODIFIED_BY="[Empty name]">
<P>A randomized, open-label, pilot study in Hospital Carlos III in Madrid Span from March 1999 to January 2002</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-02 19:53:16 +0000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: HIV-infected antiretroviral-naïve adults, aged above 18 years old with CD4 counts &gt; 100 cells/mm<SUP>3</SUP> and detectable plasma<BR/>HIV RNA below 100,000 copies/mL, no major organ failure, use of standard of care prophylaxis for opportunistic infections, negative pregnancy test in women of child-bearing age, and no current high alcohol intake or substance abuse. N = 67 (NVP = 36, EFV = 31).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-02 19:53:16 +0000" MODIFIED_BY="[Empty name]">
<P>d4T and ddI with either NVP or EFV at the following doses: NVP 400 mg once a day, d4T 40 mg twice a day, ddI 400 mg once a day, and EFV 600 mg once a day. Follow-up was for 48 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-02 19:53:13 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: the proportion of individuals achieving plasma HIV RNA &lt; 50 copies/mL and the proportion developing drug-related toxicities, which caused cessation of the NNRTI.</P>
<P>Secondary: mean changes in CD4+ lymphocyte counts, overall safety, degree of adherence, and adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-11-02 19:54:14 +0000" MODIFIED_BY="[Empty name]">
<P>All participants provided informed consent to participate in the trial.</P>
<P>This trial is referred to as the SENC trial.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-02 19:56:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sinha-2013">
<CHAR_METHODS MODIFIED="2016-11-02 19:56:31 +0000" MODIFIED_BY="[Empty name]">
<P>A randomized, open label, trial conducted at All India Institute of Medical Sciences, New Delhi, India.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-02 19:56:31 +0000" MODIFIED_BY="[Empty name]">
<P>142 participants</P>
<P>Inclusion criteria: positive for HIV by ELISA, ART-naïve and presenting with concomitant TB, CD4 count &lt; 200 cells/mm<SUP>3</SUP> and normal renal and hepatic function.</P>
<P>Exclusion criteria: positive in hepatitis B and C serologies, taking antiepileptic drugs, immunosuppressant, and other drugs that induce liver microsomal enzyme systems, and pregnant.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-15 02:00:57 +0100" MODIFIED_BY="[Empty name]">
<P>Zidovudine or Stavudine and Lamivudine/NVP once daily for the first 14 days and twice daily thereafter (200mg) or Zidovudine or Stavudine and Lamivudine/EFV (600 mg) daily.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-02 19:56:31 +0000" MODIFIED_BY="[Empty name]">
<P>Virological response (&lt; 400 copies/mL), discontinuation rate, treatment failure, mortality, and adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-04-09 22:40:00 +0100" MODIFIED_BY="[Empty name]">
<P>All participants gave signed informed consent to participate in this study. Funding was provided by the National AIDS Control Organization, Ministry of Health &amp; Family Welfare, and the Government of India.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-02 19:57:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sow-2006">
<CHAR_METHODS MODIFIED="2016-11-02 19:57:58 +0000" MODIFIED_BY="[Empty name]">
<P>A RCT to compare AZT+3TC+NVP versus AZT+3TC+EFV among 70 HIV-infected patients in Senegal</P>
<P>Age limits not given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-01 20:36:08 +0000" MODIFIED_BY="[Empty name]">
<P>70 ART treatment-naïve patients from Senegal</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-02 19:57:58 +0000" MODIFIED_BY="[Empty name]">
<P>AZT 300 mg, 3TC 150 mg and NVP 200 mg (N = 35) on one hand versus AZT 300 mg, 3TC 150 mg, and EFV 600 mg (N = 35)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-02 19:57:58 +0000" MODIFIED_BY="[Empty name]">
<P>Decrease in viral burden, side-effects and change in CD4 count. Follow-up was for 76 weeks.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-11-02 19:57:58 +0000" MODIFIED_BY="[Empty name]">
<P>This trial was reported in abstract form.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 18:06:20 +0000" MODIFIED_BY="Anne-Marie Stephani" STUDY_ID="STD-Swaminathan-2011">
<CHAR_METHODS MODIFIED="2016-11-02 19:58:51 +0000" MODIFIED_BY="[Empty name]">
<P>An open-label, parallel arm, randomized controlled clinical trial conducted at 3 sites of the Tuberculosis Research Centre in Chennai, Vellore, and Madurai, located in southern India.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 18:06:18 +0000" MODIFIED_BY="Anne-Marie Stephani">
<P>564 participants</P>
<P>Inclusion criteria: People living with HIV who were at least 18 years of age with newly diagnosed TB, not pregnant and CD4+ cell counts &lt; 250 cells/mm<SUP>3</SUP>.</P>
<P>Exclusion criteria: previous ATT or ART for &gt; 1month, HIV-2 infection, major psychiatric illness, aspartate aminotransferase and alanine aminotransferase levels &gt; 2.5 times the upper limit of normal and having a severe non-HIV related disease.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 18:06:20 +0000" MODIFIED_BY="Anne-Marie Stephani">
<P>Didanosine (250/400 mg) + lamivudine (300 mg) + nevirapine (400mg after 14 days of 200 mg) or didanosine (250/400 mg) + lamivudine (300 mg) + efavirenz (600 mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-15 03:13:32 +0100" MODIFIED_BY="[Empty name]">
<P>Change in CD4 count, discontinuation rate, adherence rate, treatment failure, mortality, and adverse events. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-15 03:14:11 +0100" MODIFIED_BY="[Empty name]">
<P>Funded by the National AIDS Control Organization (New Delhi, India) and Indian Council of Medical Research (New Delhi, India). NCT00332306</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-04 19:21:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008">
<CHAR_METHODS MODIFIED="2016-11-02 20:00:50 +0000" MODIFIED_BY="[Empty name]">
<P>The FIRST study randomized participants to 3 strategy arms, one of which was NNRTI+NRTI. NNRTI was determined by optional randomisation (NVP or EFV) or by choice.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-02 20:00:56 +0000" MODIFIED_BY="[Empty name]">
<P>228 antiretroviral-naïve, HIV-positive participants, aged at least 13 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-04 19:21:18 +0000" MODIFIED_BY="[Empty name]">
<P>There were 111 participants in the EFV arm (EFV 600 mg once daily) and 117 in the NVP arm (NVP 200 mg twice daily). We obtained information on dosing from the trial authors. They used 4 different NRTI combination drugs (ABC/3TC, ddI/d4T, AZT/3TC, d4T/3TC).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-02 20:00:56 +0000" MODIFIED_BY="[Empty name]">
<P>HIV RNA &gt; 50 copies/mL, change in CD4 count or death. Follow-up was for 32 weeks.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-11-02 20:00:56 +0000" MODIFIED_BY="[Empty name]">
<P>All participants provided informed consent to participate in the study aka FIRST or CPCRA study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-02 20:02:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Leth-2004">
<CHAR_METHODS MODIFIED="2016-11-02 20:01:54 +0000" MODIFIED_BY="[Empty name]">
<P>Multicentre, open-label, randomised trial of 1216 ARV naïve participants in North/South America, Australia, Europe, South Africa, and Thailand</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-02 20:01:54 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: ARV naïve participants of either sex, aged at least 16 years, with plasma RNA &gt; 5000 copies per mL</P>
<P>Exclusion criteria: pregnancy, lactation, HB &lt; 6.3 mmol/L in males and 5.7 mmol/L in females, neutrophils &lt; 1 x 10<SUP>9</SUP>, platelets &lt; 75 x 10<SUP>9</SUP>, serum amylases &gt; 2.0 times the upper limit of normal in combination with serum lipase &lt; 1.5 times the upper limit of normal; aspartate aminotransferase &lt; 5.0 times the upper limit of normal; or bilirubin &lt; 2.5 times the upper limit of normal; history of clinical pancreatitis or neuropathy within the previous 6 months; renal failure necessitating dialysis; radiotherapy, cytotoxic, or immunomodulating treatment within the month preceding the start of study or the expected need for it; infection with HIV-2; or likely non-adherence as judged by the trial investigator.</P>
<P>NVP once daily N = 220, NVP twice daily N = 387, EFV N = 400.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-02 20:01:58 +0000" MODIFIED_BY="[Empty name]">
<P>Four arms; only 3 of interest: d4T 40 mg BID and 3TC 150 mg BID with either NVP 400 mg once daily, NVP 200 mg twice daily or EFV 600 mg once daily. Follow-up for 48 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-02 20:01:58 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: proportion of participants with treatment failure</P>
<P>Secondary: proportion of participants with virological failure (never having a plasma HIV-1 RNA concentration &lt; 50 copies/mL, or two consecutive measurements 50 copies/mL after having had a concentration below the cut-off), the proportion of participants with plasma HIV-1 RNA concentrations below 50 copies/mL at each study week; the change in CD4-positive cells between the start of treatment and week 48; and the frequencies of clinical and laboratory adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-11-02 20:02:09 +0000" MODIFIED_BY="[Empty name]">
<P>Ethics: approved by the ethics review bodies in the participating countries, and all participants gave written informed consent. This study was industry funded (Boehringer-Ingelheim) and is also known as the 2NN study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-02 20:02:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wester-2010">
<CHAR_METHODS MODIFIED="2016-11-02 20:02:52 +0000" MODIFIED_BY="[Empty name]">
<P>Open-label, randomized, factorial design study conducted at Princes Marina Hospital in Gaborone, Botswana.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-02 20:02:52 +0000" MODIFIED_BY="[Empty name]">
<P>898 participants<BR/>Inclusion criteria: haemoglobin value greater than 8.0 g/dL; absolute neutrophil count 1.0 x 10<SUP>3</SUP>/&#956;L or greater; aminotransferase levels less than 5 times the upper limit of normal; and for women of child-bearing potential, a willingness to maintain active contraception throughout the duration of the study and a negative during pregnancy test within 14 days of study enrolment.</P>
<P>Exclusion criteria: Karnofsky performance score (40 or below); an AIDS-related malignancy other than mucocutaneous Kapsosi's sarcoma grade 2 or higher peripheral neuropathy; major psychiatric illness and for women, actively breastfeeding or less than 6 months postpartum.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-02 20:02:57 +0000" MODIFIED_BY="[Empty name]">
<P>Zidovudine or stavudine/lamivudine or didanosine/nevirapine or Zidovudine or stavudine/lamivudine or didanosine/efavirenz</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-02 20:02:57 +0000" MODIFIED_BY="[Empty name]">
<P>Change in CD4 count, treatment failure (defined as &gt; 5000 copies/mL and later as &gt; 400 copies/mL i.e. undetectable plasma HIV RNA), mortality, and adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-11-02 20:02:58 +0000" MODIFIED_BY="[Empty name]">
<P>Funding from the following research grant from the National Institute of Allergy and Infectious Diseases (NIAID), grant evaluating the risk factors for the Development of Lactic Acidosis and Pancreatitis Among HAART treated Adults in Botswana and Harvard Center for AIDS research grant evaluating the risk factors for the development of nevirapine-associated toxicity in Southern Africa.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Abbreviations: ITT: intention-to-treat; RCT: randomized controlled trial; NRTI: Nucleoside Reverse Transcriptase Inhibitor; ART: antiretroviral therapy; AZT: zidovudine; d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; DDI: didanosine; ABC: abacavir; FTC: Emtricitabine; TDF: Tenofovir; ALAT: alanine aminotransferase; ULN: Upper Limit of Normal; HIV: human immune-deficiency virus; RNA: Ribonucleic acid; NNRTI: non-nucleoside reverse transcriptase inhibitors; SENC: Spanish efavirenz vs. nevirapine comparison; ELISA: Enzyme-linked immunosorbent assay.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-11-09 18:06:21 +0000" MODIFIED_BY="Anne-Marie Stephani" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-11-09 18:06:21 +0000" MODIFIED_BY="Anne-Marie Stephani" STUDY_ID="STD-Antela-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-09 18:06:21 +0000" MODIFIED_BY="Anne-Marie Stephani">
<P>Doesn't have the comparison of interest.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-02 20:03:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bannister-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-02 20:03:37 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized clinical trial, but a retrospective cohort study from the EUROSIDA database.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:08:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bonnet-2013b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:08:47 +0000" MODIFIED_BY="[Empty name]">
<P>A sub-study of <LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>, and not a randomized clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-02 20:03:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Br_x00fc_ck-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-02 20:03:49 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-02 20:03:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Beaudrap-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-02 20:03:52 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized clinical trial, a retrospective cohort study from 'Initiative Senegalaise d'Acces aux Medicaments Antiretroviraux' (ISAARV) prospective cohort of which the EFV arm was a clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-02 20:04:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Han-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-02 20:04:00 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-02 20:04:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hartmann-2005a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-02 20:04:05 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized clinical trial, but a prospective cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-02 20:04:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hartmann-2005b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-02 20:04:11 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized clinical trial, but a prospective cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-02 20:04:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-He-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-02 20:04:22 +0000" MODIFIED_BY="[Empty name]">
<P>Not a comparison of efavirenz (EFV) to nevirapine (NVP).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-02 20:04:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lapphra-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-02 20:04:28 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized clinical trial, but a retrospective cohort study from medical records.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-02 20:04:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manfredi-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-02 20:04:33 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized clinical trial, but an observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-02 20:04:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manfredi-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-02 20:04:37 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized clinical trial, but an observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-02 20:04:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manfredi-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-02 20:04:43 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized clinical trial, but an observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:08:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mankhatitham-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:08:52 +0000" MODIFIED_BY="[Empty name]">
<P>A sub-study of <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:08:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mankhatitham-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:08:53 +0000" MODIFIED_BY="[Empty name]">
<P>A sub-study of <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-02 20:05:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manosuthi-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-02 20:05:05 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized clinical trial, but a retrospective cohort study from medical records.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:09:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manosuthi-2009b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:09:46 +0000" MODIFIED_BY="[Empty name]">
<P>A sub-study of <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-02 20:05:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Musiime-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-02 20:05:12 +0000" MODIFIED_BY="[Empty name]">
<P>Not a comparison of EFV to NVP.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-02 20:05:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nachega-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-02 20:05:16 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized clinical trial, but a retrospective cohort study from the Aid for AIDS prospective database in southern Africa.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-02 20:05:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Negredo-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-02 20:05:22 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 16:58:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Padmapriyadarsini-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 16:58:12 +0000" MODIFIED_BY="[Empty name]">
<P>A sub-study of <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-02 20:05:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PENPACT-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-02 20:05:31 +0000" MODIFIED_BY="[Empty name]">
<P>Not a comparison of EFV to NVP.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-02 20:05:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prendergast-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-02 20:05:33 +0000" MODIFIED_BY="[Empty name]">
<P>Not a comparison of EFV to NVP.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-02 20:05:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Puthanakit-2009a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-02 20:05:38 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized clinical trial, but a prospective cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-02 20:05:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Puthanakit-2009b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-02 20:05:42 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomized clinical trial, but a prospective cohort study. Data collected from 2 treatment cohorts.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 16:58:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Swaminathan-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 16:58:12 +0000" MODIFIED_BY="[Empty name]">
<P>A duplicate of <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>Abbreviations: EFV: efavirenz; NVP: nevirapine; ISAARV: Initiative Senegalaise d'Acces aux Medicaments Antiretroviraux' (ISAARV). </P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-01-07 18:05:42 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-09-20 14:33:15 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-11-04 19:34:37 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-11-04 17:05:53 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-04 17:00:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004">
<DESCRIPTION>
<P>Trial authors provided no information on methods of sequence generation<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:44:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bonnet-2013a">
<DESCRIPTION>
<P>The trial randomly allocated participants to treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:48:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Landman-2014">
<DESCRIPTION>
<P>The trial randomized participants to treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-04 17:02:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manosuthi-2009a">
<DESCRIPTION>
<P>Trial authors provided no information on methods of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:51:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mateelli-2013">
<DESCRIPTION>
<P>The trial authors did not report this.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-04 17:04:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-N_x00fa__x00f1_ez-2002">
<DESCRIPTION>
<P>Trial authors provided no information on methods of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-04 17:05:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sinha-2013">
<DESCRIPTION>
<P>Trial authors provided no information on methods of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:58:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sow-2006">
<DESCRIPTION>
<P>The trial authors did not report this information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:59:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Swaminathan-2011">
<DESCRIPTION>
<P>The trial authors performed permuted block randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 20:03:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wester-2010">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-03 18:34:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Leth-2004">
<DESCRIPTION>
<P>"A treatment allocation sequence was generated by use of the minimisation variables CD4-positive T-cell count (350 vs &gt;350 cells per &#956;L) and study region. Treatment allocation was stratified by baseline plasma HIV-1 RNA concentration (30 000 copies per mL vs &gt;30 000 copies per mL)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-04 17:05:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008">
<DESCRIPTION>
<P>Trial authors provided no information on methods of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-11-04 17:01:45 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-04 17:01:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004">
<DESCRIPTION>
<P>Trial authors provided no information on methods allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:44:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bonnet-2013a">
<DESCRIPTION>
<P>Central location randomization was conducted and communicated to site investigators.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-04 16:44:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Landman-2014">
<DESCRIPTION>
<P>Through a centralized web site, participants were randomized to 1 of the 4 treatment groups at an allocation ratio of 1:1:1:1.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:51:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manosuthi-2009a">
<DESCRIPTION>
<P>The trial authors did not report allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:51:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mateelli-2013">
<DESCRIPTION>
<P>The trial authors did not report this.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 20:20:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-N_x00fa__x00f1_ez-2002">
<DESCRIPTION>
<P>The trial authors did not report this information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:57:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sinha-2013">
<DESCRIPTION>
<P>The trial authors did not report this information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:58:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sow-2006">
<DESCRIPTION>
<P>The trial authors did not report this information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:59:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Swaminathan-2011">
<DESCRIPTION>
<P>The trial conducted randomization centrally and statisticians prepared allocation codes in sealed and opaque envelopes for each site.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 20:03:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wester-2010">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 20:02:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Leth-2004">
<DESCRIPTION>
<P>The trial authors conducted centralized study allocation, which was concealed from the investigator.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 20:21:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008">
<DESCRIPTION>
<P>Participants called a hotline to be assigned a treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-11-03 18:52:28 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-03 18:52:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-02 19:48:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bonnet-2013a">
<DESCRIPTION>
<P>Open label study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-02 19:48:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Landman-2014">
<DESCRIPTION>
<P>Open label study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-02 19:50:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Manosuthi-2009a">
<DESCRIPTION>
<P>Open-label study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-02 19:51:20 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mateelli-2013">
<DESCRIPTION>
<P>Open-label study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-02 19:55:39 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-N_x00fa__x00f1_ez-2002">
<DESCRIPTION>
<P>Open-label study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-02 19:57:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sinha-2013">
<DESCRIPTION>
<P>Open-label study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-02 19:58:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sow-2006">
<DESCRIPTION>
<P>The trial authors did not report this information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-02 19:59:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Swaminathan-2011">
<DESCRIPTION>
<P>Open-label study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-02 20:03:19 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wester-2010">
<DESCRIPTION>
<P>Open-label.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-02 20:02:27 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-van-Leth-2004">
<DESCRIPTION>
<P>"There was no masking after treatment allocation".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-02 20:21:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008">
<DESCRIPTION>
<P>Yes, in the FIRST paper (2001) the trial team was blinded to interm results so for this sub-study we assumed they were blinded to treatment as well.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" NO="9">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-11-02 20:03:19 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-02 19:38:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004">
<DESCRIPTION>
<P>Unclear. The trial authors conducted intention-to-treat (ITT) analyses but loss to follow-up was quite high and reasons for drop-outs were not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-02 19:48:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bonnet-2013a">
<DESCRIPTION>
<P>Losses to follow-up were balanced between the trial groups, and the trial authors reported the reasons for losses to follow-up. The trial authors used ITT analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-02 19:48:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Landman-2014">
<DESCRIPTION>
<P>Losses to follow-up were balanced between groups, and the trial authors reported the reasons for dropouts. The trial authors used ITT analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-02 19:50:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manosuthi-2009a">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-02 19:51:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mateelli-2013">
<DESCRIPTION>
<P>The trial authors did not report this.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-02 19:55:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-N_x00fa__x00f1_ez-2002">
<DESCRIPTION>
<P>There was no missing outcome data. Three participants were lost to follow-up right after enrolment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-02 19:57:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sinha-2013">
<DESCRIPTION>
<P>Losses to follow-up were balanced between treatment groups. The trial authors used ITT analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-02 19:58:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sow-2006">
<DESCRIPTION>
<P>The trial authors did not report this information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-02 20:00:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Swaminathan-2011">
<DESCRIPTION>
<P>Losses to follow-up were balanced between groups and the trial authors reported reasons for losses to follow-up. The trial authors used ITT analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-02 20:03:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wester-2010">
<DESCRIPTION>
<P>The trial authors provided data on losses to follow-up reasons and used ITT analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-18 05:26:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Leth-2004">
<DESCRIPTION>
<P>"All analyses were done for the intention-to-treat population, including all randomised patients (n=1216)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-02 20:01:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008">
<DESCRIPTION>
<P>The trial authors used ITT analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-11-02 20:03:19 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:38:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004">
<DESCRIPTION>
<P>The trial authors reported all outcomes of interest.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:48:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bonnet-2013a">
<DESCRIPTION>
<P>The trial authors reported all outcomes of interest.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:48:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Landman-2014">
<DESCRIPTION>
<P>The trial authors reported on all outcomes of interest.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:50:51 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Manosuthi-2009a">
<DESCRIPTION>
<P>Primary, but not all secondary outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:51:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mateelli-2013">
<DESCRIPTION>
<P>The trial authors did not report all outcomes. There was no usable data on mortality.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:55:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-N_x00fa__x00f1_ez-2002">
<DESCRIPTION>
<P>The trial authors reported primary and secondary outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:57:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sinha-2013">
<DESCRIPTION>
<P>The trial authors reported on all outcomes of interest.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:58:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sow-2006">
<DESCRIPTION>
<P>The trial authors did not report this information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 20:00:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Swaminathan-2011">
<DESCRIPTION>
<P>The trial authors reported all outcomes of interest.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 20:03:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wester-2010">
<DESCRIPTION>
<P>The trial authors reported on all outcomes of interest.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 20:02:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Leth-2004">
<DESCRIPTION>
<P>The trial authors analyzed and reported all outcome measurements.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 20:01:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008">
<DESCRIPTION>
<P>The trial authors reported all outcomes of interest.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2016-11-04 19:34:37 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Baseline data reported?</NAME>
<DESCRIPTION>
<P>What baseline data reported?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:39:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004">
<DESCRIPTION>
<P>The trial authors reported demographic characteristics, clinical stage, CD4 count, and viral load.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:48:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bonnet-2013a">
<DESCRIPTION>
<P>The trial authors reported demographic characteristics, clinical stage, CD4 count, and viral load.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:48:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Landman-2014">
<DESCRIPTION>
<P>The trial authors reported demographic characteristics, clinical stage, CD4 count, and viral load.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:50:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manosuthi-2009a">
<DESCRIPTION>
<P>The trial authors reported age, sex, body weight, body mass index, site of tuberculosis, time from tuberculosis diagnosis to initiation of ART, CD4 cell count, plasma HIV-1 RNA level, haemoglobin concentration, serum alkaline phosphatase, alanine aminotransferase, albumin, creatinine, hepatitis B virus antigen, hepatitis C antibody, cholesterol, triglycerides.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:51:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mateelli-2013">
<DESCRIPTION>
<P>The trial authors did not report baseline data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:56:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-N_x00fa__x00f1_ez-2002">
<DESCRIPTION>
<P>The trial authors reported on age, gender, HIV transmission, plasma HIV RNA, absolute CD4 count, number of participants with AIDS, positive anti-HCV antibody, positive HBsAg.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:57:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sinha-2013">
<DESCRIPTION>
<P>The trial authors reported demographic characteristics, clinical stage, CD4 count, viral load, and type of TB.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:58:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sow-2006">
<DESCRIPTION>
<P>The trial authors did not report this information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 20:00:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Swaminathan-2011">
<DESCRIPTION>
<P>Demographic characteristics, CD4 count, and viral load.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 20:03:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wester-2010">
<DESCRIPTION>
<P>The trial authors reported demographic characteristics, CD4 count, clinical stage, and HIV RNA.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-03 18:34:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Leth-2004">
<DESCRIPTION>
<P>The trial authors reported on gender, age, body mass index, geographical region, HIV risk behaviour, CDC class C, CD4 cell count, HIV RNA, and co-infection (hepatitis B, hepatitis C viruses).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 20:01:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008">
<DESCRIPTION>
<P>Socio-demographic data, CD4 count, viral load, prior AIDS event, hepatitis B or C and history of injection drug use.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-11-04 19:34:37 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-04 16:29:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004">
<DESCRIPTION>
<P>The Mexican Ministry of Health funded this trial (according to author communication).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:48:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bonnet-2013a">
<DESCRIPTION>
<P>We did not identify any other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:48:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Landman-2014">
<DESCRIPTION>
<P>Private funding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:50:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manosuthi-2009a">
<DESCRIPTION>
<P>Yes, this study was funded by the Thailand Ministry of Public Health, Thailand Research Fund, and Bamrasnaradura Infectious Diseases Institute.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:51:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mateelli-2013">
<DESCRIPTION>
<P>It is unclear whether other sources of bias may exist.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:56:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-N_x00fa__x00f1_ez-2002">
<DESCRIPTION>
<P>This trial was not funded by industry. It was funded by the Asociacíon Investigacíon y Educación en SIDA (AIES) and Comunidad Autónoma de Madrid.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:57:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sinha-2013">
<DESCRIPTION>
<P>We did not identify any other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 19:58:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sow-2006">
<DESCRIPTION>
<P>The trial authors did not report this information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 20:00:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Swaminathan-2011">
<DESCRIPTION>
<P>We did not identify any other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 20:03:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wester-2010">
<DESCRIPTION>
<P>We did not identify any other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 20:02:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-van-Leth-2004">
<DESCRIPTION>
<P>Some of the trial authors had received travel grants and honoraria from the sponsors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-02 20:01:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008">
<DESCRIPTION>
<P>This study was sponsored by non-industry funding (NIH).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-11-04 19:59:11 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-11-04 18:10:23 +0000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2016-11-03 15:13:11 +0000" MODIFIED_BY="[Empty name]">'Summary of findings' table 1</TITLE>
<TABLE COLS="6" ROWS="13">
<TR>
<TD ALIGN="LEFT" COLSPAN="6" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Efavirenz (600 mg) versus nevirapine (all doses) for three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-</B>naïve<B> individuals</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="6" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>antiretroviral-naïve individuals<BR/>
<B>Setting: </B>all settings<BR/>
<B>Intervention: </B>efavirenz 600 mg<BR/>
<B>Comparison: </B>nevirapine all doses (400 mg once daily and 400 mg twice daily) as part of a three-drug combination therapy with two NRTIs</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" ROWSPAN="1" VALIGN="BOTTOM">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="BOTTOM">
<P>Number of participants<BR/>(RCTs)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="BOTTOM">
<P>Risk with nevirapine all doses</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="BOTTOM">
<P>Risk with efavirenz 600 mg</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Virological success</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>688 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>715 per 1000<BR/>(681 to 750)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 1.04<BR/>(0.99 to 1.09)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>2438<BR/>(10 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>high<SUP>1,2,3</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Mortality</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>64 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>54 per 1000<BR/>(38 to 76)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.84<BR/>(0.59 to 1.19)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>2317<BR/>(8 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>moderate<SUP>4,5</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Progression to AIDS</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>41 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>50 per 1000<BR/>(29 to 86)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 1.23<BR/>(0.72 to 2.11)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>2005<BR/>(5 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>moderate<SUP>5,6</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>All severe adverse events</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>192 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>216 per 1000<BR/>(162 to 285)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.91<BR/>(0.71 to 1.18)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>2329<BR/>(8 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>very low<SUP>5,7,8</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Discontinuation rate</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>176 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>164 per 1000<BR/>(122 to 220)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.93<BR/>(0.69 to 1.25)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>2384<BR/>(9 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>moderate<SUP>5</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Change in CD4 count</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>The mean change in CD4 count was 0</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>MD 3.03 lower<BR/>(17.41 lower to 11.35 higher)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>1829<BR/>(9 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>moderate<SUP>5,9,10,11</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Treatment failure</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>249 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>242 per 1000<BR/>(189 to 309)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.97<BR/>(0.76 to 1.24)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>737<BR/>(5 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>low<SUP>12,13</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*<B>The risk in the intervention group</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>Abbreviations</B>: CI: confidence interval; RR: risk ratio; OR: odds ratio; RCT: randomized controlled trial; GRADE: Grading of Recommendations Assessment, Development and Evaluation; MD: mean difference.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> we are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Three trials used a cut-off point of 400 copies/mL (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>; <LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>), but we did not downgrade for this.<BR/>
<SUP>2</SUP>Nine trials were open-label (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK>; <LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>; <LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>), but we did not downgrade for this.<BR/>
<SUP>3</SUP>Two trials were industry-funded (<LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>), but we did not downgrade for this.<BR/>
<SUP>4</SUP>Seven trials were open-label but we did not downgrade for this (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>).<BR/>
<SUP>5</SUP>We downgraded by 1 for imprecision due to wide CIs including appreciable harm or benefit.<BR/>
<SUP>6</SUP>Four trials were open-labelled but we did not downgrade for this (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>)<BR/>
<SUP>7</SUP>Six trials were open-label (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>). We downgraded by 1 for this.<BR/>
<SUP>8</SUP>Trials did not report the same adverse events and used different severity scales. We downgraded by 1 for this.<BR/>
<SUP>9</SUP>Seven of the trials were open-label but we did not downgrade for this (<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>; <LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>; <LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK>; <LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>).<BR/>
<SUP>10</SUP>In one trial, the risk of bias was unclear (<LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK>).<BR/>
<SUP>11</SUP>One trial had industry funding (<LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>), but we did not downgrade for this.<BR/>
<SUP>12</SUP>All trials were open-labelled but we did not downgrade for this.<BR/>
<SUP>13</SUP>Each included trial that reported this outcome defined treatment failure differently. We downgraded by 2.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2016-11-04 19:59:11 +0000" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2016-11-03 17:40:02 +0000" MODIFIED_BY="[Empty name]">'Summary of findings' table 2</TITLE>
<TABLE COLS="6" ROWS="18">
<TR>
<TD ALIGN="LEFT" COLSPAN="6" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Efavirenz (600 mg) versus nevirapine (all doses): adverse events for three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-</B>naïve<B> individuals</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="6" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>antiretroviral-naïve individuals<BR/>
<B>Setting: </B>all settings<BR/>
<B>Intervention: </B>efavirenz 600 mg<BR/>
<B>Comparison: </B>nevirapine all doses (400 mg once daily and 400 mg twice daily) as part of a three-drug combination therapy with two NRTIs</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" ROWSPAN="1" VALIGN="BOTTOM">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="BOTTOM">
<P>Number of participants<BR/>(RCTs)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="BOTTOM">
<P>Risk with nevirapine all doses: adverse events</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="BOTTOM">
<P>Risk with efavirenz 600 mg</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Severe adverse events: central nervous system</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>2 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>7 per 1000<BR/>(2 to 18)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 4.46<BR/>(1.65 to 12.03)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>2049<BR/>(6 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>moderate<SUP>1</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Severe adverse events: gastrointestinal</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>18 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>14 per 1000<BR/>(9 to 22)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.76<BR/>(0.48 to 1.21)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>2049<BR/>(6 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>low<SUP>1,2</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Severe adverse events: pyrexia</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>0 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>0 per 1000<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.65<BR/>(0.15 to 2.73)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>1799<BR/>(3 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>low<SUP>2,3</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Severe adverse events: raised transaminases</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>257 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>134 per 1000<BR/>(90 to 201)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.52<BR/>(0.35 to 0.78)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>1299<BR/>(3 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>high<SUP>4</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Severe adverse events: raised alkaline phosphatase</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>12 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>7 per 1000<BR/>(2 to 29)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.65<BR/>(0.17 to 2.50)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>1007<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>low<SUP>2,5</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Severe adverse events: raised amylase</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>14 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>20 per 1000<BR/>(10 to 38)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 1.40<BR/>(0.72 to 2.73)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>1071<BR/>(2 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>low<SUP>2,6,7</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Severe adverse events: raised triglycerides</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>7 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>7 per 1000<BR/>(3 to 21)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 1.10<BR/>(0.39 to 3.13)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>1071<BR/>(2 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>low<SUP>2,6,7</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Severe adverse events: neutropenia</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>38 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>18 per 1000<BR/>(11 to 31)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.48<BR/>(0.28 to 0.82)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>1799<BR/>(3 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>high<SUP>3,8</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Severe adverse events: rash</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>229 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>133 per 1000<BR/>(78 to 229)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.58<BR/>(0.34 to 1.00)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>2277<BR/>(7 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>moderate<SUP>2,9</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Severe adverse events: serum glutamic oxaloacetic transaminase (SGOT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>The mean severe adverse events: SGOT was 0</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>MD 3.3 higher<BR/>(2.06 lower to 8.66 higher)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>135<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>moderate<SUP>2</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Severe adverse events: serum glutamic- pyruvic transaminase (SGPT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>The mean severe adverse events: SGPT was 0</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>MD 5.7 higher<BR/>(4.23 lower to 15.63 higher)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>135<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>moderate<SUP>2</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Raised cholesterol</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>29 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>172 per 1000<BR/>(21 to 1000)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 6.03<BR/>(0.75 to 48.78)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>64<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>moderate<SUP>2</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*<B>The risk in the intervention group</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>Abbreviations</B>: CI: confidence interval; RR: risk ratio; OR: odds ratio; RCT: randomized controlled trial; GRADE: Grading of Recommendations Assessment, Development and Evaluation; MD: mean difference; SGOT: glutamic oxaloacetic transaminase; SGPT: serum glutamic- pyruvic transaminase</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> we are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Five trials (<LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>; <LINK REF="STD-Wester-2010" TYPE="STUDY">Wester 2010</LINK>) were open-label. One trial did not report blinding (<LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK>). We downgraded by 1 for this.<BR/>
<SUP>2</SUP>We downgraded by 1 for very wide CIs.<BR/>
<SUP>3</SUP>All trials were open-label.<BR/>
<SUP>4</SUP>Two trials (<LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>) were open label. <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK> was industry-funded. We did not downgrade for this.<BR/>
<SUP>5</SUP>Data from one open-label industry-funded study (<LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>). We downgraded by 1 for this.<BR/>
<SUP>6</SUP>Both trials were open-label (<LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>), but we did not downgrade for this.<BR/>
<SUP>7</SUP>Most data came from one industry-funded trial (<LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>). We downgraded one point for this.<BR/>
<SUP>8</SUP>We upgraded by 1 due to the large effect.<BR/>
<SUP>9</SUP>Six studies were open-label (<LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>; <LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>; <LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK>; <LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>; <LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>; <LINK REF="STD-Wester-2010" TYPE="STUDY">Wester 2010</LINK>). We did not downgrade for this.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-11-04 19:21:28 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-11-04 19:21:28 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-11-03 16:05:43 +0000" MODIFIED_BY="[Empty name]">Additional characteristics of included studies</TITLE>
<TABLE COLS="6" ROWS="13">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Trial ID</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Location</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>NVP dosage</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>NRTI combination drugs</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Co-infection with tuberculosis</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Virological success cut-off point</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Ayala-Gayt_x00e1_n-2004" TYPE="STUDY">Ayala Gaytán 2004</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Mexico</P>
</TD>
<TD VALIGN="TOP">
<P>200 mg twice daily</P>
</TD>
<TD VALIGN="TOP">
<P>AZT 300 mg and 3TC 150 mg</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>&lt; 400 copies/mL</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bonnet-2013a" TYPE="STUDY">Bonnet 2013a</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Mozambique</P>
</TD>
<TD VALIGN="TOP">
<P>200 mg twice daily</P>
</TD>
<TD VALIGN="TOP">
<P>3TC and d4T/AZT<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>&lt; 50 copies/mL</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Landman-2014" TYPE="STUDY">Landman 2014</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Cameroon and Senegal</P>
</TD>
<TD VALIGN="TOP">
<P>200 mg twice daily</P>
</TD>
<TD VALIGN="TOP">
<P>TDF 300 mg and FTC 200 mg</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>&lt; 50 copies/mL</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Manosuthi-2009a" TYPE="STUDY">Manosuthi 2009a</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Thailand</P>
</TD>
<TD VALIGN="TOP">
<P>400 mg once daily</P>
</TD>
<TD VALIGN="TOP">
<P>3TC 150 mg and D4T 30 or 40 mg</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>&lt; 50 copies/mL</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Mateelli-2013" TYPE="STUDY">Mateelli 2013</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Burkina Faso</P>
</TD>
<TD VALIGN="TOP">
<P>200 mg twice daily</P>
</TD>
<TD VALIGN="TOP">
<P>D4T and 3TC<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-N_x00fa__x00f1_ez-2002" TYPE="STUDY">Núñez 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Spain</P>
</TD>
<TD VALIGN="TOP">
<P>400 mg once daily</P>
</TD>
<TD VALIGN="TOP">
<P>D4T 40 mg and DDI 400 mg</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>&lt; 50 copies/mL</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sinha-2013" TYPE="STUDY">Sinha 2013</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>India</P>
</TD>
<TD VALIGN="TOP">
<P>200 mg twice daily</P>
</TD>
<TD VALIGN="TOP">
<P>AZT, d4T, 3TC<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>&lt; 400 copies/mL</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sow-2006" TYPE="STUDY">Sow 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Senegal</P>
</TD>
<TD VALIGN="TOP">
<P>200 mg twice daily</P>
</TD>
<TD VALIGN="TOP">
<P>AZT 300 mg and 3TC 150 mg</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Swaminathan-2011" TYPE="STUDY">Swaminathan 2011</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>India</P>
</TD>
<TD VALIGN="TOP">
<P>400 mg once daily</P>
</TD>
<TD VALIGN="TOP">
<P>DDI 250 mg or 400 mg and 3TC 300 mg</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-van-den-Berg_x002d_Wolf-2008" TYPE="STUDY">van den Berg-Wolf 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>USA</P>
</TD>
<TD VALIGN="TOP">
<P>200 mg twice daily</P>
</TD>
<TD VALIGN="TOP">
<P>ABC/3TC, DDI/d4T, AZT/3TC, d4T/3TC<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>&lt; 50 copies/mL</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-van-Leth-2004" TYPE="STUDY">van Leth 2004</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>North/South America, Australia, Europe, South Africa, and Thailand</P>
</TD>
<TD VALIGN="TOP">
<P>200 mg twice daily and 400 mg twice daily</P>
</TD>
<TD VALIGN="TOP">
<P>D4T 40 mg and 3TC 150 mg</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>&lt; 50 copies/mL</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Wester-2010" TYPE="STUDY">Wester 2010</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Botswana</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD VALIGN="TOP">
<P>AZT or d4T/3TC or DDI<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Dosage not specified.<BR/>Abbreviations: NRTI: Nucleoside Reverse Transcriptase Inhibitor; ART: antiretroviral therapy; AZT: zidovudine; d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; DDI: didanosine; ABC: abacavir; FTC: Emtricitabine; TDF: Tenofovir.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-11-11 11:54:30 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2016-11-03 19:02:59 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Efavirenz 600 mg versus nevirapine all doses</NAME>
<DICH_OUTCOME CHI2="8.346534921625324" CI_END="1.093619662387725" CI_START="0.9907416031588404" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0409104176441142" ESTIMABLE="YES" EVENTS_1="806" EVENTS_2="910" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.038866309889799736" LOG_CI_START="-0.00403959975807701" LOG_EFFECT_SIZE="0.017413355065861308" METHOD="MH" MODIFIED="2016-11-03 19:00:38 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4996362186539699" P_Q="1.0" P_Z="0.11163163194201217" Q="0.0" RANDOM="YES" SCALE="5.08" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1115" TOTAL_2="1323" WEIGHT="100.00000000000001" Z="1.5909020020408904">
<NAME>Virological success</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nevirapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.277192342012207" CI_START="0.49071395943675394" EFFECT_SIZE="0.7916666666666666" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.10625630586504926" LOG_CI_START="-0.3091715873826035" LOG_EFFECT_SIZE="-0.10145764075877708" MODIFIED="2015-04-04 00:48:20 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.244024400894908" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004" TOTAL_1="24" TOTAL_2="19" VAR="0.05954790823211878" WEIGHT="1.0667015382554002"/>
<DICH_DATA CI_END="1.2133236584625626" CI_START="0.9640373069901786" EFFECT_SIZE="1.0815217391304348" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="184" LOG_CI_END="0.08397666594059615" LOG_CI_START="-0.015906159140255803" LOG_EFFECT_SIZE="0.0340352534001702" MODIFIED="2015-04-04 00:48:20 +0100" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.05867166588045062" STUDY_ID="STD-Bonnet-2013a" TOTAL_1="285" TOTAL_2="285" VAR="0.003442364377187233" WEIGHT="18.452388634986622"/>
<DICH_DATA CI_END="1.333462983960702" CI_START="0.7326382745488663" EFFECT_SIZE="0.9884057971014493" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" LOG_CI_END="0.1249809644692886" LOG_CI_START="-0.1351103966308414" LOG_EFFECT_SIZE="-0.005064716080776403" MODIFIED="2015-04-04 00:48:20 +0100" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.15277895298321792" STUDY_ID="STD-Landman-2014" TOTAL_1="30" TOTAL_2="31" VAR="0.023341408474648308" WEIGHT="2.721337291195731"/>
<DICH_DATA CI_END="1.24840921256986" CI_START="0.8327398927527776" EFFECT_SIZE="1.0196078431372548" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="51" LOG_CI_END="0.0963569648583158" LOG_CI_START="-0.0794906297845903" LOG_EFFECT_SIZE="0.008433167536862764" MODIFIED="2015-04-04 00:48:20 +0100" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.1032937475528751" STUDY_ID="STD-Manosuthi-2009a" TOTAL_1="71" TOTAL_2="71" VAR="0.010669598283517089" WEIGHT="5.953349284876173"/>
<DICH_DATA CI_END="1.6112694707026136" CI_START="0.6514244559438659" EFFECT_SIZE="1.0245098039215685" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.2071681784406601" LOG_CI_START="-0.1861359410703497" LOG_EFFECT_SIZE="0.010516118685155208" MODIFIED="2015-04-09 22:51:05 +0100" MODIFIED_BY="[Empty name]" ORDER="265" O_E="0.0" SE="0.23102878668755772" STUDY_ID="STD-Mateelli-2013" TOTAL_1="36" TOTAL_2="33" VAR="0.05337430027832504" WEIGHT="1.1900829608980843"/>
<DICH_DATA CI_END="1.601776403637903" CI_START="0.8419372455834492" EFFECT_SIZE="1.1612903225806452" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" LOG_CI_END="0.2046018916211215" LOG_CI_START="-0.07472027775509224" LOG_EFFECT_SIZE="0.06494080693301461" MODIFIED="2015-04-04 00:48:20 +0100" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="0.1640752249586257" STUDY_ID="STD-N_x00fa__x00f1_ez-2002" TOTAL_1="31" TOTAL_2="36" VAR="0.026920679445223625" WEIGHT="2.3595186533214507"/>
<DICH_DATA CI_END="1.1692144629653884" CI_START="0.8895941392566248" EFFECT_SIZE="1.0198658410732715" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="57" LOG_CI_END="0.06789417886057111" LOG_CI_START="-0.0508080869320852" LOG_EFFECT_SIZE="0.008543045964242942" MODIFIED="2015-04-04 00:48:20 +0100" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.06972629851229843" STUDY_ID="STD-Sinha-2013" TOTAL_1="68" TOTAL_2="67" VAR="0.00486175670422615" WEIGHT="13.065204446754194"/>
<DICH_DATA CI_END="1.6258772186742807" CI_START="1.0483215238589536" EFFECT_SIZE="1.3055428309665598" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="37" LOG_CI_END="0.2110877458917546" LOG_CI_START="0.020494502706987376" LOG_EFFECT_SIZE="0.11579112429937101" MODIFIED="2015-04-04 00:48:20 +0100" MODIFIED_BY="[Empty name]" ORDER="170" O_E="0.0" SE="0.11195541449850178" STUDY_ID="STD-Swaminathan-2011" TOTAL_1="59" TOTAL_2="57" VAR="0.012534014835531345" WEIGHT="5.067797201821307"/>
<DICH_DATA CI_END="1.0816214984453993" CI_START="0.8471851158083397" EFFECT_SIZE="0.9572531715388858" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="98" LOG_CI_END="0.03407531077527663" LOG_CI_START="-0.07202168295143238" LOG_EFFECT_SIZE="-0.01897318608807788" MODIFIED="2015-04-04 00:48:20 +0100" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.06232189930365791" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008" TOTAL_1="111" TOTAL_2="117" VAR="0.003884019132815277" WEIGHT="16.35415355563685"/>
<DICH_DATA CI_END="1.1366040633995547" CI_START="0.9589046825659485" EFFECT_SIZE="1.043980343980344" ESTIMABLE="YES" EVENTS_1="280" EVENTS_2="407" LOG_CI_END="0.05560920432955432" LOG_CI_START="-0.01822456060096563" LOG_EFFECT_SIZE="0.01869232186429434" MODIFIED="2015-05-18 06:12:30 +0100" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.043370319003218236" STUDY_ID="STD-van-Leth-2004" TOTAL_1="400" TOTAL_2="607" VAR="0.0018809845704409129" WEIGHT="33.769466432254205"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.337183420500338" CI_END="1.1905596566040093" CI_START="0.587208184016444" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8361258122541615" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="75" I2="6.317628493058772" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.07575116192889249" LOG_CI_START="-0.231207900216623" LOG_EFFECT_SIZE="-0.07772836914386531" METHOD="MH" MODIFIED="2016-11-03 19:00:56 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.376129727468799" P_Q="1.0" P_Z="0.3209016929836985" Q="0.0" RANDOM="YES" SCALE="276.78" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.013089804741422573" TOTALS="YES" TOTAL_1="1054" TOTAL_2="1263" WEIGHT="100.0" Z="0.9926066559767545">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nevirapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-04-04 00:48:27 +0100" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.0" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004" TOTAL_1="30" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.7080004329220688" CI_START="0.4626014382434143" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.2324879764324018" LOG_CI_START="-0.33479302132716443" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2015-04-04 00:48:27 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.33322366617019633" STUDY_ID="STD-Bonnet-2013a" TOTAL_1="285" TOTAL_2="285" VAR="0.11103801169590644" WEIGHT="26.191900180046396"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-04-04 00:48:27 +0100" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.0" STUDY_ID="STD-Landman-2014" TOTAL_1="30" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5960270953377167" CI_START="0.06961730877607697" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2030402599819847" LOG_CI_START="-1.1572827694213097" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-04-04 00:48:27 +0100" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="0.7990604811790905" STUDY_ID="STD-Manosuthi-2009a" TOTAL_1="71" TOTAL_2="71" VAR="0.6384976525821596" WEIGHT="4.989573296956676"/>
<DICH_DATA CI_END="1.6080587617099806" CI_START="0.3572260822793558" EFFECT_SIZE="0.7579185520361991" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.2063019146985718" LOG_CI_START="-0.44705683932306517" LOG_EFFECT_SIZE="-0.12037746231224666" MODIFIED="2015-04-04 00:48:27 +0100" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.3837861662903021" STUDY_ID="STD-Sinha-2013" TOTAL_1="68" TOTAL_2="67" VAR="0.1472918214358074" WEIGHT="20.271295753672945"/>
<DICH_DATA CI_END="1.553759423905636" CI_START="0.004970319883648871" EFFECT_SIZE="0.08787878787878788" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.19138377575287346" LOG_CI_START="-2.303615659710736" LOG_EFFECT_SIZE="-1.0561159419789314" MODIFIED="2015-04-04 00:48:27 +0100" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="1.4655750188377155" STUDY_ID="STD-Swaminathan-2011" TOTAL_1="59" TOTAL_2="57" VAR="2.1479101358411703" WEIGHT="1.5044625021216589"/>
<DICH_DATA CI_END="2.094724414626652" CI_START="0.6548078127150315" EFFECT_SIZE="1.1711711711711712" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.32112689456742916" LOG_CI_START="-0.1838861475270705" LOG_EFFECT_SIZE="0.06862037352017934" MODIFIED="2015-04-04 00:48:27 +0100" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.29664716078118464" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008" TOTAL_1="111" TOTAL_2="117" VAR="0.087999537999538" WEIGHT="32.16108928539217"/>
<DICH_DATA CI_END="1.721420569161093" CI_START="0.29132917124498864" EFFECT_SIZE="0.7081666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="0.2358869880218748" LOG_CI_START="-0.5356160266101332" LOG_EFFECT_SIZE="-0.1498645192941292" MODIFIED="2015-05-18 06:15:38 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.45318468979635596" STUDY_ID="STD-van-Leth-2004" TOTAL_1="400" TOTAL_2="607" VAR="0.20537636306581938" WEIGHT="14.881678981810158"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.462298697579544" CI_END="2.105485988673027" CI_START="0.7159784615185047" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2277958376370566" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="45" I2="32.770076516229835" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.32335235567685594" LOG_CI_START="-0.14510004219543696" LOG_EFFECT_SIZE="0.08912615674070945" METHOD="MH" MODIFIED="2016-11-03 19:01:09 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.21567818918197668" P_Q="1.0" P_Z="0.4557929968728641" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09877201553163178" TOTALS="YES" TOTAL_1="897" TOTAL_2="1108" WEIGHT="100.0" Z="0.7457921363437391">
<NAME>Progression to AIDS</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nevirapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-04-20 16:13:50 +0100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.0" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004" TOTAL_1="30" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.8699019605733955" CI_START="0.11484643512224581" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5876999628170224" LOG_CI_START="-0.939882480928385" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2015-04-04 00:48:30 +0100" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.8973094891111016" STUDY_ID="STD-Manosuthi-2009a" TOTAL_1="71" TOTAL_2="71" VAR="0.8051643192488263" WEIGHT="8.376609942370191"/>
<DICH_DATA CI_END="1.8074607968432617" CI_START="0.39322715656926094" EFFECT_SIZE="0.8430555555555556" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="0.2570688863819023" LOG_CI_START="-0.4053564970939241" LOG_EFFECT_SIZE="-0.07414380535601088" MODIFIED="2015-05-18 06:16:51 +0100" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="0.3891119493122326" STUDY_ID="STD-van-Leth-2004" TOTAL_1="400" TOTAL_2="607" VAR="0.15140810909756544" WEIGHT="30.265881833796062"/>
<DICH_DATA CI_END="2.0919005393381997" CI_START="0.6409101180454797" EFFECT_SIZE="1.1578947368421053" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="19" LOG_CI_END="0.3205410318953125" LOG_CI_START="-0.19320287215655796" LOG_EFFECT_SIZE="0.0636690798693773" MODIFIED="2015-04-04 00:48:30 +0100" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.30177571231340794" STUDY_ID="STD-Bonnet-2013a" TOTAL_1="285" TOTAL_2="285" VAR="0.09106858054226476" WEIGHT="39.885684336158754"/>
<DICH_DATA CI_END="7.923286180783608" CI_START="1.0993512793023954" EFFECT_SIZE="2.9513513513513514" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.8989053424708964" LOG_CI_START="0.04113648613255058" LOG_EFFECT_SIZE="0.47002091430172344" MODIFIED="2015-04-04 00:48:30 +0100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.5038576722374621" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008" TOTAL_1="111" TOTAL_2="117" VAR="0.25387255387255386" WEIGHT="21.471823887674994"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.264064867344109" CI_END="1.1828302780836306" CI_START="0.7073551742810951" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9147027481640156" ESTIMABLE="YES" EVENTS_1="204" EVENTS_2="267" I2="42.922676325374724" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.07292243306437779" LOG_CI_START="-0.1503624652721762" LOG_EFFECT_SIZE="-0.03872001610389921" METHOD="MH" MODIFIED="2016-11-03 19:01:51 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.09220265172421238" P_Q="1.0" P_Z="0.49665777094379515" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0485810455825799" TOTALS="YES" TOTAL_1="1058" TOTAL_2="1271" WEIGHT="100.0" Z="0.6797579022121392">
<NAME>All severe adverse events</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nevirapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3792843928083194" CI_START="0.25777975744361165" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5288247425384452" LOG_CI_START="-0.5887511892933317" LOG_EFFECT_SIZE="-0.02996322337744321" MODIFIED="2015-04-04 00:48:38 +0100" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="0.6564696344480687" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004" TOTAL_1="30" TOTAL_2="28" VAR="0.430952380952381" WEIGHT="3.587360487160572"/>
<DICH_DATA CI_END="1.2554225135728974" CI_START="0.7127590297110059" EFFECT_SIZE="0.9459459459459459" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="74" LOG_CI_END="0.09878991261547755" LOG_CI_START="-0.14705727204891628" LOG_EFFECT_SIZE="-0.024133679716719363" MODIFIED="2015-04-04 00:48:38 +0100" MODIFIED_BY="[Empty name]" ORDER="86" O_E="0.0" SE="0.14441185323505598" STUDY_ID="STD-Bonnet-2013a" TOTAL_1="288" TOTAL_2="288" VAR="0.02085478335478335" WEIGHT="24.77480708376146"/>
<DICH_DATA CI_END="1.3891990268502123" CI_START="0.17995981509347528" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.14276447041058557" LOG_CI_START="-0.744824461738548" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-04-04 00:48:38 +0100" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="0.5213741323804749" STUDY_ID="STD-Manosuthi-2009a" TOTAL_1="71" TOTAL_2="71" VAR="0.27183098591549304" WEIGHT="5.368897224555632"/>
<DICH_DATA CI_END="3.1554674511599816" CI_START="1.0714270801914791" EFFECT_SIZE="1.8387096774193548" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" LOG_CI_END="0.49906370475971923" LOG_CI_START="0.0299626189167182" LOG_EFFECT_SIZE="0.2645131618382187" MODIFIED="2015-04-04 00:48:38 +0100" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.27555229991200386" STUDY_ID="STD-N_x00fa__x00f1_ez-2002" TOTAL_1="31" TOTAL_2="36" VAR="0.07592906998679493" WEIGHT="13.816220945243101"/>
<DICH_DATA CI_END="2.3820243242881496" CI_START="0.2994277236824735" EFFECT_SIZE="0.8445378151260504" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3769461920124943" LOG_CI_START="-0.5237079912845406" LOG_EFFECT_SIZE="-0.07338089963602308" MODIFIED="2015-05-25 17:36:15 +0100" MODIFIED_BY="[Empty name]" ORDER="202" O_E="0.0" SE="0.5290487255787882" STUDY_ID="STD-Sinha-2013" TOTAL_1="68" TOTAL_2="67" VAR="0.27989255403654" WEIGHT="5.237130985926889"/>
<DICH_DATA CI_END="2.733983640809311" CI_START="0.21848908729050606" EFFECT_SIZE="0.7728813559322034" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4367959115750732" LOG_CI_START="-0.6605702495304917" LOG_EFFECT_SIZE="-0.11188716897770919" MODIFIED="2015-04-04 00:48:38 +0100" MODIFIED_BY="[Empty name]" ORDER="180" O_E="0.0" SE="0.6445983150835133" STUDY_ID="STD-Swaminathan-2011" TOTAL_1="59" TOTAL_2="57" VAR="0.4155069878085043" WEIGHT="3.7067520445513917"/>
<DICH_DATA CI_END="0.9012801191431967" CI_START="0.38401796943794386" EFFECT_SIZE="0.5883092394720302" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="43" LOG_CI_END="-0.04514020869789819" LOG_CI_START="-0.4156484531190544" LOG_EFFECT_SIZE="-0.2303943309084763" MODIFIED="2015-12-23 17:41:35 +0000" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.21763837681837614" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008" TOTAL_1="111" TOTAL_2="117" VAR="0.047366463064137485" WEIGHT="17.92917076104915"/>
<DICH_DATA CI_END="1.2751165146668086" CI_START="0.7463395845795415" EFFECT_SIZE="0.9755357142857143" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="112" LOG_CI_END="0.10554987054636887" LOG_CI_START="-0.12706352352960476" LOG_EFFECT_SIZE="-0.010756826491617962" MODIFIED="2015-05-18 06:17:43 +0100" MODIFIED_BY="[Empty name]" ORDER="181" O_E="0.0" SE="0.13663825913509803" STUDY_ID="STD-van-Leth-2004" TOTAL_1="400" TOTAL_2="607" VAR="0.018670013859470203" WEIGHT="25.579660467751808"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.283807745287017" CI_END="1.2467895536268763" CI_START="0.6897490942509479" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9273467341483883" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="228" I2="34.87361438826332" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.0957931548325777" LOG_CI_START="-0.16130886114536785" LOG_EFFECT_SIZE="-0.03275785315639506" METHOD="MH" MODIFIED="2016-11-03 19:02:07 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.13898333506562432" P_Q="1.0" P_Z="0.617465629003561" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06257954744766431" TOTALS="YES" TOTAL_1="1090" TOTAL_2="1294" WEIGHT="99.99999999999997" Z="0.4994454217184636">
<NAME>Discontinuation rate</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nevirapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.184805150349353" CI_START="0.140846977380024" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7913260219180813" LOG_CI_START="-0.8512524686729677" LOG_EFFECT_SIZE="-0.02996322337744321" MODIFIED="2015-04-04 00:48:34 +0100" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.964858736267844" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004" TOTAL_1="30" TOTAL_2="28" VAR="0.930952380952381" WEIGHT="2.295642940996541"/>
<DICH_DATA CI_END="2.2913204096377298" CI_START="0.7758748057670615" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="21" LOG_CI_END="0.36008582354465946" LOG_CI_START="-0.11020835032805965" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2015-04-04 00:48:34 +0100" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.27625312572654126" STUDY_ID="STD-Bonnet-2013a" TOTAL_1="285" TOTAL_2="285" VAR="0.07631578947368421" WEIGHT="16.420958461534074"/>
<DICH_DATA CI_END="4.354129221503021" CI_START="0.3831771389646205" EFFECT_SIZE="1.2916666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6389013138536588" LOG_CI_START="-0.41660040960832545" LOG_EFFECT_SIZE="0.11115045212266668" MODIFIED="2015-04-04 00:48:34 +0100" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.6200069371793655" STUDY_ID="STD-Landman-2014" TOTAL_1="30" TOTAL_2="31" VAR="0.3844086021505376" WEIGHT="5.102583950237725"/>
<DICH_DATA CI_END="1.1878023106995372" CI_START="0.26637955419842346" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.07474416579963411" LOG_CI_START="-0.5744991122328339" LOG_EFFECT_SIZE="-0.2498774732165999" MODIFIED="2015-04-04 00:48:34 +0100" MODIFIED_BY="[Empty name]" ORDER="11" O_E="0.0" SE="0.3813687153223296" STUDY_ID="STD-Manosuthi-2009a" TOTAL_1="71" TOTAL_2="71" VAR="0.14544209702660404" WEIGHT="10.964217516165112"/>
<DICH_DATA CI_END="2.9278073153759534" CI_START="0.6687789963244942" EFFECT_SIZE="1.3993055555555556" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.4665424915726442" LOG_CI_START="-0.17471737480888702" LOG_EFFECT_SIZE="0.1459125583818786" MODIFIED="2015-04-04 00:48:34 +0100" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.3766792198000443" STUDY_ID="STD-N_x00fa__x00f1_ez-2002" TOTAL_1="36" TOTAL_2="31" VAR="0.1418872346291701" WEIGHT="11.15484155870937"/>
<DICH_DATA CI_END="2.3820243242881496" CI_START="0.2994277236824735" EFFECT_SIZE="0.8445378151260504" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3769461920124943" LOG_CI_START="-0.5237079912845406" LOG_EFFECT_SIZE="-0.07338089963602308" MODIFIED="2015-04-04 00:48:34 +0100" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.5290487255787882" STUDY_ID="STD-Sinha-2013" TOTAL_1="68" TOTAL_2="67" VAR="0.27989255403654" WEIGHT="6.659796661397368"/>
<DICH_DATA CI_END="2.733983640809311" CI_START="0.21848908729050606" EFFECT_SIZE="0.7728813559322034" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4367959115750732" LOG_CI_START="-0.6605702495304917" LOG_EFFECT_SIZE="-0.11188716897770919" MODIFIED="2015-04-04 00:48:34 +0100" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="0.6445983150835133" STUDY_ID="STD-Swaminathan-2011" TOTAL_1="59" TOTAL_2="57" VAR="0.4155069878085043" WEIGHT="4.770673068347653"/>
<DICH_DATA CI_END="2.410202149240874" CI_START="0.7202650182901416" EFFECT_SIZE="1.3175675675675675" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.3820534693873404" LOG_CI_START="-0.14250767745221926" LOG_EFFECT_SIZE="0.11977289596756062" MODIFIED="2015-04-04 00:48:34 +0100" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.3081298142731119" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008" TOTAL_1="111" TOTAL_2="117" VAR="0.09494398244398244" WEIGHT="14.479072171980269"/>
<DICH_DATA CI_END="0.8372623092160069" CI_START="0.49170476893062054" EFFECT_SIZE="0.6416275167785235" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="149" LOG_CI_END="-0.0771384588549314" LOG_CI_START="-0.3082955795678629" LOG_EFFECT_SIZE="-0.19271701921139714" MODIFIED="2015-05-18 06:18:41 +0100" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.13578283695297766" STUDY_ID="STD-van-Leth-2004" TOTAL_1="400" TOTAL_2="607" VAR="0.018436978810998914" WEIGHT="28.15221367063187"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="11.254580381811639" CI_END="11.34764529673054" CI_START="-17.406795938172294" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.0295753207208778" ESTIMABLE="YES" I2="28.917829642687686" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2016-11-03 19:02:24 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.18768748656937817" P_Q="1.0" P_Z="0.6796032309811826" Q="0.0" RANDOM="YES" SCALE="267.12" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="126.61123147118334" TOTALS="YES" TOTAL_1="809" TOTAL_2="1020" UNITS="" WEIGHT="99.99999999999999" Z="0.4130046185600566">
<NAME>Change in CD4 count</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nevirapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="65.07689457849261" CI_START="-43.07689457849261" EFFECT_SIZE="11.0" ESTIMABLE="YES" MEAN_1="144.0" MEAN_2="133.0" MODIFIED="2015-04-04 00:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="61" SD_1="105.0" SD_2="105.0" SE="27.59075932264279" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004" TOTAL_1="30" TOTAL_2="28" WEIGHT="6.060502002658558"/>
<CONT_DATA CI_END="36.70347066133179" CI_START="-94.70347066133179" EFFECT_SIZE="-29.0" ESTIMABLE="YES" MEAN_1="190.0" MEAN_2="219.0" MODIFIED="2015-04-09 22:54:30 +0100" MODIFIED_BY="[Empty name]" ORDER="78" SD_1="134.0" SD_2="150.0" SE="33.52279489806567" STUDY_ID="STD-Bonnet-2013a" TOTAL_1="36" TOTAL_2="36" WEIGHT="4.3033685769886905"/>
<CONT_DATA CI_END="37.54007001393719" CI_START="-31.54007001393719" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="199.0" MEAN_2="196.0" MODIFIED="2015-04-04 00:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="59" SD_1="105.0" SD_2="105.0" SE="17.62280852423047" STUDY_ID="STD-Manosuthi-2009a" TOTAL_1="71" TOTAL_2="71" WEIGHT="12.30831943748763"/>
<CONT_DATA CI_END="38.3439734695373" CI_START="-96.3439734695373" EFFECT_SIZE="-29.0" ESTIMABLE="YES" MEAN_1="190.0" MEAN_2="219.0" MODIFIED="2015-05-18 05:45:07 +0100" MODIFIED_BY="[Empty name]" ORDER="266" SD_1="134.0" SD_2="150.0" SE="34.35980150693481" STUDY_ID="STD-Mateelli-2013" TOTAL_1="36" TOTAL_2="33" WEIGHT="4.116321274993368"/>
<CONT_DATA CI_END="48.42462697644347" CI_START="-52.42462697644347" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="117.0" MEAN_2="119.0" MODIFIED="2015-04-04 00:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="172" SD_1="105.0" SD_2="105.0" SE="25.72732324378738" STUDY_ID="STD-N_x00fa__x00f1_ez-2002" TOTAL_1="31" TOTAL_2="36" WEIGHT="6.824148568496794"/>
<CONT_DATA CI_END="-16.805294420666577" CI_START="-115.19470557933343" EFFECT_SIZE="-66.0" ESTIMABLE="YES" MEAN_1="110.0" MEAN_2="176.0" MODIFIED="2015-04-04 00:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="62" SD_1="105.0" SD_2="105.0" SE="25.099800796022265" STUDY_ID="STD-Sow-2006" TOTAL_1="35" TOTAL_2="35" WEIGHT="7.1118224890095885"/>
<CONT_DATA CI_END="50.7650385560292" CI_START="-22.765038556029197" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="215.0" MEAN_2="201.0" MODIFIED="2015-04-04 00:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="173" SD_1="101.0" SD_2="101.0" SE="18.75801741563984" STUDY_ID="STD-Swaminathan-2011" TOTAL_1="59" TOTAL_2="57" WEIGHT="11.245918741318697"/>
<CONT_DATA CI_END="46.26781842075913" CI_START="-8.26781842075913" EFFECT_SIZE="19.0" ESTIMABLE="YES" MEAN_1="172.0" MEAN_2="153.0" MODIFIED="2015-04-04 00:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="63" SD_1="105.0" SD_2="105.0" SE="13.912407899249272" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008" TOTAL_1="111" TOTAL_2="117" WEIGHT="16.806529453003456"/>
<CONT_DATA CI_END="8.253414605033496" CI_START="-18.253414605033498" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="160.0" MEAN_2="165.0" MODIFIED="2015-05-18 06:19:17 +0100" MODIFIED_BY="[Empty name]" ORDER="60" SD_1="105.0" SD_2="105.0" SE="6.762070481689837" STUDY_ID="STD-van-Leth-2004" TOTAL_1="400" TOTAL_2="607" WEIGHT="31.22306945604321"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.671999338570643" CI_END="1.2436462313861754" CI_START="0.7601951313165409" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9723239224558525" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.09469685816265547" LOG_CI_START="-0.11907491617086739" LOG_EFFECT_SIZE="-0.012189029004105985" METHOD="MH" MODIFIED="2016-11-03 19:02:43 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.4522116294704873" P_Q="1.0" P_Z="0.8231386506764631" Q="0.0" RANDOM="YES" SCALE="213.7" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="456" TOTAL_2="281" WEIGHT="100.0" Z="0.22350993651097245">
<NAME>Treatment failure</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nevirapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.722466212992025" CI_START="0.22610596447258932" EFFECT_SIZE="1.0333333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6741688594337623" LOG_CI_START="-0.6456879812045416" LOG_EFFECT_SIZE="0.014240439114610285" MODIFIED="2015-04-04 01:03:58 +0100" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="0.77529044158767" STUDY_ID="STD-Landman-2014" TOTAL_1="30" TOTAL_2="31" VAR="0.6010752688172043" WEIGHT="2.6232946202083207"/>
<DICH_DATA CI_END="3.0784923378973987" CI_START="0.00886276705103594" EFFECT_SIZE="0.16517857142857142" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.48833807700724047" LOG_CI_START="-2.0524306655415763" LOG_EFFECT_SIZE="-0.7820462942671679" MODIFIED="2015-04-04 01:37:28 +0100" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="1.49246013638129" STUDY_ID="STD-N_x00fa__x00f1_ez-2002" TOTAL_1="31" TOTAL_2="36" VAR="2.2274372586872584" WEIGHT="0.7078976132228877"/>
<DICH_DATA CI_END="1.8884291776112732" CI_START="0.6663446353045597" EFFECT_SIZE="1.1217596229379418" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" LOG_CI_END="0.2761007019782796" LOG_CI_START="-0.17630109440527925" LOG_EFFECT_SIZE="0.049899803786500184" MODIFIED="2015-04-04 01:05:41 +0100" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.26574305462071157" STUDY_ID="STD-Sinha-2013" TOTAL_1="67" TOTAL_2="68" VAR="0.0706193710791465" WEIGHT="22.32811613772728"/>
<DICH_DATA CI_END="1.3261560122728426" CI_START="0.17595073209344608" EFFECT_SIZE="0.4830508474576271" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.12259461855110707" LOG_CI_START="-0.754608921818375" LOG_EFFECT_SIZE="-0.316007151633634" MODIFIED="2015-05-25 16:11:47 +0100" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.5152737018405892" STUDY_ID="STD-Swaminathan-2011" TOTAL_1="59" TOTAL_2="57" VAR="0.26550698780850435" WEIGHT="5.938817400036567"/>
<DICH_DATA CI_END="1.3493120473381688" CI_START="0.7441126662421813" EFFECT_SIZE="1.0020180562931493" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="35" LOG_CI_END="0.1301123979783165" LOG_CI_START="-0.12836130286431752" LOG_EFFECT_SIZE="8.755475569994527E-4" MODIFIED="2015-04-04 01:38:16 +0100" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="0.15182873134041736" STUDY_ID="STD-van-Leth-2004" TOTAL_1="269" TOTAL_2="89" VAR="0.023051963660440634" WEIGHT="68.40187422880494"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.389309498608326" CI_END="0.9527592061933436" CI_START="0.6011428363906564" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7567987655964938" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="108" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-0.02101684609329003" LOG_CI_START="-0.22102232386096132" LOG_EFFECT_SIZE="-0.12101958497712567" METHOD="MH" MODIFIED="2016-11-03 19:02:59 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.7080427505798244" P_Q="1.0" P_Z="0.01769806186693003" Q="0.0" RANDOM="YES" SCALE="32.49" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="482" TOTAL_2="506" WEIGHT="100.0" Z="2.371875316881854">
<NAME>Development of drug resistance</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nevirapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2133701609719099" CI_START="0.5819054782603198" EFFECT_SIZE="0.8402777777777778" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="27" LOG_CI_END="0.08399331063062246" LOG_CI_START="-0.23514755418822164" LOG_EFFECT_SIZE="-0.07557712177879956" MODIFIED="2015-04-04 01:39:48 +0100" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="0.18746492376734814" STUDY_ID="STD-Bonnet-2013a" TOTAL_1="16" TOTAL_2="33" VAR="0.03514309764309764" WEIGHT="39.27524885616922"/>
<DICH_DATA CI_END="21.613608064382852" CI_START="0.1976121292839344" EFFECT_SIZE="2.066666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.334727271818652" LOG_CI_START="-0.7041864022614692" LOG_EFFECT_SIZE="0.31527043477859146" MODIFIED="2015-05-25 16:40:07 +0100" MODIFIED_BY="[Empty name]" ORDER="196" O_E="0.0" SE="1.1976679849401242" STUDY_ID="STD-Landman-2014" TOTAL_1="30" TOTAL_2="31" VAR="1.4344086021505376" WEIGHT="0.9622459761046942"/>
<DICH_DATA CI_END="0.988567163815834" CI_START="0.4793220208226684" EFFECT_SIZE="0.6883618312189741" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="49" LOG_CI_END="-0.004993819133614054" LOG_CI_START="-0.31937261836459285" LOG_EFFECT_SIZE="-0.16218321874910346" MODIFIED="2015-04-04 01:40:08 +0100" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="0.1846676628684312" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008" TOTAL_1="111" TOTAL_2="117" VAR="0.03410214570928856" WEIGHT="40.47410732672366"/>
<DICH_DATA CI_END="1.198840481191627" CI_START="0.4201076352055881" EFFECT_SIZE="0.7096774193548387" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="31" LOG_CI_END="0.07876139932308725" LOG_CI_START="-0.37663942534722006" LOG_EFFECT_SIZE="-0.1489390130120664" MODIFIED="2015-05-25 17:10:56 +0100" MODIFIED_BY="[Empty name]" ORDER="197" O_E="0.0" SE="0.26750469868177706" STUDY_ID="STD-Wester-2010" TOTAL_1="325" TOTAL_2="325" VAR="0.07155876381682834" WEIGHT="19.28839784100242"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-11-11 11:54:30 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Efavirenz 600 mg versus nevirapine all doses: adverse events</NAME>
<DICH_OUTCOME CHI2="7.135726058611859" CI_END="12.033297434741437" CI_START="1.6518532201609673" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="4.4583899691180395" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="20" I2="43.94403642818464" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="1.0803846515696278" LOG_CI_START="0.21797145430021755" LOG_EFFECT_SIZE="0.6491780529349227" METHOD="MH" MODIFIED="2016-11-11 11:45:31 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.12888726471262402" P_Q="1.0" P_Z="0.0031704448480631853" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5193759719865149" TOTALS="YES" TOTAL_1="919" TOTAL_2="1130" WEIGHT="100.0" Z="2.9507099551233082">
<NAME>Severe adverse events: central nervous system</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Nevirapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-05-18 06:09:25 +0100" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.0" STUDY_ID="STD-Manosuthi-2009a" TOTAL_1="71" TOTAL_2="71" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="485.92940799900055" CI_START="1.8521208743181299" EFFECT_SIZE="30.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="2.6865731829593127" LOG_CI_START="0.26766932648001235" LOG_EFFECT_SIZE="1.4771212547196624" MODIFIED="2015-05-18 06:09:25 +0100" MODIFIED_BY="[Empty name]" ORDER="182" O_E="0.0" SE="1.420876099063141" STUDY_ID="STD-N_x00fa__x00f1_ez-2002" TOTAL_1="29" TOTAL_2="35" VAR="2.018888888888889" WEIGHT="10.110416669215885"/>
<DICH_DATA CI_END="28.54475383444708" CI_START="1.716602647344187" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="1.455526302070246" LOG_CI_START="0.23466977795826757" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2015-05-18 06:09:25 +0100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.7171371656006361" STUDY_ID="STD-Sow-2006" TOTAL_1="35" TOTAL_2="35" VAR="0.5142857142857142" WEIGHT="24.827190270377248"/>
<DICH_DATA CI_END="69.74911475292275" CI_START="0.12057500700605786" EFFECT_SIZE="2.9" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8435386999691405" LOG_CI_START="-0.9187427041712286" LOG_EFFECT_SIZE="0.4623979978989561" MODIFIED="2015-05-25 17:27:28 +0100" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="1.6225777703055269" STUDY_ID="STD-Swaminathan-2011" TOTAL_1="59" TOTAL_2="57" VAR="2.632758620689655" WEIGHT="8.141440222732287"/>
<DICH_DATA CI_END="3.6513357795201715" CI_START="1.056216981276393" EFFECT_SIZE="1.9638235294117647" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.5624517728257485" LOG_CI_START="0.02375314555670652" LOG_EFFECT_SIZE="0.2931024591912275" MODIFIED="2015-05-18 06:30:03 +0100" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.31643424025904665" STUDY_ID="STD-van-Leth-2004" TOTAL_1="400" TOTAL_2="607" VAR="0.10013062840832004" WEIGHT="41.42476503708546"/>
<DICH_DATA CI_END="56.574084238817115" CI_START="0.8661209573124591" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7526175327858946" LOG_CI_START="-0.062421452757381195" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2015-05-25 17:41:31 +0100" MODIFIED_BY="[Empty name]" ORDER="203" O_E="0.0" SE="1.0661628846960003" STUDY_ID="STD-Wester-2010" TOTAL_1="325" TOTAL_2="325" VAR="1.1367032967032968" WEIGHT="15.496187800589126"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.323106594395222" CI_END="1.210527906314459" CI_START="0.47873271746381335" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7612616594546854" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="40" I2="7.473944658549943" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.08297480568909618" LOG_CI_START="-0.31990689102974973" LOG_EFFECT_SIZE="-0.11846604267032677" METHOD="MH" MODIFIED="2016-01-11 17:12:54 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3640406888950837" P_Q="1.0" P_Z="0.24905738716384485" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.024962264775977877" TOTALS="YES" TOTAL_1="919" TOTAL_2="1130" WEIGHT="100.0" Z="1.152641973640519">
<NAME>Severe adverse events: gastrointestinal tract</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Nevirapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-05-18 06:09:46 +0100" MODIFIED_BY="[Empty name]" ORDER="36" O_E="0.0" SE="0.0" STUDY_ID="STD-Manosuthi-2009a" TOTAL_1="71" TOTAL_2="71" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="10.111672770261038" CI_START="0.32411535353546916" EFFECT_SIZE="1.8103448275862069" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.0048230067087371" LOG_CI_START="-0.4893003956947355" LOG_EFFECT_SIZE="0.25776130550700077" MODIFIED="2015-05-18 06:09:46 +0100" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="0.8776554826019234" STUDY_ID="STD-N_x00fa__x00f1_ez-2002" TOTAL_1="29" TOTAL_2="35" VAR="0.7702791461412151" WEIGHT="7.04257193590887"/>
<DICH_DATA CI_END="0.9162311783218823" CI_START="0.2994619957553645" EFFECT_SIZE="0.5238095238095238" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="21" LOG_CI_END="-0.03799493375316746" LOG_CI_START="-0.523658285398221" LOG_EFFECT_SIZE="-0.2808266095756942" MODIFIED="2015-05-18 06:09:46 +0100" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.28528105682866745" STUDY_ID="STD-Sow-2006" TOTAL_1="35" TOTAL_2="35" VAR="0.0813852813852814" WEIGHT="52.662661668804795"/>
<DICH_DATA CI_END="7.749901639213644" CI_START="0.013397223000673105" EFFECT_SIZE="0.32222222222222224" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8892961905298159" LOG_CI_START="-1.8729852136105531" LOG_EFFECT_SIZE="-0.49184451154036873" MODIFIED="2015-05-25 17:29:09 +0100" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="1.6225777703055269" STUDY_ID="STD-Swaminathan-2011" TOTAL_1="59" TOTAL_2="57" VAR="2.632758620689655" WEIGHT="2.107273518986092"/>
<DICH_DATA CI_END="2.7197453282726896" CI_START="0.44784091013185257" EFFECT_SIZE="1.1036363636363635" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.4345282394371362" LOG_CI_START="-0.3488762362751089" LOG_EFFECT_SIZE="0.04282600158101369" MODIFIED="2015-05-18 06:30:33 +0100" MODIFIED_BY="[Empty name]" ORDER="185" O_E="0.0" SE="0.4601756669480697" STUDY_ID="STD-van-Leth-2004" TOTAL_1="400" TOTAL_2="607" VAR="0.2117616444511008" WEIGHT="23.658551690381408"/>
<DICH_DATA CI_END="3.892833275181417" CI_START="0.36991052485619025" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5902658038673408" LOG_CI_START="-0.4319033117720912" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2015-05-25 17:42:52 +0100" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="0.6004271983453285" STUDY_ID="STD-Wester-2010" TOTAL_1="325" TOTAL_2="325" VAR="0.3605128205128205" WEIGHT="14.52894118591883"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.152210194873357" CI_END="2.7338184705907103" CI_START="0.15323144627307217" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6472302203209094" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="13.21028016854918" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.43676967342194567" LOG_CI_START="-0.8146520993154793" LOG_EFFECT_SIZE="-0.18894121294676672" METHOD="MH" MODIFIED="2016-01-11 17:13:02 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.28308700216512994" P_Q="1.0" P_Z="0.5539606903526978" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2351432577986426" TOTALS="YES" TOTAL_1="796" TOTAL_2="1003" WEIGHT="100.0" Z="0.5918355915462827">
<NAME>Severe adverse events: pyrexia</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Nevirapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-05-18 06:09:49 +0100" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="0.0" STUDY_ID="STD-Manosuthi-2009a" TOTAL_1="71" TOTAL_2="71" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.643960942509619" CI_START="0.12606903068123673" EFFECT_SIZE="0.45525" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.21589149528794513" LOG_CI_START="-0.8993915863540298" LOG_EFFECT_SIZE="-0.3417500455330424" MODIFIED="2015-05-18 06:30:54 +0100" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.6551228028967876" STUDY_ID="STD-van-Leth-2004" TOTAL_1="400" TOTAL_2="607" VAR="0.4291858868753432" WEIGHT="81.33909046035457"/>
<DICH_DATA CI_END="73.37155101969392" CI_START="0.12266334669120302" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8655276998322314" LOG_CI_START="-0.9112851903929062" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-05-25 17:43:30 +0100" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="1.6311136371637363" STUDY_ID="STD-Wester-2010" TOTAL_1="325" TOTAL_2="325" VAR="2.6605316973415127" WEIGHT="18.660909539645438"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2209495421829821" CI_END="0.7847525417540232" CI_START="0.34823454241095886" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5227599279626827" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="81" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.10526726897872091" LOG_CI_START="-0.45812815213189534" LOG_EFFECT_SIZE="-0.2816977105553081" METHOD="MH" MODIFIED="2016-01-11 17:11:09 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5430932416145003" P_Q="1.0" P_Z="0.0017517739107693758" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="540" TOTAL_2="759" WEIGHT="100.0" Z="3.129377007063276">
<NAME>Severe adverse events: elevated transaminases</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Nevirapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7796767930942816" CI_START="0.2526119814466424" EFFECT_SIZE="0.6704980842911877" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.2503411372971465" LOG_CI_START="-0.5975460546011196" LOG_EFFECT_SIZE="-0.17360245865198654" MODIFIED="2015-05-18 06:09:52 +0100" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.0" SE="0.49805313363033155" STUDY_ID="STD-N_x00fa__x00f1_ez-2002" TOTAL_1="29" TOTAL_2="35" VAR="0.24805692391899287" WEIGHT="17.31932188143395"/>
<DICH_DATA CI_END="1.8706449227347104" CI_START="0.2910251263234639" EFFECT_SIZE="0.7378378378378379" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.27199135953016673" LOG_CI_START="-0.5360695135826448" LOG_EFFECT_SIZE="-0.13203907702623896" MODIFIED="2015-05-18 06:09:52 +0100" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.474658956832298" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008" TOTAL_1="111" TOTAL_2="117" VAR="0.2253011253011253" WEIGHT="19.06860298424773"/>
<DICH_DATA CI_END="0.7331941610489654" CI_START="0.2647280941167312" EFFECT_SIZE="0.44056451612903225" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="62" LOG_CI_END="-0.1347810022945341" LOG_CI_START="-0.5771999670007713" LOG_EFFECT_SIZE="-0.35599048464765265" MODIFIED="2015-05-18 06:31:23 +0100" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.0" SE="0.25987908987763897" STUDY_ID="STD-van-Leth-2004" TOTAL_1="400" TOTAL_2="607" VAR="0.06753714135562995" WEIGHT="63.612075134318324"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5001912718385926" CI_START="0.16917282210743273" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6503571428571429" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.39797323472262996" LOG_CI_START="-0.7716694058172283" LOG_EFFECT_SIZE="-0.1868480855472992" METHOD="MH" MODIFIED="2016-01-11 17:11:24 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.531183313834797" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="400" TOTAL_2="607" WEIGHT="100.0" Z="0.6262006967939125">
<NAME>Severe adverse events: elevated alkaline phosphatase</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Nevirapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5001912718385926" CI_START="0.16917282210743273" EFFECT_SIZE="0.6503571428571429" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.39797323472262996" LOG_CI_START="-0.7716694058172283" LOG_EFFECT_SIZE="-0.1868480855472992" MODIFIED="2015-05-18 06:31:56 +0100" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="0.6870538768775605" STUDY_ID="STD-van-Leth-2004" TOTAL_1="400" TOTAL_2="607" VAR="0.472043029732486" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.359498063874551" CI_END="2.72723345883076" CI_START="0.7178715261925112" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3992152248221568" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.4357223163582774" LOG_CI_START="-0.14395327227312962" LOG_EFFECT_SIZE="0.14588452204257388" METHOD="MH" MODIFIED="2016-01-11 17:11:37 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.5487853675971432" P_Q="1.0" P_Z="0.3238820322578698" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="429" TOTAL_2="642" WEIGHT="100.00000000000001" Z="0.9865118169987149">
<NAME>Severe adverse events: elevated amylase</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Nevirapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="85.17052701598001" CI_START="0.1521653141534324" EFFECT_SIZE="3.6" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.930289334569975" LOG_CI_START="-0.8176843330354004" LOG_EFFECT_SIZE="0.5563025007672873" MODIFIED="2015-05-18 06:09:57 +0100" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="1.6141733350404335" STUDY_ID="STD-N_x00fa__x00f1_ez-2002" TOTAL_1="29" TOTAL_2="35" VAR="2.6055555555555556" WEIGHT="4.449845063533078"/>
<DICH_DATA CI_END="2.6502144602241646" CI_START="0.6764894928569382" EFFECT_SIZE="1.338970588235294" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.423281019266376" LOG_CI_START="-0.16973894441697107" LOG_EFFECT_SIZE="0.12677103742470247" MODIFIED="2015-05-18 06:32:27 +0100" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="0.34834286216376137" STUDY_ID="STD-van-Leth-2004" TOTAL_1="400" TOTAL_2="607" VAR="0.12134274962044125" WEIGHT="95.55015493646694"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6101482912697602" CI_END="3.12951562969973" CI_START="0.385095383877317" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0977987168735812" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.4954771248860865" LOG_CI_START="-0.4144316872163352" LOG_EFFECT_SIZE="0.04052271883487568" METHOD="MH" MODIFIED="2016-01-11 17:11:51 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.4347321641165741" P_Q="1.0" P_Z="0.8614146234535105" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="429" TOTAL_2="642" WEIGHT="100.00000000000001" Z="0.174573690056887">
<NAME>Severe adverse events: elevated triglycerides</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Nevirapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="85.17052701598001" CI_START="0.1521653141534324" EFFECT_SIZE="3.6" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.930289334569975" LOG_CI_START="-0.8176843330354004" LOG_EFFECT_SIZE="0.5563025007672873" MODIFIED="2015-05-18 06:09:59 +0100" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.0" SE="1.6141733350404335" STUDY_ID="STD-N_x00fa__x00f1_ez-2002" TOTAL_1="29" TOTAL_2="35" VAR="2.6055555555555556" WEIGHT="10.964039928147724"/>
<DICH_DATA CI_END="2.8784721165279437" CI_START="0.3125038753167708" EFFECT_SIZE="0.9484375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.45916202684423507" LOG_CI_START="-0.5051445926614943" LOG_EFFECT_SIZE="-0.02299128290862957" MODIFIED="2015-05-18 06:32:49 +0100" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.5664384816924163" STUDY_ID="STD-van-Leth-2004" TOTAL_1="400" TOTAL_2="607" VAR="0.32085255354200987" WEIGHT="89.03596007185229"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5819958093753698" CI_END="0.822508537488951" CI_START="0.2817096302810919" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.481361170015877" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="-0.08485958545689677" LOG_CI_START="-0.550198306345966" LOG_EFFECT_SIZE="-0.3175289459014314" METHOD="MH" MODIFIED="2016-11-11 11:54:30 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.4455312251002882" P_Q="1.0" P_Z="0.007477260361197242" Q="0.0" RANDOM="YES" SCALE="174.45" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="796" TOTAL_2="1003" WEIGHT="100.0" Z="2.6748055559474144">
<NAME>Severe adverse events: neutropenia</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Nevirapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-05-18 06:10:01 +0100" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.0" STUDY_ID="STD-Manosuthi-2009a" TOTAL_1="71" TOTAL_2="71" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2699820612901789" CI_START="0.2776445543954797" EFFECT_SIZE="0.5938043478260869" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="23" LOG_CI_END="0.10379758651681524" LOG_CI_START="-0.5565108401787608" LOG_EFFECT_SIZE="-0.22635662683097282" MODIFIED="2015-05-18 06:33:36 +0100" MODIFIED_BY="[Empty name]" ORDER="194" O_E="0.0" SE="0.38786843842040847" STUDY_ID="STD-van-Leth-2004" TOTAL_1="400" TOTAL_2="607" VAR="0.1504419255226862" WEIGHT="49.66434408370444"/>
<DICH_DATA CI_END="0.8326450645371519" CI_START="0.18389479401131698" EFFECT_SIZE="0.391304347826087" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="23" LOG_CI_END="-0.07954008786410423" LOG_CI_START="-0.7354305652924317" LOG_EFFECT_SIZE="-0.40748532657826797" MODIFIED="2015-05-25 17:44:56 +0100" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="0.38527331315162505" STUDY_ID="STD-Wester-2010" TOTAL_1="325" TOTAL_2="325" VAR="0.14843552582683014" WEIGHT="50.33565591629556"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.111370089937223" CI_END="0.9965583034801517" CI_START="0.33989755829281765" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5820032079373243" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="76" I2="26.029759048431778" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-0.001497287892751746" LOG_CI_START="-0.46865195522795694" LOG_EFFECT_SIZE="-0.23507462156035436" METHOD="MH" MODIFIED="2016-11-03 17:33:32 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.23005716470541437" P_Q="1.0" P_Z="0.048549382148154636" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.12951661013260768" TOTALS="YES" TOTAL_1="1030" TOTAL_2="1247" WEIGHT="99.99999999999999" Z="1.9725278335154754">
<NAME>Severe adverse events: rash</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Nevirapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.707279411290138" CI_START="0.25840447902505315" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9398824809283848" LOG_CI_START="-0.5876999628170224" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2015-05-18 06:10:03 +0100" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.8973094891111016" STUDY_ID="STD-Manosuthi-2009a" TOTAL_1="71" TOTAL_2="71" VAR="0.8051643192488263" WEIGHT="8.056255047207534"/>
<DICH_DATA CI_END="3.7213987064514074" CI_START="0.22016912546125" EFFECT_SIZE="0.9051724137931034" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5707062023342307" LOG_CI_START="-0.6572435826481915" LOG_EFFECT_SIZE="-0.04326869015698041" MODIFIED="2015-05-18 06:10:03 +0100" MODIFIED_BY="[Empty name]" ORDER="195" O_E="0.0" SE="0.7213037821481425" STUDY_ID="STD-N_x00fa__x00f1_ez-2002" TOTAL_1="29" TOTAL_2="35" VAR="0.5202791461412151" WEIGHT="11.588299680560958"/>
<DICH_DATA CI_END="1.7235292932709172" CI_START="0.2266425070493993" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2364186691178012" LOG_CI_START="-0.6446586344296507" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2015-05-18 06:10:03 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.5175491695067657" STUDY_ID="STD-Sow-2006" TOTAL_1="35" TOTAL_2="35" VAR="0.26785714285714285" WEIGHT="18.94948495768423"/>
<DICH_DATA CI_END="3.9412501850551647" CI_START="0.009483736383828318" EFFECT_SIZE="0.19333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5956340041475716" LOG_CI_START="-2.023020526461022" LOG_EFFECT_SIZE="-0.7136932611567252" MODIFIED="2015-05-25 17:30:17 +0100" MODIFIED_BY="[Empty name]" ORDER="200" O_E="0.0" SE="1.5382106338284716" STUDY_ID="STD-Swaminathan-2011" TOTAL_1="59" TOTAL_2="57" VAR="2.3660919540229886" WEIGHT="3.0173113135655694"/>
<DICH_DATA CI_END="1.2235737162323228" CI_START="0.30435034266762806" EFFECT_SIZE="0.6102418207681366" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.0876301392689442" LOG_CI_START="-0.5166262049391436" LOG_EFFECT_SIZE="-0.2144980328350997" MODIFIED="2015-05-18 06:10:03 +0100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.3549431677049747" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008" TOTAL_1="111" TOTAL_2="117" VAR="0.12598465230044179" WEIGHT="29.471588058516712"/>
<DICH_DATA CI_END="1.2272202911308323" CI_START="0.2481244060139657" EFFECT_SIZE="0.5518181818181818" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="22" LOG_CI_END="0.08892252738497351" LOG_CI_START="-0.6053305155509087" LOG_EFFECT_SIZE="-0.2582039940829675" MODIFIED="2015-05-18 06:34:25 +0100" MODIFIED_BY="[Empty name]" ORDER="196" O_E="0.0" SE="0.4078076740285246" STUDY_ID="STD-van-Leth-2004" TOTAL_1="400" TOTAL_2="607" VAR="0.16630709899655535" WEIGHT="25.45444371928294"/>
<DICH_DATA CI_END="0.4228897265871223" CI_START="0.0015546894487830192" EFFECT_SIZE="0.02564102564102564" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="19" LOG_CI_END="-0.3737728651976665" LOG_CI_START="-2.8083563488553316" LOG_EFFECT_SIZE="-1.5910646070264993" MODIFIED="2015-05-25 17:45:34 +0100" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="1.4300863896831189" STUDY_ID="STD-Wester-2010" TOTAL_1="325" TOTAL_2="325" VAR="2.0451470819568973" WEIGHT="3.4626172231820593"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="8.663418072544804" CI_START="-2.063418072544809" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.299999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.10" MODIFIED="2016-01-11 17:12:21 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.227846345281825" Q="0.0" RANDOM="YES" SCALE="12.53" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="67" UNITS="" WEIGHT="100.0" Z="1.2059252255741697">
<NAME>Severe adverse events: elevated SGOT</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Nevirapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.663418072544804" CI_START="-2.063418072544809" EFFECT_SIZE="3.299999999999997" ESTIMABLE="YES" MEAN_1="34.4" MEAN_2="31.1" MODIFIED="2015-05-18 06:10:04 +0100" MODIFIED_BY="[Empty name]" ORDER="97" SD_1="19.6" SD_2="11.1" SE="2.7364880757252497" STUDY_ID="STD-Sinha-2013" TOTAL_1="68" TOTAL_2="67" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="15.627476667232171" CI_START="-4.22747666723218" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.699999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.11" MODIFIED="2016-01-11 17:12:30 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.26044465769438707" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="67" UNITS="" WEIGHT="100.0" Z="1.1253408178488369">
<NAME>Severe adverse events: elevated SGPT</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Nevirapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="15.627476667232171" CI_START="-4.22747666723218" EFFECT_SIZE="5.699999999999996" ESTIMABLE="YES" MEAN_1="36.8" MEAN_2="31.1" MODIFIED="2015-05-18 06:10:06 +0100" MODIFIED_BY="[Empty name]" ORDER="98" SD_1="40.1" SD_2="11.6" SE="5.06513218892737" STUDY_ID="STD-Sinha-2013" TOTAL_1="68" TOTAL_2="67" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="48.781634536698945" CI_START="0.7464895858849294" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="6.03448275862069" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="1.6882563482199382" LOG_CI_START="-0.12697624664526144" LOG_EFFECT_SIZE="0.7806400507873384" METHOD="MH" MODIFIED="2016-01-11 17:12:41 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.09184136950795882" Q="0.0" RANDOM="YES" SCALE="138.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="35" WEIGHT="100.0" Z="1.6857634539625737">
<NAME>Severe adverse events: elevated cholesterol</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Nevirapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="48.781634536698945" CI_START="0.7464895858849294" EFFECT_SIZE="6.0344827586206895" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6882563482199382" LOG_CI_START="-0.12697624664526144" LOG_EFFECT_SIZE="0.7806400507873383" MODIFIED="2015-04-02 23:47:54 +0100" MODIFIED_BY="[Empty name]" ORDER="197" O_E="0.0" SE="1.06627661177008" STUDY_ID="STD-N_x00fa__x00f1_ez-2002" TOTAL_1="29" TOTAL_2="35" VAR="1.1369458128078818" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2016-11-03 17:32:24 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Efavirenz versus nevirapine: subgroup analyses for concurrent TB treatments</NAME>
<DICH_OUTCOME CHI2="8.347080140901019" CI_END="1.0967208883367505" CI_START="0.9887669590133968" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0413459452301141" ESTIMABLE="YES" EVENTS_1="787" EVENTS_2="893" I2="4.15810241476313" I2_Q="19.94998845770938" ID="CMP-003.01" LOG_CI_END="0.040096115196876156" LOG_CI_START="-0.004906054550880346" LOG_EFFECT_SIZE="0.01759503032299789" METHOD="MH" MODIFIED="2015-05-18 07:13:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.40032139939628086" P_Q="0.2637017733512831" P_Z="0.1253693678539395" Q="1.249219057853224" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.8039280680901486E-4" TOTALS="YES" TOTAL_1="1079" TOTAL_2="1290" WEIGHT="100.00000000000003" Z="1.532620579552622">
<NAME>Virological success</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Nevirapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.902457321382017" CI_END="1.1821477854689468" CI_START="0.9883214829895981" DF="3" EFFECT_SIZE="1.080898724417574" ESTIMABLE="YES" EVENTS_1="360" EVENTS_2="329" I2="23.12536043475347" ID="CMP-003.01.01" LOG_CI_END="0.07267177299332427" LOG_CI_START="-0.005101764341216312" LOG_EFFECT_SIZE="0.03378500432605396" MODIFIED="2015-04-03 22:39:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.27219150109891754" P_Z="0.08860067921281618" STUDIES="4" TAU2="0.001970927075315196" TOTAL_1="483" TOTAL_2="480" WEIGHT="44.194560855344236" Z="1.7028257673754401">
<NAME>Concurrent treatment for TB</NAME>
<DICH_DATA CI_END="1.2133236584625626" CI_START="0.9640373069901786" EFFECT_SIZE="1.0815217391304348" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="184" LOG_CI_END="0.08397666594059615" LOG_CI_START="-0.015906159140255803" LOG_EFFECT_SIZE="0.0340352534001702" MODIFIED="2015-04-03 22:39:36 +0100" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.05867166588045062" STUDY_ID="STD-Bonnet-2013a" TOTAL_1="285" TOTAL_2="285" VAR="0.003442364377187233" WEIGHT="18.77056739402285"/>
<DICH_DATA CI_END="1.24840921256986" CI_START="0.8327398927527776" EFFECT_SIZE="1.0196078431372548" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="51" LOG_CI_END="0.0963569648583158" LOG_CI_START="-0.0794906297845903" LOG_EFFECT_SIZE="0.008433167536862764" MODIFIED="2015-04-03 22:39:36 +0100" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.1032937475528751" STUDY_ID="STD-Manosuthi-2009a" TOTAL_1="71" TOTAL_2="71" VAR="0.010669598283517089" WEIGHT="6.381581869552302"/>
<DICH_DATA CI_END="1.1692144629653884" CI_START="0.8895941392566248" EFFECT_SIZE="1.0198658410732715" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="57" LOG_CI_END="0.06789417886057111" LOG_CI_START="-0.0508080869320852" LOG_EFFECT_SIZE="0.008543045964242942" MODIFIED="2015-04-03 22:39:36 +0100" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.06972629851229843" STUDY_ID="STD-Sinha-2013" TOTAL_1="68" TOTAL_2="67" VAR="0.00486175670422615" WEIGHT="13.589310163740674"/>
<DICH_DATA CI_END="1.6258772186742807" CI_START="1.0483215238589536" EFFECT_SIZE="1.3055428309665598" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="37" LOG_CI_END="0.2110877458917546" LOG_CI_START="0.020494502706987376" LOG_EFFECT_SIZE="0.11579112429937101" MODIFIED="2015-04-03 22:39:46 +0100" MODIFIED_BY="[Empty name]" ORDER="170" O_E="0.0" SE="0.11195541449850178" STUDY_ID="STD-Swaminathan-2011" TOTAL_1="59" TOTAL_2="57" VAR="0.012534014835531345" WEIGHT="5.453101428028403"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.0876543892748196" CI_END="1.0835696512819304" CI_START="0.9498602623939763" DF="4" EFFECT_SIZE="1.0145145406985567" ESTIMABLE="YES" EVENTS_1="427" EVENTS_2="564" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.03485683277183014" LOG_CI_START="-0.02234028074795312" LOG_EFFECT_SIZE="0.006258276011938464" MODIFIED="2015-05-18 07:13:36 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5432654025734234" P_Z="0.6679941031484627" STUDIES="5" TAU2="0.0" TOTAL_1="596" TOTAL_2="810" WEIGHT="55.80543914465579" Z="0.42890260832718013">
<NAME>No treatment for TB</NAME>
<DICH_DATA CI_END="1.277192342012207" CI_START="0.49071395943675394" EFFECT_SIZE="0.7916666666666666" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.10625630586504926" LOG_CI_START="-0.3091715873826035" LOG_EFFECT_SIZE="-0.10145764075877708" MODIFIED="2015-04-03 22:39:57 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.244024400894908" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004" TOTAL_1="24" TOTAL_2="19" VAR="0.05954790823211878" WEIGHT="1.1679800930385338"/>
<DICH_DATA CI_END="1.333462983960702" CI_START="0.7326382745488663" EFFECT_SIZE="0.9884057971014493" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" LOG_CI_END="0.1249809644692886" LOG_CI_START="-0.1351103966308414" LOG_EFFECT_SIZE="-0.005064716080776403" MODIFIED="2015-04-03 22:39:57 +0100" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.15277895298321792" STUDY_ID="STD-Landman-2014" TOTAL_1="30" TOTAL_2="31" VAR="0.023341408474648308" WEIGHT="2.958210670777145"/>
<DICH_DATA CI_END="1.601776403637903" CI_START="0.8419372455834492" EFFECT_SIZE="1.1612903225806452" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" LOG_CI_END="0.2046018916211215" LOG_CI_START="-0.07472027775509224" LOG_EFFECT_SIZE="0.06494080693301461" MODIFIED="2015-04-03 22:39:57 +0100" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="0.1640752249586257" STUDY_ID="STD-N_x00fa__x00f1_ez-2002" TOTAL_1="31" TOTAL_2="36" VAR="0.026920679445223625" WEIGHT="2.568952575336898"/>
<DICH_DATA CI_END="1.0816214984453993" CI_START="0.8471851158083397" EFFECT_SIZE="0.9572531715388858" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="98" LOG_CI_END="0.03407531077527663" LOG_CI_START="-0.07202168295143238" LOG_EFFECT_SIZE="-0.01897318608807788" MODIFIED="2015-04-03 22:39:57 +0100" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.06232189930365791" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008" TOTAL_1="111" TOTAL_2="117" VAR="0.003884019132815277" WEIGHT="16.77986367028057"/>
<DICH_DATA CI_END="1.1366040633995547" CI_START="0.9589046825659485" EFFECT_SIZE="1.043980343980344" ESTIMABLE="YES" EVENTS_1="280" EVENTS_2="407" LOG_CI_END="0.05560920432955432" LOG_CI_START="-0.01822456060096563" LOG_EFFECT_SIZE="0.01869232186429434" MODIFIED="2015-04-03 22:53:06 +0100" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.043370319003218236" STUDY_ID="STD-van-Leth-2004" TOTAL_1="400" TOTAL_2="607" VAR="0.0018809845704409129" WEIGHT="32.330432135222644"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.337183420500341" CI_END="1.1905596566040093" CI_START="0.5872081840164438" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8361258122541615" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="75" I2="6.317628493058819" I2_Q="1.7437226788428277" ID="CMP-003.02" LOG_CI_END="0.07575116192889249" LOG_CI_START="-0.23120790021662316" LOG_EFFECT_SIZE="-0.07772836914386531" METHOD="MH" MODIFIED="2015-06-26 20:40:08 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3761297274687987" P_Q="0.3130543870526713" P_Z="0.3209016929836985" Q="1.0177466796665149" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.013089804741422677" TOTALS="YES" TOTAL_1="1054" TOTAL_2="1263" WEIGHT="100.0" Z="0.9926066559767545">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Nevirapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.525474810032544" CI_END="1.1885320403389033" CI_START="0.4039881584322546" DF="3" EFFECT_SIZE="0.6929306388190983" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="42" I2="14.905079126850815" ID="CMP-003.02.01" LOG_CI_END="0.07501089389324697" LOG_CI_START="-0.3936313645995414" LOG_EFFECT_SIZE="-0.1593102353531472" MODIFIED="2015-04-09 20:50:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3174732601253263" P_Z="0.18268274183515174" STUDIES="4" TAU2="0.0498465392180002" TOTAL_1="483" TOTAL_2="480" WEIGHT="52.95723173279767" Z="1.332540196716268">
<NAME>Concurrent treatment for TB</NAME>
<DICH_DATA CI_END="1.7080004329220688" CI_START="0.4626014382434143" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.2324879764324018" LOG_CI_START="-0.33479302132716443" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2015-04-09 20:43:26 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.33322366617019633" STUDY_ID="STD-Bonnet-2013a" TOTAL_1="285" TOTAL_2="285" VAR="0.11103801169590644" WEIGHT="26.19190018004639"/>
<DICH_DATA CI_END="1.5960270953377167" CI_START="0.06961730877607697" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2030402599819847" LOG_CI_START="-1.1572827694213097" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-04-09 20:43:26 +0100" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="0.7990604811790905" STUDY_ID="STD-Manosuthi-2009a" TOTAL_1="71" TOTAL_2="71" VAR="0.6384976525821596" WEIGHT="4.98957329695668"/>
<DICH_DATA CI_END="1.6080587617099806" CI_START="0.3572260822793558" EFFECT_SIZE="0.7579185520361991" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.2063019146985718" LOG_CI_START="-0.44705683932306517" LOG_EFFECT_SIZE="-0.12037746231224666" MODIFIED="2015-04-09 20:43:26 +0100" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.3837861662903021" STUDY_ID="STD-Sinha-2013" TOTAL_1="68" TOTAL_2="67" VAR="0.1472918214358074" WEIGHT="20.271295753672945"/>
<DICH_DATA CI_END="1.553759423905636" CI_START="0.004970319883648871" EFFECT_SIZE="0.08787878787878788" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.19138377575287346" LOG_CI_START="-2.303615659710736" LOG_EFFECT_SIZE="-1.0561159419789314" MODIFIED="2015-04-09 20:43:26 +0100" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="1.4655750188377155" STUDY_ID="STD-Swaminathan-2011" TOTAL_1="59" TOTAL_2="57" VAR="2.1479101358411703" WEIGHT="1.5044625021216598"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8716134656731311" CI_END="1.6381500478109374" CI_START="0.6191784625023353" DF="1" EFFECT_SIZE="1.0071282082990742" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="33" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.2143536788357553" LOG_CI_START="-0.20818415855750544" LOG_EFFECT_SIZE="0.0030847601391249466" MODIFIED="2015-05-18 07:14:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.35050911583524624" P_Z="0.9771695397036101" STUDIES="4" TAU2="0.0" TOTAL_1="571" TOTAL_2="783" WEIGHT="47.04276826720232" Z="0.02861764433182606">
<NAME>No treatment for TB</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-04-09 20:49:39 +0100" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.0" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004" TOTAL_1="30" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-04-09 20:49:39 +0100" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.0" STUDY_ID="STD-Landman-2014" TOTAL_1="30" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.094724414626652" CI_START="0.6548078127150315" EFFECT_SIZE="1.1711711711711712" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.32112689456742916" LOG_CI_START="-0.1838861475270705" LOG_EFFECT_SIZE="0.06862037352017934" MODIFIED="2015-04-09 20:49:39 +0100" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.29664716078118464" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008" TOTAL_1="111" TOTAL_2="117" VAR="0.087999537999538" WEIGHT="32.16108928539216"/>
<DICH_DATA CI_END="1.721420569161093" CI_START="0.29132917124498864" EFFECT_SIZE="0.7081666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="0.2358869880218748" LOG_CI_START="-0.5356160266101332" LOG_EFFECT_SIZE="-0.1498645192941292" MODIFIED="2015-05-18 07:14:02 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.45318468979635596" STUDY_ID="STD-van-Leth-2004" TOTAL_1="400" TOTAL_2="607" VAR="0.20537636306581938" WEIGHT="14.881678981810161"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.462298697579543" CI_END="2.1054859886730264" CI_START="0.7159784615185047" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2277958376370566" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="45" I2="32.77007651622982" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.32335235567685583" LOG_CI_START="-0.14510004219543696" LOG_EFFECT_SIZE="0.08912615674070945" METHOD="MH" MODIFIED="2015-06-26 20:40:08 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.21567818918197657" P_Q="0.6371974588216232" P_Z="0.4557929968728641" Q="0.22242622725103614" RANDOM="YES" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09877201553163172" TOTALS="YES" TOTAL_1="897" TOTAL_2="1108" WEIGHT="100.0" Z="0.7457921363437392">
<NAME>Progression to AIDS</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Nevirapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.34021683948148634" CI_END="1.9176887093312178" CI_START="0.6249347750466685" DF="1" EFFECT_SIZE="1.0947284422063037" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.2827781112852717" LOG_CI_START="-0.20416530796074145" LOG_EFFECT_SIZE="0.03930640166226507" MODIFIED="2015-04-09 20:50:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5597042615574306" P_Z="0.7516843209780434" STUDIES="2" TAU2="0.0" TOTAL_1="356" TOTAL_2="356" WEIGHT="48.26229427852894" Z="0.3164192330155848">
<NAME>Concurrent treatment for TB</NAME>
<DICH_DATA CI_END="3.8699019605733955" CI_START="0.11484643512224581" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5876999628170224" LOG_CI_START="-0.939882480928385" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2015-04-09 20:43:43 +0100" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.8973094891111016" STUDY_ID="STD-Manosuthi-2009a" TOTAL_1="71" TOTAL_2="71" VAR="0.8051643192488263" WEIGHT="8.376609942370191"/>
<DICH_DATA CI_END="2.0919005393381997" CI_START="0.6409101180454797" EFFECT_SIZE="1.1578947368421053" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="19" LOG_CI_END="0.3205410318953125" LOG_CI_START="-0.19320287215655796" LOG_EFFECT_SIZE="0.0636690798693773" MODIFIED="2015-04-09 20:43:43 +0100" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.30177571231340794" STUDY_ID="STD-Bonnet-2013a" TOTAL_1="285" TOTAL_2="285" VAR="0.09106858054226476" WEIGHT="39.885684336158754"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.8796822413180987" CI_END="5.1611988773701425" CI_START="0.4442889066415231" DF="1" EFFECT_SIZE="1.5142864346570095" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" I2="74.22469321455934" ID="CMP-003.03.02" LOG_CI_END="0.7127505941368625" LOG_CI_START="-0.35233453043349083" LOG_EFFECT_SIZE="0.18020803185168588" MODIFIED="2015-05-18 07:16:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.04887386159219309" P_Z="0.5071795990439418" STUDIES="3" TAU2="0.5835397639523391" TOTAL_1="541" TOTAL_2="752" WEIGHT="51.73770572147106" Z="0.6632357245560626">
<NAME>No treatment for TB</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-04-09 20:50:46 +0100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.0" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004" TOTAL_1="30" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.8074607968432617" CI_START="0.39322715656926094" EFFECT_SIZE="0.8430555555555556" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="0.2570688863819023" LOG_CI_START="-0.4053564970939241" LOG_EFFECT_SIZE="-0.07414380535601088" MODIFIED="2015-05-18 07:15:47 +0100" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="0.3891119493122326" STUDY_ID="STD-van-Leth-2004" TOTAL_1="400" TOTAL_2="607" VAR="0.15140810909756544" WEIGHT="30.265881833796065"/>
<DICH_DATA CI_END="7.923286180783608" CI_START="1.0993512793023954" EFFECT_SIZE="2.9513513513513514" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.8989053424708964" LOG_CI_START="0.04113648613255058" LOG_EFFECT_SIZE="0.47002091430172344" MODIFIED="2015-04-09 20:50:46 +0100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.5038576722374621" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008" TOTAL_1="111" TOTAL_2="117" VAR="0.25387255387255386" WEIGHT="21.47182388767499"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.283807745287012" CI_END="1.2467895536268763" CI_START="0.6897490942509479" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9273467341483882" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="228" I2="34.87361438826329" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.0957931548325777" LOG_CI_START="-0.16130886114536785" LOG_EFFECT_SIZE="-0.032757853156395116" METHOD="MH" MODIFIED="2015-06-26 20:40:08 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.13898333506562455" P_Q="0.8199560631333078" P_Z="0.617465629003561" Q="0.051802438087686864" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06257954744766422" TOTALS="YES" TOTAL_1="1090" TOTAL_2="1294" WEIGHT="100.0" Z="0.49944542171846384">
<NAME>Discontinuation rate</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Nevirapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.5471515289231488" CI_END="1.4210618327229207" CI_START="0.5945243937445868" DF="3" EFFECT_SIZE="0.9191604455007656" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="49" I2="15.425096009057558" ID="CMP-003.04.01" LOG_CI_END="0.1526129752013155" LOG_CI_START="-0.22583032127855612" LOG_EFFECT_SIZE="-0.0366086730386203" MODIFIED="2015-04-09 20:51:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.314698166814097" P_Z="0.7045439371202751" STUDIES="4" TAU2="0.03255279536041518" TOTAL_1="483" TOTAL_2="480" WEIGHT="38.81564570744421" Z="0.37919382557389075">
<NAME>Concurrent treatment for TB</NAME>
<DICH_DATA CI_END="2.2913204096377298" CI_START="0.7758748057670615" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="21" LOG_CI_END="0.36008582354465946" LOG_CI_START="-0.11020835032805965" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2015-04-09 20:43:46 +0100" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.27625312572654126" STUDY_ID="STD-Bonnet-2013a" TOTAL_1="285" TOTAL_2="285" VAR="0.07631578947368421" WEIGHT="16.420958461534084"/>
<DICH_DATA CI_END="1.1878023106995372" CI_START="0.26637955419842346" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.07474416579963411" LOG_CI_START="-0.5744991122328339" LOG_EFFECT_SIZE="-0.2498774732165999" MODIFIED="2015-04-09 20:43:46 +0100" MODIFIED_BY="[Empty name]" ORDER="11" O_E="0.0" SE="0.3813687153223296" STUDY_ID="STD-Manosuthi-2009a" TOTAL_1="71" TOTAL_2="71" VAR="0.14544209702660404" WEIGHT="10.964217516165112"/>
<DICH_DATA CI_END="2.3820243242881496" CI_START="0.2994277236824735" EFFECT_SIZE="0.8445378151260504" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3769461920124943" LOG_CI_START="-0.5237079912845406" LOG_EFFECT_SIZE="-0.07338089963602308" MODIFIED="2015-04-09 20:43:46 +0100" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.5290487255787882" STUDY_ID="STD-Sinha-2013" TOTAL_1="68" TOTAL_2="67" VAR="0.27989255403654" WEIGHT="6.659796661397366"/>
<DICH_DATA CI_END="2.733983640809311" CI_START="0.21848908729050606" EFFECT_SIZE="0.7728813559322034" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4367959115750732" LOG_CI_START="-0.6605702495304917" LOG_EFFECT_SIZE="-0.11188716897770919" MODIFIED="2015-04-09 20:43:46 +0100" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="0.6445983150835133" STUDY_ID="STD-Swaminathan-2011" TOTAL_1="59" TOTAL_2="57" VAR="0.4155069878085043" WEIGHT="4.770673068347652"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.070994171495053" CI_END="1.5547228627371903" CI_START="0.62878089212629" DF="4" EFFECT_SIZE="0.9887264680593061" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="179" I2="50.43981057343462" ID="CMP-003.04.02" LOG_CI_END="0.191652985060188" LOG_CI_START="-0.20150066444034323" LOG_EFFECT_SIZE="-0.0049238396900775985" MODIFIED="2015-05-18 07:17:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.08901199212350186" P_Z="0.9608451721387887" STUDIES="5" TAU2="0.11870566326080939" TOTAL_1="607" TOTAL_2="814" WEIGHT="61.18435429255578" Z="0.049093012212712214">
<NAME>No treatment for TB</NAME>
<DICH_DATA CI_END="6.184805150349353" CI_START="0.140846977380024" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7913260219180813" LOG_CI_START="-0.8512524686729677" LOG_EFFECT_SIZE="-0.02996322337744321" MODIFIED="2015-04-09 20:51:02 +0100" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.964858736267844" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004" TOTAL_1="30" TOTAL_2="28" VAR="0.930952380952381" WEIGHT="2.29564294099654"/>
<DICH_DATA CI_END="4.354129221503021" CI_START="0.3831771389646205" EFFECT_SIZE="1.2916666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6389013138536588" LOG_CI_START="-0.41660040960832545" LOG_EFFECT_SIZE="0.11115045212266668" MODIFIED="2015-04-09 20:51:02 +0100" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.6200069371793655" STUDY_ID="STD-Landman-2014" TOTAL_1="30" TOTAL_2="31" VAR="0.3844086021505376" WEIGHT="5.102583950237724"/>
<DICH_DATA CI_END="2.9278073153759534" CI_START="0.6687789963244942" EFFECT_SIZE="1.3993055555555556" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.4665424915726442" LOG_CI_START="-0.17471737480888702" LOG_EFFECT_SIZE="0.1459125583818786" MODIFIED="2015-04-09 20:51:02 +0100" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.3766792198000443" STUDY_ID="STD-N_x00fa__x00f1_ez-2002" TOTAL_1="36" TOTAL_2="31" VAR="0.1418872346291701" WEIGHT="11.15484155870937"/>
<DICH_DATA CI_END="2.410202149240874" CI_START="0.7202650182901416" EFFECT_SIZE="1.3175675675675675" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.3820534693873404" LOG_CI_START="-0.14250767745221926" LOG_EFFECT_SIZE="0.11977289596756062" MODIFIED="2015-04-09 20:51:02 +0100" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.3081298142731119" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008" TOTAL_1="111" TOTAL_2="117" VAR="0.09494398244398244" WEIGHT="14.479072171980272"/>
<DICH_DATA CI_END="0.8372623092160069" CI_START="0.49170476893062054" EFFECT_SIZE="0.6416275167785235" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="149" LOG_CI_END="-0.0771384588549314" LOG_CI_START="-0.3082955795678629" LOG_EFFECT_SIZE="-0.19271701921139714" MODIFIED="2015-05-18 07:16:58 +0100" MODIFIED_BY="[Empty name]" ORDER="200" O_E="0.0" SE="0.13578283695297766" STUDY_ID="STD-van-Leth-2004" TOTAL_1="400" TOTAL_2="607" VAR="0.018436978810998914" WEIGHT="28.152213670631884"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2016-11-11 11:47:08 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Efavirenz 600 mg versus nevirapine: subgroup analyses for dosage</NAME>
<DICH_OUTCOME CHI2="8.956499709690963" CI_END="1.0918611041013717" CI_START="0.9884857504115889" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0388884169307455" ESTIMABLE="YES" EVENTS_1="787" EVENTS_2="893" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.03816739518287542" LOG_CI_START="-0.005029586908954948" LOG_EFFECT_SIZE="0.016568904136960255" METHOD="MH" MODIFIED="2016-11-11 11:46:02 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.44129945819580985" P_Q="0.3563999372269444" P_Z="0.132696746757518" Q="0.8505391597999088" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1079" TOTAL_2="1290" WEIGHT="100.0" Z="1.5035520445712125">
<NAME>Virological success</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Nevirapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.8559023588334065" CI_END="1.0876116844972672" CI_START="0.9708693678889588" DF="6" EFFECT_SIZE="1.0275839959032582" ESTIMABLE="YES" EVENTS_1="574" EVENTS_2="679" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.036473864679924126" LOG_CI_START="-0.012839201216156499" LOG_EFFECT_SIZE="0.011817331731883787" MODIFIED="2016-11-11 11:45:52 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6961694607929036" P_Z="0.3475421280421549" STUDIES="7" TAU2="0.0" TOTAL_1="789" TOTAL_2="977" WEIGHT="76.73311061603204" Z="0.9393674543239243">
<NAME>Nevirapine 200 mg twice daily</NAME>
<DICH_DATA CI_END="1.277192342012207" CI_START="0.49071395943675394" EFFECT_SIZE="0.7916666666666666" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.10625630586504926" LOG_CI_START="-0.3091715873826035" LOG_EFFECT_SIZE="-0.10145764075877708" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.244024400894908" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004" TOTAL_1="24" TOTAL_2="19" VAR="0.05954790823211878" WEIGHT="1.081223574734512"/>
<DICH_DATA CI_END="1.2133236584625626" CI_START="0.9640373069901786" EFFECT_SIZE="1.0815217391304348" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="184" LOG_CI_END="0.08397666594059615" LOG_CI_START="-0.015906159140255803" LOG_EFFECT_SIZE="0.0340352534001702" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.05867166588045062" STUDY_ID="STD-Bonnet-2013a" TOTAL_1="285" TOTAL_2="285" VAR="0.003442364377187233" WEIGHT="18.703598791974194"/>
<DICH_DATA CI_END="1.333462983960702" CI_START="0.7326382745488663" EFFECT_SIZE="0.9884057971014493" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" LOG_CI_END="0.1249809644692886" LOG_CI_START="-0.1351103966308414" LOG_EFFECT_SIZE="-0.005064716080776403" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.15277895298321792" STUDY_ID="STD-Landman-2014" TOTAL_1="30" TOTAL_2="31" VAR="0.023341408474648308" WEIGHT="2.7583854794634126"/>
<DICH_DATA CI_END="1.24840921256986" CI_START="0.8327398927527776" EFFECT_SIZE="1.0196078431372548" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="51" LOG_CI_END="0.0963569648583158" LOG_CI_START="-0.0794906297845903" LOG_EFFECT_SIZE="0.008433167536862764" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.1032937475528751" STUDY_ID="STD-Manosuthi-2009a" TOTAL_1="71" TOTAL_2="71" VAR="0.010669598283517089" WEIGHT="6.034397968493207"/>
<DICH_DATA CI_END="1.1692144629653884" CI_START="0.8895941392566248" EFFECT_SIZE="1.0198658410732715" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="57" LOG_CI_END="0.06789417886057111" LOG_CI_START="-0.0508080869320852" LOG_EFFECT_SIZE="0.008543045964242942" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.06972629851229843" STUDY_ID="STD-Sinha-2013" TOTAL_1="68" TOTAL_2="67" VAR="0.00486175670422615" WEIGHT="13.243073671442037"/>
<DICH_DATA CI_END="1.0816214984453993" CI_START="0.8471851158083397" EFFECT_SIZE="0.9572531715388858" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="98" LOG_CI_END="0.03407531077527663" LOG_CI_START="-0.07202168295143238" LOG_EFFECT_SIZE="-0.01897318608807788" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.06232189930365791" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008" TOTAL_1="111" TOTAL_2="117" VAR="0.003884019132815277" WEIGHT="16.576798415518066"/>
<DICH_DATA CI_END="1.202620294148245" CI_START="0.9533413698292104" EFFECT_SIZE="1.0707509881422925" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="253" LOG_CI_END="0.08012852826570223" LOG_CI_START="-0.02075156055100165" LOG_EFFECT_SIZE="0.029688483857350328" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.05925746353542516" STUDY_ID="STD-van-Leth-2004" TOTAL_1="200" TOTAL_2="387" VAR="0.0035114469846522427" WEIGHT="18.335632714406618"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.516709207488486" CI_END="1.3493793561590397" CI_START="0.9367334108365243" DF="2" EFFECT_SIZE="1.1242814268710706" ESTIMABLE="YES" EVENTS_1="213" EVENTS_2="214" I2="55.71997425284549" ID="CMP-004.01.02" LOG_CI_END="0.1301340616998193" LOG_CI_START="-0.028383989342733014" LOG_EFFECT_SIZE="0.050875036178543165" MODIFIED="2016-11-11 11:46:02 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.10452245044099284" P_Z="0.2083672129131342" STUDIES="3" TAU2="0.014414881876253092" TOTAL_1="290" TOTAL_2="313" WEIGHT="23.266889383967964" Z="1.2580679356870215">
<NAME>Nevirapine 400 mg once daily</NAME>
<DICH_DATA CI_END="1.601776403637903" CI_START="0.8419372455834492" EFFECT_SIZE="1.1612903225806452" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" LOG_CI_END="0.2046018916211215" LOG_CI_START="-0.07472027775509224" LOG_EFFECT_SIZE="0.06494080693301461" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="0.1640752249586257" STUDY_ID="STD-N_x00fa__x00f1_ez-2002" TOTAL_1="31" TOTAL_2="36" VAR="0.026920679445223625" WEIGHT="2.391641055631585"/>
<DICH_DATA CI_END="1.6258772186742807" CI_START="1.0483215238589536" EFFECT_SIZE="1.3055428309665598" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="37" LOG_CI_END="0.2110877458917546" LOG_CI_START="0.020494502706987376" LOG_EFFECT_SIZE="0.11579112429937101" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="170" O_E="0.0" SE="0.11195541449850178" STUDY_ID="STD-Swaminathan-2011" TOTAL_1="59" TOTAL_2="57" VAR="0.012534014835531345" WEIGHT="5.1367900111444795"/>
<DICH_DATA CI_END="1.1335561398990897" CI_START="0.8821795099526532" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="154" LOG_CI_END="0.054443033632922515" LOG_CI_START="-0.054443033632922494" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.06396021490668313" STUDY_ID="STD-van-Leth-2004" TOTAL_1="200" TOTAL_2="220" VAR="0.004090909090909091" WEIGHT="15.738458317191899"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.224756064335007" CI_END="1.1167278742595383" CI_START="0.5683613153750247" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.796683703567549" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="82" I2="3.110915612009583" I2_Q="70.87131726704679" ID="CMP-004.02" LOG_CI_END="0.04794735654823495" LOG_CI_START="-0.24537548931405917" LOG_EFFECT_SIZE="-0.09871406638291212" METHOD="MH" MODIFIED="2016-11-11 11:47:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4058597905793786" P_Q="0.06390438305179058" P_Z="0.18710165269769136" Q="3.4330423011841256" RANDOM="YES" SCALE="410.35842620216533" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.008010408342132687" TOTALS="YES" TOTAL_1="1125" TOTAL_2="1334" WEIGHT="100.0" Z="1.3192018119777469">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Nevirapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.55179904238861" CI_END="1.2770008742390702" CI_START="0.6355139147008374" DF="4" EFFECT_SIZE="0.9008617122866657" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="64" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.10619119458297212" LOG_CI_START="-0.19687493604367348" LOG_EFFECT_SIZE="-0.04534187073035069" MODIFIED="2016-11-11 11:47:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6353851214111977" P_Z="0.5575648759157792" STUDIES="7" TAU2="0.0" TOTAL_1="795" TOTAL_2="986" WEIGHT="87.77665110043975" Z="0.5864623238459951">
<NAME>Nevirapine 200 mg twice daily</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.0" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004" TOTAL_1="30" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.7080004329220688" CI_START="0.4626014382434143" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.2324879764324018" LOG_CI_START="-0.33479302132716443" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.33322366617019633" STUDY_ID="STD-Bonnet-2013a" TOTAL_1="285" TOTAL_2="285" VAR="0.11103801169590644" WEIGHT="24.936950769328977"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.0" STUDY_ID="STD-Landman-2014" TOTAL_1="30" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5960270953377167" CI_START="0.06961730877607697" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2030402599819847" LOG_CI_START="-1.1572827694213097" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.7990604811790905" STUDY_ID="STD-Manosuthi-2009a" TOTAL_1="71" TOTAL_2="71" VAR="0.6384976525821596" WEIGHT="4.591906534638894"/>
<DICH_DATA CI_END="1.6080587617099806" CI_START="0.3572260822793558" EFFECT_SIZE="0.7579185520361991" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.2063019146985718" LOG_CI_START="-0.44705683932306517" LOG_EFFECT_SIZE="-0.12037746231224666" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.3837861662903021" STUDY_ID="STD-Sinha-2013" TOTAL_1="68" TOTAL_2="67" VAR="0.1472918214358074" WEIGHT="19.1156597938085"/>
<DICH_DATA CI_END="2.094724414626652" CI_START="0.6548078127150315" EFFECT_SIZE="1.1711711711711712" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.32112689456742916" LOG_CI_START="-0.1838861475270705" LOG_EFFECT_SIZE="0.06862037352017934" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.29664716078118464" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008" TOTAL_1="111" TOTAL_2="117" VAR="0.087999537999538" WEIGHT="30.92080250821354"/>
<DICH_DATA CI_END="2.758081665662549" CI_START="0.2681573969356461" EFFECT_SIZE="0.86" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.44060712131101293" LOG_CI_START="-0.5716102188238774" LOG_EFFECT_SIZE="-0.06550154875643228" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.5945814761518775" STUDY_ID="STD-van-Leth-2004" TOTAL_1="200" TOTAL_2="387" VAR="0.3535271317829457" WEIGHT="8.211331494449839"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1287072215392278" CI_END="0.8957410657524277" CI_START="0.1315169436011614" DF="2" EFFECT_SIZE="0.34322751525162754" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="18" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="-0.047817514854590654" LOG_CI_START="-0.8810182925091178" LOG_EFFECT_SIZE="-0.46441790368185426" MODIFIED="2016-11-11 11:47:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5687278021817859" P_Z="0.028894036256410235" STUDIES="3" TAU2="0.0" TOTAL_1="330" TOTAL_2="348" WEIGHT="12.223348899560253" Z="2.1849292257128523">
<NAME>Nevirapine 400 mg once daily</NAME>
<DICH_DATA CI_END="1.5960270953377167" CI_START="0.06961730877607697" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2030402599819847" LOG_CI_START="-1.1572827694213097" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="0.7990604811790905" STUDY_ID="STD-Manosuthi-2009a" TOTAL_1="71" TOTAL_2="71" VAR="0.6384976525821596" WEIGHT="4.591906534638894"/>
<DICH_DATA CI_END="1.553759423905636" CI_START="0.004970319883648871" EFFECT_SIZE="0.08787878787878788" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.19138377575287346" LOG_CI_START="-2.303615659710736" LOG_EFFECT_SIZE="-1.0561159419789314" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="1.4655750188377155" STUDY_ID="STD-Swaminathan-2011" TOTAL_1="59" TOTAL_2="57" VAR="2.1479101358411703" WEIGHT="1.3770009278238828"/>
<DICH_DATA CI_END="1.798389541231708" CI_START="0.12357995465596919" EFFECT_SIZE="0.4714285714285714" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.2548837682002635" LOG_CI_START="-0.9080519684730021" LOG_EFFECT_SIZE="-0.32658410013636935" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.6831142083466144" STUDY_ID="STD-van-Leth-2004" TOTAL_1="200" TOTAL_2="220" VAR="0.46664502164502164" WEIGHT="6.254441437097477"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.518327230756099" CI_END="1.8907823649919613" CI_START="0.7623768606603416" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2006201412663824" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="45" I2="11.471662061744071" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.27664154305842253" LOG_CI_START="-0.1178302936919137" LOG_EFFECT_SIZE="0.07940562468325449" METHOD="MH" MODIFIED="2016-11-11 11:46:33 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.34037999962658505" P_Q="0.4353905573229524" P_Z="0.4300734176649117" Q="0.6084013182650113" RANDOM="YES" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03305607180931631" TOTALS="YES" TOTAL_1="897" TOTAL_2="1108" WEIGHT="99.99999999999999" Z="0.7890660374194676">
<NAME>Progression to AIDS</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Nevirapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.8918188039229804" CI_END="2.2273248576642986" CI_START="0.7525337561359331" DF="3" EFFECT_SIZE="1.294657152018652" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="38" I2="22.91521904935607" ID="CMP-004.03.01" LOG_CI_END="0.3477835639590009" LOG_CI_START="-0.12347401430586694" LOG_EFFECT_SIZE="0.11215477482656698" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2733852440927993" P_Z="0.3508689355976502" STUDIES="5" TAU2="0.07389379008853125" TOTAL_1="697" TOTAL_2="888" WEIGHT="85.34486041693812" Z="0.9329051860073112">
<NAME>Nevirapine 200 mg twice daily</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.0" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004" TOTAL_1="30" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.8699019605733955" CI_START="0.11484643512224581" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5876999628170224" LOG_CI_START="-0.939882480928385" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.8973094891111016" STUDY_ID="STD-Manosuthi-2009a" TOTAL_1="71" TOTAL_2="71" VAR="0.8051643192488263" WEIGHT="6.405440288238731"/>
<DICH_DATA CI_END="2.4965388870827865" CI_START="0.30986907939396224" EFFECT_SIZE="0.8795454545454545" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.39733833518741946" LOG_CI_START="-0.5088217581219716" LOG_EFFECT_SIZE="-0.055741711467276044" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.5322829243747403" STUDY_ID="STD-van-Leth-2004" TOTAL_1="200" TOTAL_2="387" VAR="0.2833251115809255" WEIGHT="16.970575195947802"/>
<DICH_DATA CI_END="2.0919005393381997" CI_START="0.6409101180454797" EFFECT_SIZE="1.1578947368421053" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="19" LOG_CI_END="0.3205410318953125" LOG_CI_START="-0.19320287215655796" LOG_EFFECT_SIZE="0.0636690798693773" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.30177571231340794" STUDY_ID="STD-Bonnet-2013a" TOTAL_1="285" TOTAL_2="285" VAR="0.09106858054226476" WEIGHT="43.25627956724472"/>
<DICH_DATA CI_END="7.923286180783608" CI_START="1.0993512793023954" EFFECT_SIZE="2.9513513513513514" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.8989053424708964" LOG_CI_START="0.04113648613255058" LOG_EFFECT_SIZE="0.47002091430172344" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.5038576722374621" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008" TOTAL_1="111" TOTAL_2="117" VAR="0.25387255387255386" WEIGHT="18.712565365506876"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4360720750436142" CI_START="0.25341899572674076" DF="0" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="0.38669013343976366" LOG_CI_START="-0.5961608344797896" LOG_EFFECT_SIZE="-0.104735350520013" MODIFIED="2016-11-11 11:46:33 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6761529473484841" STUDIES="1" TAU2="0.0" TOTAL_1="200" TOTAL_2="220" WEIGHT="14.655139583061867" Z="0.41771849777372544">
<NAME>Nevirapine 400 mg once daily</NAME>
<DICH_DATA CI_END="2.4360720750436142" CI_START="0.25341899572674076" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.38669013343976366" LOG_CI_START="-0.5961608344797896" LOG_EFFECT_SIZE="-0.104735350520013" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="0.5773315237467016" STUDY_ID="STD-van-Leth-2004" TOTAL_1="200" TOTAL_2="220" VAR="0.33331168831168834" WEIGHT="14.655139583061867"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.260019912714911" CI_END="1.1416974700555256" CI_START="0.6605658891115572" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8684275470087552" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="228" I2="36.886483643861034" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.05755103868075481" LOG_CI_START="-0.18008385655000966" LOG_EFFECT_SIZE="-0.061266408934627405" METHOD="MH" MODIFIED="2016-11-11 11:46:49 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.11337187009154726" P_Q="0.6821550695852415" P_Z="0.3121956694205922" Q="0.16771029013117827" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06339307597486435" TOTALS="YES" TOTAL_1="1090" TOTAL_2="1294" WEIGHT="100.0" Z="1.0106256057837337">
<NAME>Discontinuation rate</NAME>
<GROUP_LABEL_1>Efavirenz</GROUP_LABEL_1>
<GROUP_LABEL_2>Nevirapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Efavirenz</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Nevirapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.683139849934904" CI_END="1.2060841148942156" CI_START="0.706371753637247" DF="6" EFFECT_SIZE="0.923007990903575" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="151" I2="10.221839812937004" ID="CMP-004.04.01" LOG_CI_END="0.08137759748946559" LOG_CI_START="-0.15096667563199562" LOG_EFFECT_SIZE="-0.03479453907126503" MODIFIED="2016-11-11 11:46:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.35114654361988074" P_Z="0.5571863704803668" STUDIES="7" TAU2="0.014056927535235124" TOTAL_1="795" TOTAL_2="986" WEIGHT="67.28624931820292" Z="0.5870258175263978">
<NAME>Nevirapine 200 mg twice daily</NAME>
<DICH_DATA CI_END="6.184805150349353" CI_START="0.140846977380024" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7913260219180813" LOG_CI_START="-0.8512524686729677" LOG_EFFECT_SIZE="-0.02996322337744321" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.964858736267844" STUDY_ID="STD-Ayala-Gayt_x00e1_n-2004" TOTAL_1="30" TOTAL_2="28" VAR="0.930952380952381" WEIGHT="1.9595589777162792"/>
<DICH_DATA CI_END="2.2913204096377298" CI_START="0.7758748057670615" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="21" LOG_CI_END="0.36008582354465946" LOG_CI_START="-0.11020835032805965" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.27625312572654126" STUDY_ID="STD-Bonnet-2013a" TOTAL_1="285" TOTAL_2="285" VAR="0.07631578947368421" WEIGHT="13.946706680477321"/>
<DICH_DATA CI_END="4.354129221503021" CI_START="0.3831771389646205" EFFECT_SIZE="1.2916666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6389013138536588" LOG_CI_START="-0.41660040960832545" LOG_EFFECT_SIZE="0.11115045212266668" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.6200069371793655" STUDY_ID="STD-Landman-2014" TOTAL_1="30" TOTAL_2="31" VAR="0.3844086021505376" WEIGHT="4.3512087208559524"/>
<DICH_DATA CI_END="1.1878023106995372" CI_START="0.26637955419842346" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.07474416579963411" LOG_CI_START="-0.5744991122328339" LOG_EFFECT_SIZE="-0.2498774732165999" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="11" O_E="0.0" SE="0.3813687153223296" STUDY_ID="STD-Manosuthi-2009a" TOTAL_1="71" TOTAL_2="71" VAR="0.14544209702660404" WEIGHT="9.33022219901376"/>
<DICH_DATA CI_END="2.3820243242881496" CI_START="0.2994277236824735" EFFECT_SIZE="0.8445378151260504" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3769461920124943" LOG_CI_START="-0.5237079912845406" LOG_EFFECT_SIZE="-0.07338089963602308" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.5290487255787882" STUDY_ID="STD-Sinha-2013" TOTAL_1="68" TOTAL_2="67" VAR="0.27989255403654" WEIGHT="5.675968921298711"/>
<DICH_DATA CI_END="2.410202149240874" CI_START="0.7202650182901416" EFFECT_SIZE="1.3175675675675675" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.3820534693873404" LOG_CI_START="-0.14250767745221926" LOG_EFFECT_SIZE="0.11977289596756062" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.3081298142731119" STUDY_ID="STD-van-den-Berg_x002d_Wolf-2008" TOTAL_1="111" TOTAL_2="117" VAR="0.09494398244398244" WEIGHT="12.305890904698357"/>
<DICH_DATA CI_END="1.0534989966045052" CI_START="0.5037208384955817" EFFECT_SIZE="0.7284705882352941" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="85" LOG_CI_END="0.022634126304504294" LOG_CI_START="-0.2978100823834175" LOG_EFFECT_SIZE="-0.13758797803945658" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.18823051440770056" STUDY_ID="STD-van-Leth-2004" TOTAL_1="200" TOTAL_2="387" VAR="0.03543072655418757" WEIGHT="19.716692914142538"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.248714157154521" CI_END="1.5678365448538898" CI_START="0.399917370124925" DF="2" EFFECT_SIZE="0.7918365158312141" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="77" I2="61.89542924005872" ID="CMP-004.04.02" LOG_CI_END="0.19530078324109612" LOG_CI_START="-0.39802973218662374" LOG_EFFECT_SIZE="-0.10136447447276387" MODIFIED="2016-11-11 11:46:49 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.07248647271470376" P_Z="0.5030619597076205" STUDIES="3" TAU2="0.21901690964542841" TOTAL_1="295" TOTAL_2="308" WEIGHT="32.71375068179709" Z="0.6696797623335762">
<NAME>Nevirapine 400 mg once daily</NAME>
<DICH_DATA CI_END="2.9278073153759534" CI_START="0.6687789963244942" EFFECT_SIZE="1.3993055555555556" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.4665424915726442" LOG_CI_START="-0.17471737480888702" LOG_EFFECT_SIZE="0.1459125583818786" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.3766792198000443" STUDY_ID="STD-N_x00fa__x00f1_ez-2002" TOTAL_1="36" TOTAL_2="31" VAR="0.1418872346291701" WEIGHT="9.491794713968465"/>
<DICH_DATA CI_END="2.733983640809311" CI_START="0.21848908729050606" EFFECT_SIZE="0.7728813559322034" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4367959115750732" LOG_CI_START="-0.6605702495304917" LOG_EFFECT_SIZE="-0.11188716897770919" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="0.6445983150835133" STUDY_ID="STD-Swaminathan-2011" TOTAL_1="59" TOTAL_2="57" VAR="0.4155069878085043" WEIGHT="4.068653805722977"/>
<DICH_DATA CI_END="0.7820591505604473" CI_START="0.36300215904744093" EFFECT_SIZE="0.5328125" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="64" LOG_CI_END="-0.10676039810319238" LOG_CI_START="-0.4400907918795865" LOG_EFFECT_SIZE="-0.2734255949913894" MODIFIED="2015-04-04 00:47:55 +0100" MODIFIED_BY="[Empty name]" ORDER="200" O_E="0.0" SE="0.1957999233163141" STUDY_ID="STD-van-Leth-2004" TOTAL_1="200" TOTAL_2="220" VAR="0.03833760997067449" WEIGHT="19.153302162105646"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-11-09 18:07:08 +0000" MODIFIED_BY="Anne-Marie Stephani">
<FIGURE FILENAME="PRISMA flow diagram_EFV vs NVP_31.10.2016.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2016-10-31 16:59:02 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow diagram of study screening and selection</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-11-04 19:34:38 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAW4AAAKCCAIAAAB+rqS8AAAn70lEQVR42u2dv44TOxuHR0JCFCm2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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-11-09 18:07:08 +0000" MODIFIED_BY="Anne-Marie Stephani" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAAEACAMAAABWJIaGAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-11-03 19:00:39 +0000" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Efavirenz 600 mg versus Nevirapine all doses, outcome: 1.1 Virological success.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2010-03-09 10:13:37 +0000" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2016-11-03 17:50:21 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2016-11-03 17:48:51 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-11-03 17:48:45 +0000" MODIFIED_BY="[Empty name]">MEDLINE search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-03 17:48:51 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="22">
<TR>
<TH>
<P>Search</P>
</TH>
<TH>
<P>Most recent queries</P>
</TH>
<TH>
<P>Result</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=11&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#11</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search #8 AND #9 Limits: <B>Publication Date from 1996 to 2009</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=11&amp;tab=&amp;">645</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=10&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#10</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search #8 AND #9</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=10&amp;tab=&amp;">656</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=9&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#9</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search NNRTI OR (NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR) OR (NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR) OR (NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR) OR (NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS) OR (NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS) OR (NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS) OR (PI SPARING) OR (PROTEASE INHIBITOR SPARING) OR (PROTEASE-INHIBITOR SPARING) OR (NON-PROTEASE INHIBITOR CONTAINING) OR (NON-PI CONTAINING) OR (NON PROTEASE INHIBITOR CONTAINING)</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=9&amp;tab=&amp;">13943</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=8&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#8</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search #3 AND #4 AND #7</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=8&amp;tab=&amp;">1744</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=7&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#7</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search #5 OR #6</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=7&amp;tab=&amp;">4073</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=6&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#6</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search NEVIRAPINE OR NVP OR VIRAMUNE OR NEVIMUNE</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=6&amp;tab=&amp;">2872</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=5&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#5</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search EFAVIRENZ OR SUSTIVA OR STOCRIN OR EFV OR EFZ</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=5&amp;tab=&amp;">1794</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=4&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#4</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search randomised controlled trial [pt] OR controlled clinical trial [pt] OR randomised controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR ( placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR comparative study [mh] OR evaluation studies [mh] OR follow-up studies [mh] OR prospective studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT human [mh])</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=4&amp;tab=&amp;">3082417</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=3&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#3</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search #1 OR #2</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=3&amp;tab=&amp;">283409</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=2&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#2</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search Antiretroviral Therapy, Highly Active[MeSH] OR Anti-Retroviral Agents[MeSH] OR Antiviral Agents[MeSH:NoExp] OR ((anti) AND (hiv[tw])) OR antiretroviral*[tw] OR ((anti) AND (retroviral*[tw])) OR HAART[tw] OR ((anti) AND (acquired immunodeficiency[tw])) OR ((anti) AND (acquired immunedeficiency[tw])) OR ((anti) AND (acquired immuno-deficiency[tw])) OR ((anti) AND (acquired immune-deficiency[tw])) OR ((anti) AND (acquired immun*) AND (deficiency[tw]))</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=2&amp;tab=&amp;">97848</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?querykey=1&amp;dbase=pubmed&amp;tab=History&amp;querytype=eSearch&amp;">#1</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tw] OR hiv-1*[tw] OR hiv-2*[tw] OR hiv1[tw] OR hiv2[tw] OR hiv infect*[tw] OR human immunodeficiency virus[tw] OR human immunedeficiency virus[tw] OR human immuno-deficiency virus[tw] OR human immune-deficiency virus[tw] OR ((human immun*) AND (deficiency virus[tw])) OR acquired immunodeficiency syndrome[tw] OR acquired immunedeficiency syndrome[tw] OR acquired immuno-deficiency syndrome[tw] OR acquired immune-deficiency syndrome[tw] OR ((acquired immun*) AND (deficiency syndrome[tw])) OR "sexually transmitted diseases, viral"[MH]</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=HistorySearch&amp;querykey=1&amp;tab=&amp;">250716</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Search</P>
</TD>
<TD VALIGN="TOP">
<P>Query</P>
</TD>
<TD VALIGN="TOP">
<P>Items found</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed">#9</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search ((#3 AND #4 AND #7)) AND (<B>"2009/05/01"[Date - Publication] : "2014/02/07"[Date - Publication])</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=9">236</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed">#8</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (#3 AND #4 AND #7)</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=8">607</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed">#7</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (#5 AND #6)</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=7">893</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed">#6</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (nevirapine[mh] OR nevirapine[tiab] OR viramune[tiab] OR nevimune[tiab] OR NVP[tiab])</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=6">4505</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed">#5</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (efavirenz[tiab] OR sustiva[tiab] OR stocrin[tiab] OR EFV[tiab])</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=5">2763</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed">#4</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh])</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=4">2838401</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed">#3</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (#1 AND #2)</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=3">85427</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed">#2</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (antiretroviral therapy, highly active[MeSH] OR anti-retroviral agents[MeSH] OR antiviral agents[MeSH:NoExp] OR ((anti[tiab]) AND (hiv[tiab])) OR antiretroviral*[tiab] OR ((anti[tiab]) AND (retroviral*[tiab])) OR HAART[tiab] OR ((anti[tiab]) AND (acquired immunodeficiency[tiab])) OR ((anti[tiab]) AND (acquired immuno-deficiency[tiab])) OR ((anti[tiab]) AND (acquired immune-deficiency[tiab])) OR ((anti[tiab]) AND (acquired immun*[tiab]) AND (deficiency[tiab])))</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=2">135207</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed">#1</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tiab] OR hiv-1*[tiab] OR hiv-2*[tiab] OR hiv1[tiab] OR hiv2[tiab] OR hiv infect*[tiab] OR human immunodeficiency virus[tiab] OR human immunedeficiency virus[tiab] OR human immuno-deficiency virus[tiab] OR human immune-deficiency virus[tiab] OR ((human immun*[tiab]) AND (deficiency virus[tiab])) OR acquired immunodeficiency syndrome[tiab] OR acquired immunedeficiency syndrome[tiab] OR acquired immuno-deficiency syndrome[tiab] OR acquired immune-deficiency syndrome[tiab] OR ((acquired immun*[tiab]) AND (deficiency syndrome[tiab])) OR "sexually transmitted diseases, Viral"[MeSH:NoExp]))</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=1">307747</A>
</P>
</TD>
</TR>
</TABLE>
<P/>
<TABLE COLS="3" ROWS="10">
<TR>
<TD>
<P>Search</P>
</TD>
<TD>
<P>Query</P>
</TD>
<TD>
<P>Items found</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/advanced">#9</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (((#3 AND #4 AND #7))) AND <B>("2014/02/07"[Date - Publication] : "2015/03/13"[Date - Publication])</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=9">33</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/advanced">#8</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (#3 AND #4 AND #7)</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=8">675</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/advanced">#7</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (#5 AND #6)</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=7">997</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/advanced">#6</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (nevirapine[mh] OR nevirapine[tiab] OR viramune[tiab] OR nevimune[tiab] OR NVP[tiab])</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=6">4901</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/advanced">#5</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (efavirenz[tiab] OR sustiva[tiab] OR stocrin[tiab] OR EFV[tiab])</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=5">3120</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/advanced">#4</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh])</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=4">3038686</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/advanced">#3</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (#1 AND #2)</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=3">91917</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/advanced">#2</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (antiretroviral therapy, highly active[MeSH] OR anti-retroviral agents[MeSH] OR antiviral agents[MeSH:NoExp] OR ((anti[tiab]) AND (hiv[tiab])) OR antiretroviral*[tiab] OR ((anti[tiab]) AND (retroviral*[tiab])) OR HAART[tiab] OR ((anti[tiab]) AND (acquired immunodeficiency[tiab])) OR ((anti[tiab]) AND (acquired immuno-deficiency[tiab])) OR ((anti[tiab]) AND (acquired immune-deficiency[tiab])) OR ((anti[tiab]) AND (acquired immun*[tiab]) AND (deficiency[tiab]))</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=2">145438</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/advanced">#1</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tiab] OR hiv-1*[tiab] OR hiv-2*[tiab] OR hiv1[tiab] OR hiv2[tiab] OR hiv infect*[tiab] OR human immunodeficiency virus[tiab] OR human immunedeficiency virus[tiab] OR human immuno-deficiency virus[tiab] OR human immune-deficiency virus[tiab] OR ((human immun*[tiab]) AND (deficiency virus[tiab])) OR acquired immunodeficiency syndrome[tiab] OR acquired immunedeficiency syndrome[tiab] OR acquired immuno-deficiency syndrome[tiab] OR acquired immune-deficiency syndrome[tiab] OR ((acquired immun*[tiab]) AND (deficiency syndrome[tiab])) OR "sexually transmitted diseases, Viral"[MeSH:NoExp])</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=1">324200</A>
</P>
</TD>
</TR>
</TABLE>
<TABLE COLS="3" ROWS="10">
<TR>
<TD>
<P>Search</P>
</TD>
<TD>
<P>Query</P>
</TD>
<TD>
<P>Items found</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed">#9</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (((#3 AND #4 AND #7))) AND <B>("2015/03/13"[Date - Publication] : "2016/08/12"[Date - Publication])</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=9">54</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed">#8</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (#3 AND #4 AND #7)</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=8">767</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed">#7</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (#5 AND #6)</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=7">1101</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed">#6</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (nevirapine[mh] OR nevirapine[tiab] OR viramune[tiab] OR nevimune[tiab] OR NVP[tiab])</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=6">5337</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed">#5</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (efavirenz[tiab] OR sustiva[tiab] OR stocrin[tiab] OR EFV[tiab])</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=5">3552</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed">#4</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh])</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=4">3326892</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed">#3</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (#1 AND #2)</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=3">100806</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed">#2</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (antiretroviral therapy, highly active[MeSH] OR anti-retroviral agents[MeSH] OR antiviral agents[MeSH:NoExp] OR ((anti[tiab]) AND (hiv[tiab])) OR antiretroviral*[tiab] OR ((anti[tiab]) AND (retroviral*[tiab])) OR HAART[tiab] OR ((anti[tiab]) AND (acquired immunodeficiency[tiab])) OR ((anti[tiab]) AND (acquired immuno-deficiency[tiab])) OR ((anti[tiab]) AND (acquired immune-deficiency[tiab])) OR ((anti[tiab]) AND (acquired immun*[tiab]) AND (deficiency[tiab]))</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=2">159959</A>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed">#1</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>Search (HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tiab] OR hiv-1*[tiab] OR hiv-2*[tiab] OR hiv1[tiab] OR hiv2[tiab] OR hiv infect*[tiab] OR human immunodeficiency virus[tiab] OR human immunedeficiency virus[tiab] OR human immuno-deficiency virus[tiab] OR human immune-deficiency virus[tiab] OR ((human immun*[tiab]) AND (deficiency virus[tiab])) OR acquired immunodeficiency syndrome[tiab] OR acquired immunedeficiency syndrome[tiab] OR acquired immuno-deficiency syndrome[tiab] OR acquired immune-deficiency syndrome[tiab] OR ((acquired immun*[tiab]) AND (deficiency syndrome[tiab])) OR "sexually transmitted diseases, Viral"[MeSH:NoExp])</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://www.ncbi.nlm.nih.gov/pubmed/?cmd=HistorySearch&amp;querykey=1">348268</A>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-11-03 17:49:00 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2016-11-03 17:49:00 +0000" MODIFIED_BY="[Empty name]">Embase search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2016-10-28 18:06:42 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="4" ROWS="11">
<TR>
<TD>
<P>No.</P>
</TD>
<TD>
<P>Query</P>
</TD>
<TD>
<P>Results</P>
</TD>
<TD>
<P>Date</P>
</TD>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>(('human immunodeficiency virus infection'/exp OR 'human immunodeficiency virus infection') OR ('human immunodeficiency virus infection'/de OR 'human immunodeficiency virus infection')) OR (('human immunodeficiency virus'/exp OR 'human immunodeficiency virus') OR ('human immunodeficiency virus'/de OR 'human immunodeficiency virus')) OR (hiv:ti OR hiv:ab) OR ('hiv-1':ti OR 'hiv-1':ab) OR ('hiv-2':ti OR 'hiv-2':ab) OR ('human immunodeficiency virus':ti OR 'human immunodeficiency virus':ab) OR ('human immuno-deficiency virus':ti OR 'human immuno-deficiency virus':ab) OR ('human immunedeficiency virus':ti OR 'human immunedeficiency virus':ab) OR ('human immune-deficiency virus':ti OR 'human immune-deficiency virus':ab) OR ('acquired immune-deficiency syndrome':ti OR 'acquired immune-deficiency syndrome':ab) OR ('acquired immunedeficiency syndrome':ti OR 'acquired immunedeficiency syndrome':ab) OR ('acquired immunodeficiency syndrome':ti OR 'acquired immunodeficiency syndrome':ab) OR ('acquired immuno-deficiency syndrome':ti OR 'acquired immuno-deficiency syndrome':ab)</P>
</TD>
<TD>
<P>292,932</P>
</TD>
<TD>
<P>22 May 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>('human immunodeficiency virus vaccine'/de OR 'human immunodeficiency virus vaccine') OR ('anti human immunedeficiency':ti OR 'anti human immunedeficiency':ab) OR ('anti human immunodeficiency':ti OR 'anti human immunodeficiency':ab) OR ('anti human immuno-deficiency':ti OR 'anti human immuno-deficiency':ab) OR ('anti human immune-deficiency':ti OR 'anti human immune-deficiency':ab) OR ('anti acquired immune-deficiency':ti OR 'anti acquired immune-deficiency':ab) OR ('anti acquired immunedeficiency':ti OR 'anti acquired immunedeficiency':ab) OR ('anti acquired immunodeficiency':ti OR 'anti acquired immunodeficiency':ab) OR ('anti acquired immuno-deficiency':ti OR 'anti acquired immuno-deficiency':ab) OR ('anti hiv':ti OR 'anti hiv':ab) OR (antiretrovir*:ti OR antiretrovir*:ab) OR ('anti retroviral':ti OR 'anti retroviral':ab OR 'anti retrovirals':ti OR 'anti retrovirals':ab OR 'anti retrovirus':ti OR 'anti retrovirus':ab) OR (haart:ti OR haart:ab) OR ('aids vaccine':ti OR 'aids vaccine':ab OR 'aids vaccines':ti OR 'aids vaccines':ab) OR (('anti human immunodeficiency virus agent'/de OR 'anti human immunodeficiency virus agent')) OR (('antiretrovirus agent'/de OR 'antiretrovirus agent')) OR (('antivirus agent'/de OR 'antivirus agent')) OR (('highly active antiretroviral therapy'/de OR 'highly active antiretroviral therapy'))</P>
</TD>
<TD>
<P>92,810</P>
</TD>
<TD>
<P>22 May 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>((random*:ti OR random*:ab) OR (factorial*:ti OR factorial*:ab) OR (cross?over*:ti OR cross?over*:ab OR crossover*:ti OR crossover*:ab) OR (placebo*:ti OR placebo*:ab) OR ((doubl*:ti AND blind*:ti) OR (doubl*:ab AND blind*:ab)) OR ((singl*:ti AND blind*:ti) OR (singl*:ab AND blind*:ab)) OR (assign*:ti OR assign*:ab) OR (allocat*:ti OR allocat*:ab) OR (volunteer*:ti OR volunteer*:ab) OR (((('crossover procedure'/exp OR 'crossover procedure') OR ('crossover procedure'/de OR 'crossover procedure')) OR (('crossover procedure'/exp OR 'crossover procedure') OR ('crossover procedure'/de OR 'crossover procedure')))) OR (((('double-blind procedure'/exp OR 'double-blind procedure') OR ('double-blind procedure'/de OR 'double-blind procedure')) OR (('double-blind procedure'/exp OR 'double-blind procedure') OR ('double-blind procedure'/de OR 'double-blind procedure')))) OR (((('single-blind procedure'/exp OR 'single-blind procedure') OR ('single-blind procedure'/de OR 'single-blind procedure')) OR (('single-blind procedure'/exp OR 'single-blind procedure') OR ('single-blind procedure'/de OR 'single-blind procedure')))) OR (((('randomised controlled trial'/exp OR 'randomised controlled trial') OR ('randomised controlled trial'/de OR 'randomised controlled trial')) OR (('randomised controlled trial'/exp OR 'randomised controlled trial') OR ('randomised controlled trial'/de OR 'randomised controlled trial')))))</P>
</TD>
<TD>
<P>865,259</P>
</TD>
<TD>
<P>22 May 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>#1 OR #2</P>
</TD>
<TD>
<P>321,839</P>
</TD>
<TD>
<P>22 May 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>('efavirenz'/de OR 'efavirenz') OR ('sustiva'/de OR 'sustiva') OR ('stocrin'/de OR 'stocrin') OR efv OR efz</P>
</TD>
<TD>
<P>7,680</P>
</TD>
<TD>
<P>22 May 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>('nevirapine'/de OR 'nevirapine') OR nvp OR ('viramune'/de OR 'viramune') OR nevimune</P>
</TD>
<TD>
<P>9,696</P>
</TD>
<TD>
<P>22 May 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>#5 OR #6</P>
</TD>
<TD>
<P>12,972</P>
</TD>
<TD>
<P>22 May 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>#3 AND #4 AND #7</P>
</TD>
<TD>
<P>1,088</P>
</TD>
<TD>
<P>22 May 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>('nnrti'/de OR 'nnrti') OR 'non-nucleoside reverse transcriptase inhibitor' OR 'non nucleoside reverse transcriptase inhibitor' OR ('nonnucleoside reverse transcriptase inhibitor'/de OR 'nonnucleoside reverse transcriptase inhibitor') OR 'non-nucleoside reverse transcriptase inhibitors' OR 'non nucleoside reverse transcriptase inhibitors' OR 'nonnucleoside reverse transcriptase inhibitors' OR 'pi sparing' OR 'protease inhibitor sparing' OR 'protease-inhibitor sparing' OR 'non-protease inhibitor containing' OR 'non-pi containing' OR 'non protease inhibitor containing'</P>
</TD>
<TD>
<P>13,324</P>
</TD>
<TD>
<P>22 May 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>#8 AND #9 AND <B>[1996-2009]/</B>py</P>
</TD>
<TD>
<P>523</P>
</TD>
<TD>
<P>22 May 2009</P>
</TD>
</TR>
</TABLE>
<P/>
<TABLE COLS="3" ROWS="15">
<TR>
<TD>
<P>No.</P>
</TD>
<TD>
<P>Query</P>
</TD>
<TD>
<P>Results</P>
</TD>
</TR>
<TR>
<TD>
<P>#14</P>
</TD>
<TD>
<P>#3 AND #9 AND #12 AND [embase]/lim AND <B>[1-5-2009]/sd NOT [7-2-2014]/</B>sd</P>
</TD>
<TD>
<P>554</P>
</TD>
</TR>
<TR>
<TD>
<P>#13</P>
</TD>
<TD>
<P>#3 AND #9 AND #12</P>
</TD>
<TD>
<P>1115</P>
</TD>
</TR>
<TR>
<TD>
<P>#12</P>
</TD>
<TD>
<P>#10 AND #11</P>
</TD>
<TD>
<P>7336</P>
</TD>
</TR>
<TR>
<TD>
<P>#11</P>
</TD>
<TD>
<P>'nevirapine'/de OR nevirapine OR 'viramune'/de OR viramune OR 'nevimune'/de OR nevimune OR nvp</P>
</TD>
<TD>
<P>16047</P>
</TD>
</TR>
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>'efavirenz'/de OR efavirenz OR 'sustiva'/de OR sustiva OR 'stocrin'/de OR stocrin OR efv</P>
</TD>
<TD>
<P>13719</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>#4 NOT #8</P>
</TD>
<TD>
<P>1551893</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>#5 NOT #7</P>
</TD>
<TD>
<P>4886059</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>#5 AND #6</P>
</TD>
<TD>
<P>1247730</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>'human'/de OR 'normal human'/de OR 'human cell'/de</P>
</TD>
<TD>
<P>14535586</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>'animal'/de OR 'animal experiment'/de OR 'invertebrate'/de OR 'animal tissue'/de OR 'animal cell'/de OR 'nonhuman'/de</P>
</TD>
<TD>
<P>6133789</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>'randomized controlled trial'/de OR 'randomized controlled trial' OR random*:ab,ti OR trial:ti OR allocat*:ab,ti OR factorial*:ab,ti OR placebo*:ab,ti OR assign*:ab,ti OR volunteer*:ab,ti OR 'crossover procedure'/de OR 'crossover procedure' OR 'double-blind procedure'/de OR 'double-blind procedure' OR 'single-blind procedure'/de OR 'single-blind procedure' OR (doubl* NEAR/3 blind*):ab,ti OR (singl*:ab,ti AND blind*:ab,ti) OR crossover*:ab,ti OR cross+over*:ab,ti OR (cross NEXT/1 over*):ab,ti</P>
</TD>
<TD>
<P>1782714</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>#1 AND #2</P>
</TD>
<TD>
<P>116833</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>'human immunodeficiency virus vaccine'/exp OR 'human immunodeficiency virus vaccine':ab,ti OR 'anti human immunedeficiency':ab,ti OR 'anti human immunodeficiency':ab,ti OR 'anti human immuno-deficiency':ab,ti OR 'anti human immune-deficiency':ab,ti OR 'anti acquired immune-deficiency':ab,ti OR 'anti acquired immunedeficiency':ab,ti OR 'anti acquired immunodeficiency':ab,ti OR 'anti acquired immuno-deficiency':ab,ti OR 'anti hiv':ab,ti OR antiretrovir*:ab,ti OR 'anti retroviral':ab,ti OR 'anti retrovirals':ab,ti OR 'anti retrovirus':ab,ti OR haart:ab,ti OR 'aids vaccine':ab,ti OR 'aids vaccines':ab,ti OR 'anti human immunodeficiency virus agent'/exp OR 'anti human immunodeficiency virus agent':ab,ti OR 'antiretrovirus agent'/exp OR 'antiretrovirus agent':ab,ti OR 'highly active antiretroviral therapy'/exp OR 'highly active antiretroviral therapy':ab,ti</P>
</TD>
<TD>
<P>165003</P>
</TD>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>'human immunodeficiency virus infection'/exp OR 'human immunodeficiency virus'/exp OR 'human immunodeficiency virus':ab,ti OR 'human immuno+deficiency virus':ab,ti OR 'human immunedeficiency virus':ab,ti OR 'human immune+deficiency virus':ab,ti OR hiv:ab,ti OR 'hiv-1':ab,ti OR 'hiv-2':ab,ti OR 'acquired immunodeficiency syndrome':ab,ti OR 'acquired immuno+deficiency syndrome':ab,ti OR 'acquired immunedeficiency syndrome':ab,ti OR 'acquired immune+deficiency syndrome':ab,ti</P>
</TD>
<TD>
<P>384563</P>
</TD>
</TR>
</TABLE>
<P/>
<TABLE COLS="3" ROWS="15">
<TR>
<TD>
<P>No.</P>
</TD>
<TD>
<P>Query</P>
</TD>
<TD>
<P>Results</P>
</TD>
</TR>
<TR>
<TD>
<P>#14</P>
</TD>
<TD>
<P>#3 AND #9 AND #12 AND <B>[7-2-2014]/sd NOT [13-3-2015]</B>/sd</P>
</TD>
<TD>
<P>85</P>
</TD>
</TR>
<TR>
<TD>
<P>#13</P>
</TD>
<TD>
<P>#3 AND #9 AND #12</P>
</TD>
<TD>
<P>796</P>
</TD>
</TR>
<TR>
<TD>
<P>#12</P>
</TD>
<TD>
<P>#10 AND #11</P>
</TD>
<TD>
<P>7647</P>
</TD>
</TR>
<TR>
<TD>
<P>#11</P>
</TD>
<TD>
<P>'nevirapine'/de OR nevirapine:ab,ti OR 'viramune'/de OR viramune:ab,ti OR 'nevimune'/de OR nevimune:ab,ti OR nvp:ab,ti</P>
</TD>
<TD>
<P>16066</P>
</TD>
</TR>
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>'efavirenz'/de OR efavirenz:ab,ti OR 'sustiva'/de OR sustiva:ab,ti OR 'stocrin'/de OR stocrin:ab,ti OR efv:ab,ti</P>
</TD>
<TD>
<P>14587</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>#4 NOT #8</P>
</TD>
<TD>
<P>1438290</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>#5 NOT #7</P>
</TD>
<TD>
<P>5079643</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>#5 AND #6</P>
</TD>
<TD>
<P>1341085</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>'human'/de OR 'normal human'/de OR 'human cell'/de</P>
</TD>
<TD>
<P>15656505</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>'animal'/de OR 'animal experiment'/de OR 'invertebrate'/de OR 'animal tissue'/de OR 'animal cell'/de OR 'nonhuman'/de</P>
</TD>
<TD>
<P>6420728</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>'randomized controlled trial'/de OR 'randomized controlled trial' OR random*:ab,ti OR trial:ti OR allocat*:ab,ti OR factorial*:ab,ti OR placebo*:ab,ti OR assign*:ab,ti OR volunteer*:ab,ti OR 'crossover procedure'/de OR 'crossover procedure' OR 'double-blind procedure'/de OR 'double-blind procedure' OR 'single-blind procedure'/de OR 'single-blind procedure' OR (doubl* NEAR/3 blind*):ab,ti OR (singl*:ab,ti AND blind*:ab,ti) OR crossover*:ab,ti OR cross+over*:ab,ti OR (cross NEXT/1 over*):ab,ti</P>
</TD>
<TD>
<P>1617084</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>#1 AND #2</P>
</TD>
<TD>
<P>126453</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>'human immunodeficiency virus vaccine'/exp OR 'human immunodeficiency virus vaccine' OR 'human immunodeficiency virus vaccine':ab,ti OR 'anti human immunedeficiency':ab,ti OR 'anti human immunodeficiency':ab,ti OR 'anti human immuno-deficiency':ab,ti OR 'anti human immune-deficiency':ab,ti OR 'anti acquired immune-deficiency':ab,ti OR 'anti acquired immunedeficiency':ab,ti OR 'anti acquired immunodeficiency':ab,ti OR 'anti acquired immuno-deficiency':ab,ti OR 'anti hiv':ab,ti OR antiretrovir*:ab,ti OR 'anti retroviral':ab,ti OR 'anti retrovirals':ab,ti OR 'anti retrovirus':ab,ti OR haart:ab,ti OR 'aids vaccine':ab,ti OR 'aids vaccines':ab,ti OR 'anti human immunodeficiency virus agent'/exp OR 'anti human immunodeficiency virus agent' OR 'anti human immunodeficiency virus agent':ab,ti OR 'antiretrovirus agent'/exp OR 'antiretrovirus agent' OR 'antiretrovirus agent':ab,ti OR 'highly active antiretroviral therapy'/exp OR 'highly active antiretroviral therapy' OR 'highly active antiretroviral therapy':ab,ti</P>
</TD>
<TD>
<P>178964</P>
</TD>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>'human immunodeficiency virus infection'/exp OR 'human immunodeficiency virus'/exp OR 'human immunodeficiency virus':ab,ti OR 'human immuno+deficiency virus':ab,ti OR 'human immunedeficiency virus':ab,ti OR 'human immune+deficiency virus':ab,ti OR hiv:ab,ti OR 'hiv-1':ab,ti OR 'hiv-2':ab,ti OR 'acquired immunodeficiency syndrome':ab,ti OR 'acquired immuno+deficiency syndrome':ab,ti OR 'acquired immunedeficiency syndrome':ab,ti OR 'acquired immune+deficiency syndrome':ab,ti</P>
</TD>
<TD>
<P>410883</P>
</TD>
</TR>
</TABLE>
<TABLE COLS="3" ROWS="15">
<TR>
<TD>
<P>No.</P>
</TD>
<TD>
<P>Query</P>
</TD>
<TD>
<P>Results</P>
</TD>
</TR>
<TR>
<TD>
<P>#14</P>
</TD>
<TD>
<P>#3 AND #9 AND #12 AND <B>[13-3-2015]/sd NOT [12-8-2016]</B>/sd</P>
</TD>
<TD>
<P>113</P>
</TD>
</TR>
<TR>
<TD>
<P>#13</P>
</TD>
<TD>
<P>#3 AND #9 AND #12</P>
</TD>
<TD>
<P>907</P>
</TD>
</TR>
<TR>
<TD>
<P>#12</P>
</TD>
<TD>
<P>#10 AND #11</P>
</TD>
<TD>
<P>8277</P>
</TD>
</TR>
<TR>
<TD>
<P>#11</P>
</TD>
<TD>
<P>'nevirapine'/de OR nevirapine:ab,ti OR 'viramune'/de OR viramune:ab,ti OR 'nevimune'/de OR nevimune:ab,ti OR nvp:ab,ti</P>
</TD>
<TD>
<P>17485</P>
</TD>
</TR>
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>'efavirenz'/de OR efavirenz:ab,ti OR 'sustiva'/de OR sustiva:ab,ti OR 'stocrin'/de OR stocrin:ab,ti OR efv:ab,ti</P>
</TD>
<TD>
<P>16217</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>#4 NOT #8</P>
</TD>
<TD>
<P>1648816</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>#5 NOT #7</P>
</TD>
<TD>
<P>5394456</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>#5 AND #6</P>
</TD>
<TD>
<P>1491807</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>'human'/de OR 'normal human'/de OR 'human cell'/de</P>
</TD>
<TD>
<P>17407367</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>'animal'/de OR 'animal experiment'/de OR 'invertebrate'/de OR 'animal tissue'/de OR 'animal cell'/de OR 'nonhuman'/de</P>
</TD>
<TD>
<P>6886263</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>'randomized controlled trial'/de OR 'randomized controlled trial' OR random*:ab,ti OR trial:ti OR allocat*:ab,ti OR factorial*:ab,ti OR placebo*:ab,ti OR assign*:ab,ti OR volunteer*:ab,ti OR 'crossover procedure'/de OR 'crossover procedure' OR 'double-blind procedure'/de OR 'double-blind procedure' OR 'single-blind procedure'/de OR 'single-blind procedure' OR (doubl* NEAR/3 blind*):ab,ti OR (singl*:ab,ti AND blind*:ab,ti) OR crossover*:ab,ti OR cross+over*:ab,ti OR (cross NEXT/1 over*):ab,ti</P>
</TD>
<TD>
<P>1847056</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>#1 AND #2</P>
</TD>
<TD>
<P>140484</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>'human immunodeficiency virus vaccine'/exp OR 'human immunodeficiency virus vaccine':ab,ti OR 'anti human immunedeficiency':ab,ti OR 'anti human immunodeficiency':ab,ti OR 'anti human immuno-deficiency':ab,ti OR 'anti human immune-deficiency':ab,ti OR 'anti acquired immune-deficiency':ab,ti OR 'anti acquired immunedeficiency':ab,ti OR 'anti acquired immunodeficiency':ab,ti OR 'anti acquired immuno-deficiency':ab,ti OR 'anti hiv':ab,ti OR antiretrovir*:ab,ti OR 'anti retroviral':ab,ti OR 'anti retrovirals':ab,ti OR 'anti retrovirus':ab,ti OR haart:ab,ti OR 'aids vaccine':ab,ti OR 'aids vaccines':ab,ti OR 'anti human immunodeficiency virus agent'/exp OR 'anti human immunodeficiency virus agent':ab,ti OR 'antiretrovirus agent'/exp OR 'antiretrovirus agent':ab,ti OR 'highly active antiretroviral therapy'/exp OR 'highly active antiretroviral therapy':ab,ti</P>
</TD>
<TD>
<P>198729</P>
</TD>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>'human immunodeficiency virus infection'/exp OR 'human immunodeficiency virus'/exp OR 'human immunodeficiency virus':ab,ti OR 'human immuno+deficiency virus':ab,ti OR 'human immunedeficiency virus':ab,ti OR 'human immune+deficiency virus':ab,ti OR hiv:ab,ti OR 'hiv-1':ab,ti OR 'hiv-2':ab,ti OR 'acquired immunodeficiency syndrome':ab,ti OR 'acquired immuno+deficiency syndrome':ab,ti OR 'acquired immunedeficiency syndrome':ab,ti OR 'acquired immune+deficiency syndrome':ab,ti</P>
</TD>
<TD>
<P>448264</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-11-03 17:50:09 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2016-11-03 17:50:09 +0000" MODIFIED_BY="[Empty name]">CENTRAL search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2016-10-28 18:06:42 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="27">
<TR>
<TD>
<P>
<B>ID</B>
</P>
</TD>
<TD>
<P>
<B>Search</B>
</P>
</TD>
<TD>
<P>
<B>Hits</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>
<A HREF="http://www3.interscience.wiley.com/cochrane/searchHistory?mode=runquery&amp;qnum=1">HIV INFECTIONS explode all trees (MESH) OR HIV explode all trees (MeSH) OR hiv OR hiv-1* OR hiv-2* OR hiv1 OR hiv2 OR HIV INFECT* OR HUMAN IMMUNODEFICIENCY VIRUS OR HUMAN IMMUNEDEFICIENCY VIRUS OR HUMAN IMMUNE-DEFICIENCY VIRUS OR HUMAN IMMUNO-DEFICIENCY VIRUS OR HUMAN IMMUN* DEFICIENCY VIRUS OR ACQUIRED IMMUNODEFICIENCY SYNDROME OR ACQUIRED IMMUNEDEFICIENCY SYNDROME OR ACQUIRED IMMUNO-DEFICIENCY SYNDROME OR ACQUIRED IMMUNE-DEFICIENCY SYNDROME OR ACQUIRED IMMUN* DEFICIENCY SYNDROME OR LYMPHOMA AIDS-RELATED single term (MeSH) OR SEXUALLY TRANSMITTED DISEASES VIRAL single term (MeSH) </A>
</P>
</TD>
<TD>
<P>8223</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>
<A HREF="http://www3.interscience.wiley.com/cochrane/searchHistory?mode=runquery&amp;qnum=2">ANTIRETROVIRAL THERAPY HIGHLY ACTIVE single term (MeSH) OR ANTI-HIV AGENTS explode all trees (MeSH) OR ANTIVIRAL AGENTS single term (MeSH) OR AIDS VACCINES single term (MeSH) OR ANTI HIV OR ANTIRETROVIRAL* OR ANTI RETROVIRAL* OR AIDS VACCIN* </A>
</P>
</TD>
<TD>
<P>3577</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>
<A HREF="http://www3.interscience.wiley.com/cochrane/searchHistory?mode=runquery&amp;qnum=3">(#1 OR #2)</A>
</P>
</TD>
<TD>
<P>8432</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>
<A HREF="http://www3.interscience.wiley.com/cochrane/searchHistory?mode=runquery&amp;qnum=4">NEVIRAPINE OR NVP OR VIRAMUNE OR NEVIMUNE</A>
</P>
</TD>
<TD>
<P>315</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>
<A HREF="http://www3.interscience.wiley.com/cochrane/searchHistory?mode=runquery&amp;qnum=5">EFAVIRENZ OR SUSTIVA OR STOCRIN OR EFV OR EFZ</A>
</P>
</TD>
<TD>
<P>227</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>
<A HREF="http://www3.interscience.wiley.com/cochrane/searchHistory?mode=runquery&amp;qnum=6">(#4 OR #5)</A>
</P>
</TD>
<TD>
<P>487</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>
<A HREF="http://www3.interscience.wiley.com/cochrane/searchHistory?mode=runquery&amp;qnum=7">NNRTI OR (NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR) OR (NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR) OR (NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR) OR (NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS) OR (NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS) OR (NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS) OR (PI SPARING) OR (PROTEASE INHIBITOR SPARING) OR (PROTEASE-INHIBITOR SPARING) OR (NON-PROTEASE INHIBITOR CONTAINING) OR (NON-PI CONTAINING) OR (NON PROTEASE INHIBITOR CONTAINING)</A>
</P>
</TD>
<TD>
<P>493</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>
<A HREF="http://www3.interscience.wiley.com/cochrane/searchHistory?mode=runquery&amp;qnum=8">(#3 AND #6 AND #7), from 1996 to 2009</A>
</P>
</TD>
<TD>
<P>146</P>
</TD>
</TR>
<TR>
<TD>
<P>ID</P>
</TD>
<TD>
<P>Search</P>
</TD>
<TD>
<P>Hits</P>
</TD>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>MeSH descriptor: [HIV Infections] explode all trees</P>
</TD>
<TD>
<P>7543</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>MeSH descriptor: [HIV] explode all trees</P>
</TD>
<TD>
<P>2495</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>hiv or hiv-1* or hiv-2* or hiv1 or hiv2 or (hiv near infect*) or (human immunodeficiency virus) or (human immunedeficiency virus) or (human immune-deficiency virus) or (human immuno-deficiency virus) or (human immune deficiency virus) or (human immuno deficiency virus) or (acquired immunodeficiency syndrome) or (acquired immunedeficiency syndrome) or (acquired immuno-deficiency syndrome) or (acquired immune-deficiency syndrome) or (acquired immun* deficiency syndrome) (Word variations have been searched)</P>
</TD>
<TD>
<P>12832</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>MeSH descriptor: [Lymphoma, AIDS-Related] this term only</P>
</TD>
<TD>
<P>21</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>MeSH descriptor: [Sexually Transmitted Diseases, Viral] this term only</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>#1 or #2 or #3 or #4 or #5</P>
</TD>
<TD>
<P>12913</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>MeSH descriptor: [Antiretroviral Therapy, Highly Active] this term only</P>
</TD>
<TD>
<P>961</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>MeSH descriptor: [Anti-HIV Agents] explode all trees</P>
</TD>
<TD>
<P>2570</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>MeSH descriptor: [Antiviral Agents] this term only</P>
</TD>
<TD>
<P>3288</P>
</TD>
</TR>
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>MeSH descriptor: [AIDS Vaccines] this term only</P>
</TD>
<TD>
<P>312</P>
</TD>
</TR>
<TR>
<TD>
<P>#11</P>
</TD>
<TD>
<P>(anti hiv) or antiretroviral* or (anti near retroviral*) or (aids near vaccin*) (Word variations have been searched)</P>
</TD>
<TD>
<P>5678</P>
</TD>
</TR>
<TR>
<TD>
<P>#12</P>
</TD>
<TD>
<P>#7 or #8 or #9 or #10 or #11</P>
</TD>
<TD>
<P>8955</P>
</TD>
</TR>
<TR>
<TD>
<P>#13</P>
</TD>
<TD>
<P>#6 and #12 from 1980 to 2014, in Trials (Word variations have been searched)</P>
</TD>
<TD>
<P>4943</P>
</TD>
</TR>
<TR>
<TD>
<P>#14</P>
</TD>
<TD>
<P>nevirapine:ti,ab,kw or viramune:ti,ab,kw or nevimune:ti,ab,kw or NVP:ti,ab,kw</P>
</TD>
<TD>
<P>562</P>
</TD>
</TR>
<TR>
<TD>
<P>#15</P>
</TD>
<TD>
<P>efavirenz:ti,ab,kw or sustiva:ti,ab,kw or efv:ti,ab,kw or stocrin:ti,ab,kw</P>
</TD>
<TD>
<P>523</P>
</TD>
</TR>
<TR>
<TD>
<P>#16</P>
</TD>
<TD>
<P>#14 and #15</P>
</TD>
<TD>
<P>121</P>
</TD>
</TR>
<TR>
<TD>
<P>#17</P>
</TD>
<TD>
<P>#13 and #16 from<B> 2009 to 2014, in Trials</B>
</P>
</TD>
<TD>
<P>61</P>
</TD>
</TR>
</TABLE>
<P/>
<TABLE COLS="3" ROWS="18">
<TR>
<TD VALIGN="TOP">
<P>ID</P>
</TD>
<TD VALIGN="TOP">
<P>Search</P>
</TD>
<TD VALIGN="TOP">
<P>Hits</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#1</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [HIV Infections] explode all trees</P>
</TD>
<TD VALIGN="TOP">
<P>8172</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#2</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [HIV] explode all trees</P>
</TD>
<TD VALIGN="TOP">
<P>2638</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#3</P>
</TD>
<TD VALIGN="TOP">
<P>hiv or hiv-1* or hiv-2* or hiv1 or hiv2 or (hiv near infect*) or (human immunodeficiency virus) or (human immunedeficiency virus) or (human immune-deficiency virus) or (human immuno-deficiency virus) or (human immune deficiency virus) or (human immuno deficiency virus) or (acquired immunodeficiency syndrome) or (acquired immunedeficiency syndrome) or (acquired immuno-deficiency syndrome) or (acquired immune-deficiency syndrome) or (acquired immun* deficiency syndrome) (Word variations have been searched)</P>
</TD>
<TD VALIGN="TOP">
<P>14285</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#4</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Lymphoma, AIDS-Related] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>21</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#5</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Sexually Transmitted Diseases, Viral] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#6</P>
</TD>
<TD VALIGN="TOP">
<P>#1 or #2 or #3 or #4 or #5</P>
</TD>
<TD VALIGN="TOP">
<P>14369</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#7</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Antiretroviral Therapy, Highly Active] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>1056</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#8</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Anti-HIV Agents] explode all trees</P>
</TD>
<TD VALIGN="TOP">
<P>2753</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#9</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Antiviral Agents] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>3434</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#10</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [AIDS Vaccines] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>336</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#11</P>
</TD>
<TD VALIGN="TOP">
<P>(anti hiv) or antiretroviral* or (anti near retroviral*) or (aids near vaccin*) (Word variations have been searched)</P>
</TD>
<TD VALIGN="TOP">
<P>6380</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#12</P>
</TD>
<TD VALIGN="TOP">
<P>#7 or #8 or #9 or #10 or #11</P>
</TD>
<TD VALIGN="TOP">
<P>9803</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#13</P>
</TD>
<TD VALIGN="TOP">
<P>#6 and #12 in Trials (Word variations have been searched)</P>
</TD>
<TD VALIGN="TOP">
<P>5538</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#14</P>
</TD>
<TD VALIGN="TOP">
<P>nevirapine:ti,ab,kw or viramune:ti,ab,kw or nevimune:ti,ab,kw or NVP:ti,ab,kw</P>
</TD>
<TD VALIGN="TOP">
<P>633</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#15</P>
</TD>
<TD VALIGN="TOP">
<P>efavirenz:ti,ab,kw or sustiva:ti,ab,kw or efv:ti,ab,kw or stocrin:ti,ab,kw</P>
</TD>
<TD VALIGN="TOP">
<P>634</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#16</P>
</TD>
<TD VALIGN="TOP">
<P>#14 and #15</P>
</TD>
<TD VALIGN="TOP">
<P>148</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#17</P>
</TD>
<TD VALIGN="TOP">
<P>#13 and #16 <B>Publication Year from 2014 to 2015,</B> in Trials</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
</TR>
</TABLE>
<TABLE COLS="3" ROWS="18">
<TR>
<TD VALIGN="TOP">
<P>ID</P>
</TD>
<TD VALIGN="TOP">
<P>Search</P>
</TD>
<TD VALIGN="TOP">
<P>Hits</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#1</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [HIV Infections] explode all trees</P>
</TD>
<TD VALIGN="TOP">
<P>8983</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#2</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [HIV] explode all trees</P>
</TD>
<TD VALIGN="TOP">
<P>2834</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#3</P>
</TD>
<TD VALIGN="TOP">
<P>hiv or hiv-1* or hiv-2* or hiv1 or hiv2 or (hiv near infect*) or (human immunodeficiency virus) or (human immunedeficiency virus) or (human immune-deficiency virus) or (human immuno-deficiency virus) or (human immune deficiency virus) or (human immuno deficiency virus) or (acquired immunodeficiency syndrome) or (acquired immunedeficiency syndrome) or (acquired immuno-deficiency syndrome) or (acquired immune-deficiency syndrome) or (acquired immun* deficiency syndrome) (Word variations have been searched)</P>
</TD>
<TD VALIGN="TOP">
<P>16377</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#4</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Lymphoma, AIDS-Related] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#5</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Sexually Transmitted Diseases, Viral] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#6</P>
</TD>
<TD VALIGN="TOP">
<P>#1 or #2 or #3 or #4 or #5</P>
</TD>
<TD VALIGN="TOP">
<P>16462</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#7</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Antiretroviral Therapy, Highly Active] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>1164</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#8</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Anti-HIV Agents] explode all trees</P>
</TD>
<TD VALIGN="TOP">
<P>3041</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#9</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Antiviral Agents] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>3784</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#10</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [AIDS Vaccines] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>375</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#11</P>
</TD>
<TD VALIGN="TOP">
<P>(anti hiv) or antiretroviral* or (anti near retroviral*) or (aids near vaccin*) (Word variations have been searched)</P>
</TD>
<TD VALIGN="TOP">
<P>7445</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#12</P>
</TD>
<TD VALIGN="TOP">
<P>#7 or #8 or #9 or #10 or #11</P>
</TD>
<TD VALIGN="TOP">
<P>11216</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#13</P>
</TD>
<TD VALIGN="TOP">
<P>#6 and #12 in Trials (Word variations have been searched)</P>
</TD>
<TD VALIGN="TOP">
<P>6006</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#14</P>
</TD>
<TD VALIGN="TOP">
<P>nevirapine:ti,ab,kw or viramune:ti,ab,kw or nevimune:ti,ab,kw or NVP:ti,ab,kw</P>
</TD>
<TD VALIGN="TOP">
<P>767</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#15</P>
</TD>
<TD VALIGN="TOP">
<P>efavirenz:ti,ab,kw or sustiva:ti,ab,kw or efv:ti,ab,kw or stocrin:ti,ab,kw</P>
</TD>
<TD VALIGN="TOP">
<P>859</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#16</P>
</TD>
<TD VALIGN="TOP">
<P>#14 and #15</P>
</TD>
<TD VALIGN="TOP">
<P>226</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#17</P>
</TD>
<TD VALIGN="TOP">
<P>#13 and #16 <B>Publication Year from 2015 to 2016</B>, in Trials</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2016-11-03 17:50:21 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2016-11-03 17:50:21 +0000" MODIFIED_BY="[Empty name]">NLM Gateway search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-10-28 18:06:42 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="9">
<TR>
<TD>
<P>Search<BR/>Number</P>
</TD>
<TD>
<P>Search</P>
</TD>
<TD>
<P>Items<BR/>Found</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P> Search: ((((((HIV INFECTIONS) OR HIV OR HIV OR HIV-1* OR HIV-2* OR HIV1 OR HIV2 OR (HIV INFECT*) OR (HUMAN IMMUNODEFICIENCY VIRUS) OR (HUMAN IMMUNEDEFICIENCY VIRUS) OR (HUMAN IMMUNO-DEFICIENCY VIRUS) OR (HUMAN IMMUNE-DEFICIENCY VIRUS) OR ((HUMAN IMMUN*) AND (DEFICIENCY VIRUS)) OR (ACQUIRED IMMUNODEFICIENCY SYNDROME))) OR (((ACQUIRED IMMUNEDEFICIENCY SYNDROME) OR (ACQUIRED IMMUNO-DEFICIENCY SYNDROME) OR (ACQUIRED IMMUNE-DEFICIENCY SYNDROME) OR ((ACQUIRED IMMUN*) AND (DEFICIENCY SYNDROME)) OR (SEXUALLY TRANSMITTED DISEASES, VIRAL)))) OR ((("Antiretroviral Therapy, Highly Active"[MeSH] OR "Anti-Retroviral Agents"[MeSH] OR "Antiviral Agents"[MeSH:noexp] OR ((anti) AND (hiv[tw])) OR antiretroviral*[tw] OR ((anti) AND (retroviral*[tw])) OR HAART[tw] OR ((anti) AND (acquired immunodeficiency[tw])))) OR ((((anti) AND (acquired immunedeficiency[tw])) OR ((anti) AND (acquired immuno-deficiency[tw])) OR ((anti) AND (acquired immune-deficiency[tw])) OR ((anti) AND (acquired immun*) AND (deficiency[tw])))))) AND ((((RANDOMIZED CONTROLLED TRIAL) OR (CONTROLLED CLINICAL TRIAL) OR (RANDOMIZED CONTROLLED TRIALS) OR (RANDOM ALLOCATION) OR (DOUBLE-BLIND METHOD) OR (SINGLE-BLIND METHOD) OR (CLINICAL TRIAL) OR (CLINICAL TRIALS) OR (CLINICAL TRIAL) OR ((SINGL* OR DOUBL* OR TREBL* OR TRIPL*) AND (MASK* OR BLIND* )))) OR ((PLACEBOS OR PLACEBO* OR RANDOM* OR (COMPARATIVE STUDY) OR (EVALUATION STUDIES) OR (FOLLOW-UP STUDIES) OR (PROSPECTIVE STUDIES) OR CONTROL* OR PROSPECTIV* OR VOLUNTEER*))) AND ((EFAVIRENZ OR SUSTIVA OR STOCRIN OR EFV OR EFZ) OR (NEVIRAPINE OR NVP OR VIRAMUNE OR NEVIMUNE))) AND ((NNRTI OR (NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR) OR (NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR) OR (NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR) OR (NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS) OR (NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS)) OR ((NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS) OR (PI SPARING) OR (PROTEASE INHIBITOR SPARING) OR (PROTEASE-INHIBITOR SPARING) OR (NON-PROTEASE INHIBITOR CONTAINING) OR (NON-PI CONTAINING) OR (NON PROTEASE INHIBITOR CONTAINING))) <B>Limit: 1996:2009</B>
</P>
</TD>
<TD>
<P>260 </P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P> Search: (NNRTI OR (NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR) OR (NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR) OR (NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR) OR (NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS) OR (NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS)) OR ((NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS) OR (PI SPARING) OR (PROTEASE INHIBITOR SPARING) OR (PROTEASE-INHIBITOR SPARING) OR (NON-PROTEASE INHIBITOR CONTAINING) OR (NON-PI CONTAINING) OR (NON PROTEASE INHIBITOR CONTAINING))</P>
</TD>
<TD>
<P>16334 </P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P> Search: (((((HIV INFECTIONS) OR HIV OR HIV OR HIV-1* OR HIV-2* OR HIV1 OR HIV2 OR (HIV INFECT*) OR (HUMAN IMMUNODEFICIENCY VIRUS) OR (HUMAN IMMUNEDEFICIENCY VIRUS) OR (HUMAN IMMUNO-DEFICIENCY VIRUS) OR (HUMAN IMMUNE-DEFICIENCY VIRUS) OR ((HUMAN IMMUN*) AND (DEFICIENCY VIRUS)) OR (ACQUIRED IMMUNODEFICIENCY SYNDROME))) OR (((ACQUIRED IMMUNEDEFICIENCY SYNDROME) OR (ACQUIRED IMMUNO-DEFICIENCY SYNDROME) OR (ACQUIRED IMMUNE-DEFICIENCY SYNDROME) OR ((ACQUIRED IMMUN*) AND (DEFICIENCY SYNDROME)) OR (SEXUALLY TRANSMITTED DISEASES, VIRAL)))) OR ((("Antiretroviral Therapy, Highly Active"[MeSH] OR "Anti-Retroviral Agents"[MeSH] OR "Antiviral Agents"[MeSH:noexp] OR ((anti) AND (hiv[tw])) OR antiretroviral*[tw] OR ((anti) AND (retroviral*[tw])) OR HAART[tw] OR ((anti) AND (acquired immunodeficiency[tw])))) OR ((((anti) AND (acquired immunedeficiency[tw])) OR ((anti) AND (acquired immuno-deficiency[tw])) OR ((anti) AND (acquired immune-deficiency[tw])) OR ((anti) AND (acquired immun*) AND (deficiency[tw])))))) AND ((((RANDOMIZED CONTROLLED TRIAL) OR (CONTROLLED CLINICAL TRIAL) OR (RANDOMIZED CONTROLLED TRIALS) OR (RANDOM ALLOCATION) OR (DOUBLE-BLIND METHOD) OR (SINGLE-BLIND METHOD) OR (CLINICAL TRIAL) OR (CLINICAL TRIALS) OR (CLINICAL TRIAL) OR ((SINGL* OR DOUBL* OR TREBL* OR TRIPL*) AND (MASK* OR BLIND* )))) OR ((PLACEBOS OR PLACEBO* OR RANDOM* OR (COMPARATIVE STUDY) OR (EVALUATION STUDIES) OR (FOLLOW-UP STUDIES) OR (PROSPECTIVE STUDIES) OR CONTROL* OR PROSPECTIV* OR VOLUNTEER*))) AND ((EFAVIRENZ OR SUSTIVA OR STOCRIN OR EFV OR EFZ) OR (NEVIRAPINE OR NVP OR VIRAMUNE OR NEVIMUNE))</P>
</TD>
<TD>
<P>756 </P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P> Search: (EFAVIRENZ OR SUSTIVA OR STOCRIN OR EFV OR EFZ) OR (NEVIRAPINE OR NVP OR VIRAMUNE OR NEVIMUNE)</P>
</TD>
<TD>
<P>6894 </P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P> Search: (((RANDOMIZED CONTROLLED TRIAL) OR (CONTROLLED CLINICAL TRIAL) OR (RANDOMIZED CONTROLLED TRIALS) OR (RANDOM ALLOCATION) OR (DOUBLE-BLIND METHOD) OR (SINGLE-BLIND METHOD) OR (CLINICAL TRIAL) OR (CLINICAL TRIALS) OR (CLINICAL TRIAL) OR ((SINGL* OR DOUBL* OR TREBL* OR TRIPL*) AND (MASK* OR BLIND* )))) OR ((PLACEBOS OR PLACEBO* OR RANDOM* OR (COMPARATIVE STUDY) OR (EVALUATION STUDIES) OR (FOLLOW-UP STUDIES) OR (PROSPECTIVE STUDIES) OR CONTROL* OR PROSPECTIV* OR VOLUNTEER*))</P>
</TD>
<TD>
<P>5030795 </P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P> Search: ((((HIV INFECTIONS) OR HIV OR HIV OR HIV-1* OR HIV-2* OR HIV1 OR HIV2 OR (HIV INFECT*) OR (HUMAN IMMUNODEFICIENCY VIRUS) OR (HUMAN IMMUNEDEFICIENCY VIRUS) OR (HUMAN IMMUNO-DEFICIENCY VIRUS) OR (HUMAN IMMUNE-DEFICIENCY VIRUS) OR ((HUMAN IMMUN*) AND (DEFICIENCY VIRUS)) OR (ACQUIRED IMMUNODEFICIENCY SYNDROME))) OR (((ACQUIRED IMMUNEDEFICIENCY SYNDROME) OR (ACQUIRED IMMUNO-DEFICIENCY SYNDROME) OR (ACQUIRED IMMUNE-DEFICIENCY SYNDROME) OR ((ACQUIRED IMMUN*) AND (DEFICIENCY SYNDROME)) OR (SEXUALLY TRANSMITTED DISEASES, VIRAL)))) OR ((("Antiretroviral Therapy, Highly Active"[MeSH] OR "Anti-Retroviral Agents"[MeSH] OR "Antiviral Agents"[MeSH:noexp] OR ((anti) AND (hiv[tw])) OR antiretroviral*[tw] OR ((anti) AND (retroviral*[tw])) OR HAART[tw] OR ((anti) AND (acquired immunodeficiency[tw])))) OR ((((anti) AND (acquired immunedeficiency[tw])) OR ((anti) AND (acquired immuno-deficiency[tw])) OR ((anti) AND (acquired immune-deficiency[tw])) OR ((anti) AND (acquired immun*) AND (deficiency[tw])))))</P>
</TD>
<TD>
<P>390683 </P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P> Search: (("Antiretroviral Therapy, Highly Active"[MeSH] OR "Anti-Retroviral Agents"[MeSH] OR "Antiviral Agents"[MeSH:noexp] OR ((anti) AND (hiv[tw])) OR antiretroviral*[tw] OR ((anti) AND (retroviral*[tw])) OR HAART[tw] OR ((anti) AND (acquired immunodeficiency[tw])))) OR ((((anti) AND (acquired immunedeficiency[tw])) OR ((anti) AND (acquired immuno-deficiency[tw])) OR ((anti) AND (acquired immune-deficiency[tw])) OR ((anti) AND (acquired immun*) AND (deficiency[tw]))))</P>
</TD>
<TD>
<P>122073 </P>
</TD>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P> Search: (((HIV INFECTIONS) OR HIV OR HIV OR HIV-1* OR HIV-2* OR HIV1 OR HIV2 OR (HIV INFECT*) OR (HUMAN IMMUNODEFICIENCY VIRUS) OR (HUMAN IMMUNEDEFICIENCY VIRUS) OR (HUMAN IMMUNO-DEFICIENCY VIRUS) OR (HUMAN IMMUNE-DEFICIENCY VIRUS) OR ((HUMAN IMMUN*) AND (DEFICIENCY VIRUS)) OR (ACQUIRED IMMUNODEFICIENCY SYNDROME))) OR (((ACQUIRED IMMUNEDEFICIENCY SYNDROME) OR (ACQUIRED IMMUNO-DEFICIENCY SYNDROME) OR (ACQUIRED IMMUNE-DEFICIENCY SYNDROME) OR ((ACQUIRED IMMUN*) AND (DEFICIENCY SYNDROME)) OR (SEXUALLY TRANSMITTED DISEASES, VIRAL)))</P>
</TD>
<TD>
<P>366953 </P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2016-11-03 17:43:39 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2016-11-03 17:42:56 +0000" MODIFIED_BY="[Empty name]">Cochrane 'Risk of bias' assessment tool</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-03 17:43:18 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="14">
<TR>
<TD VALIGN="TOP">
<P>
<B>Domain</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Support for judgement</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Review authors&#8217; judgement</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Selection bias.</I>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Random sequence generation.</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
</TD>
<TD VALIGN="TOP">
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Allocation concealment.</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen in advance of, or during, enrolment.</P>
</TD>
<TD VALIGN="TOP">
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Performance bias.</I>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Blinding of participants and personnel </B>
<I>Assessments should be made for each main outcome (or class of outcomes).</I>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>Describe all measures used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective.</P>
</TD>
<TD VALIGN="TOP">
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Detection bias.</I>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Blinding of outcome assessment</B>
<I>Assessments should be made for each main outcome (or class of outcomes)</I>.</P>
</TD>
<TD VALIGN="TOP">
<P>Describe all measures used, if any, to blind outcome assessors from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective.</P>
</TD>
<TD VALIGN="TOP">
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Attrition bias.</I>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Incomplete outcome data</B>
<I>Assessments should be made for each main outcome (or class of outcomes).</I>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>Describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. State whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomized participants), reasons for attrition/exclusions where reported, and any re-inclusions in analyses performed by the review authors.</P>
</TD>
<TD VALIGN="TOP">
<P>Attrition bias due to amount, nature or handling of incomplete outcome data.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Reporting bias.</I>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Selective reporting.</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>State how the possibility of selective outcome reporting was examined by the review authors, and what was found.</P>
</TD>
<TD VALIGN="TOP">
<P>Reporting bias due to selective outcome reporting.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Other bias.</I>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Other sources of bias.</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>State any important concerns about bias not addressed in the other domains in the tool.</P>
<P>If particular questions/entries were pre-specified in the review&#8217;s protocol, responses should be provided for each question/entry.</P>
</TD>
<TD VALIGN="TOP">
<P>Bias due to problems not covered elsewhere in the table.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2010-03-09 10:13:37 +0000" MODIFIED_BY="[Empty name]"><EXTENSION ID="AFF_7E01F44282E26AA200E51E67BD33208D_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="7E01F44282E26AA200E51E67BD33208D"><ADDRESS><DEPARTMENT>Department of Clinical Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>McMaster University</ORGANISATION><CITY>Hamilton</CITY><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></ALIAS></EXTENSION><EXTENSION ID="AFF_4979_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="4979"><ADDRESS><DEPARTMENT>Alcohol, Tobacco and Other Drug Research Unit</DEPARTMENT><ORGANISATION>Medical Research Council</ORGANISATION><ADDRESS_1>Francie van Zijl Drive</ADDRESS_1><CITY>Tygerberg</CITY><ZIP>7505</ZIP><COUNTRY CODE="ZA">South Africa</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>